{"protocolSection":{"identificationModule":{"nctId":"NCT02564523","orgStudyIdInfo":{"id":"CR107249"},"secondaryIdInfos":[{"id":"VAC52150EBL2002","type":"OTHER","domain":"Janssen Vaccines & Prevention B.V."},{"id":"2019-000690-22","type":"EUDRACT_NUMBER"},{"id":"2019","type":"NIH","link":"https://reporter.nih.gov/quickSearch/2019"}],"organization":{"fullName":"Janssen Vaccines & Prevention B.V.","class":"INDUSTRY"},"briefTitle":"Safety, Tolerability and Immunogenicity Study of 3 Prime-boost Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo in Healthy Adults, Children and Human Immunodeficiency Virus Positive (HIV+) Adults","officialTitle":"A Randomized, Observer-blind, Placebo-controlled, Phase 2 Study to Evaluate the Safety, Tolerability and Immunogenicity of Different Prime-boost Regimens of the Candidate Prophylactic Vaccines for Ebola Ad26.ZEBOV and MVA-BN-Filo in Healthy Adults, Including Elderly Subjects, HIV-infected Subjects, and Healthy Children in Two Age Strata in Africa"},"statusModule":{"statusVerifiedDate":"2022-02","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2015-11-06","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2019-02-12","type":"ACTUAL"},"completionDateStruct":{"date":"2019-02-12","type":"ACTUAL"},"studyFirstSubmitDate":"2015-09-29","studyFirstSubmitQcDate":"2015-09-29","studyFirstPostDateStruct":{"date":"2015-09-30","type":"ESTIMATED"},"resultsFirstSubmitDate":"2022-02-09","resultsFirstSubmitQcDate":"2022-02-09","resultsFirstPostDateStruct":{"date":"2022-03-07","type":"ACTUAL"},"dispFirstSubmitDate":"2020-02-10","dispFirstSubmitQcDate":"2020-02-10","dispFirstPostDateStruct":{"date":"2020-02-17","type":"ACTUAL"},"lastUpdateSubmitDate":"2022-02-09","lastUpdatePostDateStruct":{"date":"2022-03-07","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Janssen Vaccines & Prevention B.V.","class":"INDUSTRY"},"collaborators":[{"name":"EBOVAC2 Consortium","class":"INDUSTRY"},{"name":"Institut National de la Santé Et de la Recherche Médicale, France","class":"OTHER_GOV"},{"name":"Centre Muraz","class":"OTHER"}]},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"The purpose of this study is to assess the safety, tolerability and immunogenicity of three heterologous prime-boost regimens for Ebola vaccines Ad26.ZEBOV and MVA-BN-Filo. The study will include healthy adults and elderly participants, HIV infected participants and healthy children in 2 age strata.","detailedDescription":"This is a randomized, observer-blind, placebo-controlled, parallel-group, multicenter, Phase 2 study evaluating the safety, tolerability and immunogenicity of 3 heterologous prime-boost regimens using Ad26.ZEBOV as prime and MVA-BN-Filo as boost vaccination, administered at 28-, 56- and 84-day (Group 1, 2 and 3 as above) intervals, in healthy adults and elderly participants. A 28- and 56-day (Groups 1 and 2, as above) schedule will be evaluated in HIV-infected participants and in healthy children in 2 age strata. The study consists of a screening phase of up to 8 weeks, a vaccination phase in which participants will be vaccinated at baseline (Day 1) followed by a boost vaccination on Day 29, 57 or 85, a post-vaccination phase and long-term follow-up phase until Day 365. Participants in Cohort 1 substudy (Group 1 and 2) who received Ad26.ZEBOV and MVA-BN-Filo (at selected sites) will receive Ad26.ZEBOV as third vaccination and who received placebo will receive placebo as third vaccination (at least 1 year post prime vaccination). All participants within a cohort will be followed in a blinded manner by the site until the last subject in that cohort has completed the study. This study will be conducted in Africa and the enrollment will take place sequentially in three cohorts: the first cohort will consist of healthy participants (18 - 70 years); the second cohort (2a) will include HIV-infected participants (18 to 50 years) and healthy children 12 to 17 years (cohort 2b); the third cohort will include children aged 4 to 11 years inclusive will be enrolled. Within each cohort, participants will be randomized in a 5:1 ratio to receive active vaccine versus placebo. Safety evaluations will include assessments of adverse events, an electrocardiogram (ECG) for adult participants at screening, physical examination, vital signs (blood pressure, pulse/heart rate, body temperature), clinical laboratory and pregnancy testing. An independent data monitoring committee (IDMC) will be established to monitor data on a regular basis to ensure the continuing safety of the participants enrolled in the study."},"conditionsModule":{"conditions":["Hemorrhagic Fever, Ebola"],"keywords":["Healthy","Vaccine","Ebola viruses","Ebola virus disease (EVD)","Filoviruses","Hemorrhagic fever","Monovalent vaccine","Human adenovirus serotype 26 (Ad26) expressing the Ebola virus Mayinga variant glycoprotein (Ad26.ZEBOV)","Modified Vaccinia Virus Ankara - Bavarian Nordic (MVA-BN) Filo-vector","Safety","Immunogenicity","Inserm, Centre Muraz"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"PREVENTION","maskingInfo":{"masking":"TRIPLE","whoMasked":["PARTICIPANT","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":1075,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Group 1","type":"EXPERIMENTAL","description":"Participants will receive Ad26.ZEBOV, MVA-BN-Filo (Day 1/Day 29) or placebo (Day 1/Day 29) followed by a subset of participants who received Ad26.ZEBOV and MVA-BN-Filo (at selected sites) will receive Ad26.ZEBOV as third vaccination and who received placebo will receive placebo as third vaccination (at least 1 year post prime vaccination).","interventionNames":["Biological: Ad26.ZEBOV","Biological: MVA-BN-Filo","Biological: Placebo"]},{"label":"Group 2","type":"EXPERIMENTAL","description":"Participants will receive Ad26.ZEBOV, MVA-BN-Filo (Day 1/Day 57) or placebo (Day 1/Day 57) followed by a subset of participants who received Ad26.ZEBOV and MVA-BN-Filo (at selected sites) will receive Ad26.ZEBOV as third vaccination and who received placebo will receive placebo as third vaccination (at least 1 year post prime vaccination).","interventionNames":["Biological: Ad26.ZEBOV","Biological: MVA-BN-Filo","Biological: Placebo"]},{"label":"Group 3","type":"EXPERIMENTAL","description":"Participants will receive Ad26.ZEBOV, MVA-BN-Filo (Day 1/Day 85) or placebo (Day 1/Day 85)","interventionNames":["Biological: Ad26.ZEBOV","Biological: MVA-BN-Filo","Biological: Placebo"]}],"interventions":[{"type":"BIOLOGICAL","name":"Ad26.ZEBOV","description":"One 0.5 mL intramuscular (IM) injection of (5x10\\*10 viral particles)","armGroupLabels":["Group 1","Group 2","Group 3"]},{"type":"BIOLOGICAL","name":"MVA-BN-Filo","description":"One 0.5 mL IM injection of (1x10\\*8 infectious units)","armGroupLabels":["Group 1","Group 2","Group 3"]},{"type":"BIOLOGICAL","name":"Placebo","description":"One 0.5 mL IM injection of 0.9% saline","armGroupLabels":["Group 1","Group 2","Group 3"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Number of Participants With Adverse Events (Day 29)","description":"An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product.","timeFrame":"Up to 28 days post-dose 1 (Day 29)"},{"measure":"Number of Participants With Adverse Events (AEs) (28-Day Interval)","description":"An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product.","timeFrame":"Up to 28 days post-dose 2 (Day 57 for Cohorts 1, 2a, 2b and 3 [28-Day Interval])"},{"measure":"Number of Participants With Adverse Events (56-day Interval)","description":"An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product.","timeFrame":"Up 28 days post-dose 2 (Day 85 for Cohorts 1, 2a, 2b and 3 [56-Day Interval])"},{"measure":"Number of Participants With Adverse Events (84-day Interval)","description":"An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product.","timeFrame":"Up to 28 days post-dose 2 (Day 113 for Cohort 1 [84-Day Interval])"},{"measure":"Number of Participants With Adverse Events Post-dose 3 (Day 393)","description":"An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product.","timeFrame":"Up 28 days post-dose 3 (Day 393)"},{"measure":"Number of Participants With Serious Adverse Events","description":"A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.","timeFrame":"Up to 3 years and 3 months"},{"measure":"Number of Participants With Immediate Reportable Events (IREs)","description":"The following neuroinflammatory disorders were considered immediate reportable events which had to be reported to the sponsor within 24 hours of becoming aware of the event. Neuroinflammatory disorders included: cranial nerve disorders including paralyses/paresis (example: bell's palsy), optic neuritis, multiple sclerosis, transverse myelitis, guillain-barre syndrome including miller fisher syndrome, bickerstaff's encephalitis and other variants, acute disseminated encephalomyelitis, including site-specific variants (example: non-infectious encephalitis, encephalomyelitis, myelitis, myeloradiculomyelitis), myasthenia gravis and lambert-eaton myasthenic syndrome, immune-mediated peripheral neuropathies and plexopathies, including chronic inflammatory, demyelinating polyneuropathy, multifocal motor neuropathy, and polyneuropathies associated with monoclonal gammopathy, narcolepsy, isolated paresthesia of more than 7 days duration.","timeFrame":"Up to 3 years and 3 months"},{"measure":"Number of Participants With Solicited Local Adverse Events (Day 8)","description":"An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. Solicited local AEs were pre-defined local (at the injection site) AEs for which participants were specifically questioned and which were noted by participants in their diary for 7 days post vaccination. Solicited local AEs were: injection site pain/tenderness, erythema, induration/swelling, itching at the vaccination site.","timeFrame":"7 days post-dose 1 (Day 8)"},{"measure":"Number of Participants With Solicited Local Adverse Events (28-day Interval)","description":"An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. Solicited local AEs were pre-defined local (at the injection site) AEs for which participants were specifically questioned and which were noted by participants in their diary for 7 days post vaccination. Solicited local AEs were: injection site pain/tenderness, erythema, induration/swelling, itching at the vaccination site.","timeFrame":"Up to 7 days post-dose 2 (Day 36 for Cohort 1, 2a, 2b and 3 [28-Day Interval])"},{"measure":"Number of Participants With Solicited Local Adverse Events Post-dose 2 (56-day Interval)","description":"An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. Solicited local AEs were pre-defined local (at the injection site) AEs for which participants were specifically questioned and which were noted by participants in their diary for 7 days post vaccination. Solicited local AEs were: injection site pain/tenderness, erythema, induration/swelling, itching at the vaccination site.","timeFrame":"Up to 7 days post-dose 2 (Day 64 for Cohort 1, 2a, 2b and 3 [56-Day Interval])"},{"measure":"Number of Participants With Solicited Local Adverse Events (84-day Interval)","description":"An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. Solicited local AEs were pre-defined local (at the injection site) AEs for which participants were specifically questioned and which were noted by participants in their diary for 7 days post vaccination. Solicited local AEs were: injection site pain/tenderness, erythema, induration/swelling, itching at the vaccination site.","timeFrame":"Up to 7 days post-dose 2 (Day 92 for Cohort 1 [84-Day Interval])"},{"measure":"Number of Participants With Solicited Local Adverse Events (Day 372)","description":"An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. Solicited local AEs were pre-defined local (at the injection site) AEs for which participants were specifically questioned and which were noted by participants in their diary for 7 days post vaccination. Solicited local AEs were: injection site pain/tenderness, erythema, induration/swelling, itching at the vaccination site.","timeFrame":"Up 7 days post-dose 3 (Day 372)"},{"measure":"Number of Participants With Solicited Systemic Adverse Events (Day 8)","description":"An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. Participants were instructed on how to note signs and symptoms in the diary on a daily basis for 7 days post-vaccination (Day of vaccination and the subsequent 7 days) for solicited systemic AEs. Solicited systemic events included fever, headache, fatigue/malaise, myalgia, nausea/vomiting, arthralgia and chills.","timeFrame":"Up to 7 days post-dose 1 (Day 8)"},{"measure":"Number of Participants With Solicited Systemic Adverse Events (28-Day Interval)","description":"An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. Participants were instructed on how to note signs and symptoms in the diary on a daily basis for 7 days post-vaccination (Day of vaccination and the subsequent 7 days) for solicited systemic AEs. Solicited systemic events included fever, headache, fatigue/malaise, myalgia, nausea/vomiting, arthralgia and chills.","timeFrame":"Up to 7 days post-dose 2 (Day 36 for Cohorts 1, 2a, 2b and 3 [28-Day Interval])"},{"measure":"Number of Participants With Solicited Systemic Adverse Events (56-Day Interval)","description":"An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. Participants were instructed on how to note signs and symptoms in the diary on a daily basis for 7 days post-vaccination (Day of vaccination and the subsequent 7 days) for solicited systemic AEs. Solicited systemic events included fever, headache, fatigue/malaise, myalgia, nausea/vomiting, arthralgia and chills.","timeFrame":"Up 7 days post-dose 2 (Day 64 for Cohort 1, 2a, 2b and 3 [56-Day Interval])"},{"measure":"Number of Participants With Solicited Systemic Adverse Events (84-Day Interval)","description":"An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. Participants were instructed on how to note signs and symptoms in the diary on a daily basis for 7 days post-vaccination (Day of vaccination and the subsequent 7 days) for solicited systemic AEs. Solicited systemic events included fever, headache, fatigue/malaise, myalgia, nausea/vomiting, arthralgia and chills.","timeFrame":"Up 7 days post-dose 2 (Day 92 for Cohort 1 [84-Day Interval])"},{"measure":"Number of Participants With Solicited Systemic Adverse Events (Day 372)","description":"An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. Participants were instructed on how to note signs and symptoms in the diary on a daily basis for 7 days post-vaccination (Day of vaccination and the subsequent 7 days) for solicited systemic AEs. Solicited systemic events included fever, headache, fatigue/malaise, myalgia, nausea/vomiting, arthralgia and chills.","timeFrame":"Up to 7 days post-dose 3 (Day 372)"}],"secondaryOutcomes":[{"measure":"Geometric Mean Concentrations (GMCs) of Binding Antibody Levels Against Ebola Virus Glycoprotein (EBOV GP) Measured Using Filovirus Animal Non-Clinical Group (FANG) Enzyme-linked Immunosorbent Assay","description":"GMCs of antibodies binding to EBOV GP using FANG ELISA were reported and were measured in ELISA unit per milliliter (EU/mL). Serum samples were collected for analysis of binding antibodies against EBOV GP using FANG ELISA to determine humoral responses following vaccination. For ELISA binding antibody responses, values below the lower limit of quantification (LLOQ) (36.11 ELISA units/mL).","timeFrame":"21-days post-dose 2 (Day 50 for Cohorts 1, 2a, 2b, 3 [28-day interval] , Day 78 for Cohort 1, 2a, 2b, 3 [56-day interval] and Day 106 Cohort 1 [84-day interval]"},{"measure":"Number of Participants With Serious Adverse Events Post-dose 3","description":"A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.","timeFrame":"Up 28 days post-dose 3 (Day 393)"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\nCriteria for healthy adults and elderly participants:\n\n* Participant must be healthy in the investigator's clinical judgment on the basis of clinical laboratory tests, medical history, ECG, physical examination and vital signs performed at screening. Participants with hemoglobin values outside the local laboratory reference ranges may be included if the hemoglobin is above the age/gender specific limits\n* Female participants of childbearing potential must use adequate birth control measures, must have a negative pregnancy test at screening and immediately prior to each study vaccination\n* A man who is sexually active with a woman of childbearing potential must be willing to use condoms for sexual intercourse beginning prior to enrollment, unless a vasectomy was performed more than 1 year prior to screening\n* Participant must pass the test of understanding (TOU)\n* Participant must be available and willing to participate for the duration of the study visits and follow-up, provide verifiable identification, and have a means to be contacted Additional Inclusion Criteria HIV-infected Participants\n* Participant must be between 18 to 50 years of age and must have a documented HIV-infection for at least 6 months prior to screening\n* Participant must be on a stable 3 drug regimen of Highly Active Antiretroviral Therapy for at least 4 weeks prior to screening and having a CD4 positive cell count of \\>350 cells/microliter. Also participant must be in an otherwise reasonable good medical condition Additional Inclusion Criteria Children Participants\n* Parent/legal guardian must pass the TOU before signing the inform consent form. Informed assent must be obtained from adolescents and older children, depending on local regulations and practice\n* Pediatric participant's age on the day of randomization must be within one of the 2 age strata: 12-17 years or 4-11 years (all ages inclusive)\n* Pediatric participants must have received all routine immunizations appropriate for his or her age as reported by the parent(s)/legal guardian, according to local routine vaccination schedules\n\nExclusion criteria:\n\n* Diagnosed with Ebola virus disease or previously exposed to Ebola virus including travel to epidemic Ebola areas less than 1 month prior to screening\n* Having received any candidate Ebola vaccine or any experimental candidate Ad26- or MVA-based vaccine in the past\n* Having HIV type 1 or type 2 infection (for healthy adults/elderly/children)\n* Pediatric participants with weight-per-height below 10th percentile according to the Centers for Disease Control and Prevention (CDC) growth charts (4- to 11-year-olds)\n* A woman who is pregnant, breast-feeding or planning to become pregnant while enrolled in the study or within at least 3 months after the prime vaccination or up to 1 month after the boost vaccination (whichever takes longer) or within at least 3 months after the third vaccination\n* For HIV+ adults, no AIDS-defining illnesses","healthyVolunteers":true,"sex":"ALL","minimumAge":"4 Years","maximumAge":"70 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Janssen Vaccines & Prevention B.V. Clinical Trial","affiliation":"Janssen Vaccines & Prevention B.V.","role":"STUDY_DIRECTOR"}],"locations":[{"city":"BoboDioulasso","country":"Burkina Faso"},{"city":"Ouagadougou","country":"Burkina Faso","geoPoint":{"lat":12.36566,"lon":-1.53388}},{"city":"Abidjan","country":"Côte d’Ivoire","geoPoint":{"lat":5.35444,"lon":-4.00167}},{"city":"Toupah/Ousrou","country":"Côte d’Ivoire"},{"city":"Nairobi","country":"Kenya","geoPoint":{"lat":-1.28333,"lon":36.81667}},{"city":"Entebbe","country":"Uganda","geoPoint":{"lat":0.05621,"lon":32.47949}},{"city":"Kampala","country":"Uganda","geoPoint":{"lat":0.31628,"lon":32.58219}}]},"referencesModule":{"references":[{"pmid":"38603720","type":"DERIVED","citation":"Barry H, Lhomme E, Surenaud M, Nouctara M, Robinson C, Bockstal V, Valea I, Somda S, Tinto H, Meda N, Greenwood B, Thiebaut R, Lacabaratz C. Helminth exposure and immune response to the two-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccine regimen. PLoS Negl Trop Dis. 2024 Apr 11;18(4):e0011500. doi: 10.1371/journal.pntd.0011500. eCollection 2024 Apr."},{"pmid":"35015777","type":"DERIVED","citation":"Anywaine Z, Barry H, Anzala O, Mutua G, Sirima SB, Eholie S, Kibuuka H, Betard C, Richert L, Lacabaratz C, McElrath MJ, De Rosa SC, Cohen KW, Shukarev G, Katwere M, Robinson C, Gaddah A, Heerwegh D, Bockstal V, Luhn K, Leyssen M, Thiebaut R, Douoguih M; EBL2002 Study group. Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in children and adolescents in Africa: A randomised, placebo-controlled, multicentre Phase II clinical trial. PLoS Med. 2022 Jan 11;19(1):e1003865. doi: 10.1371/journal.pmed.1003865. eCollection 2022 Jan."},{"pmid":"34714820","type":"DERIVED","citation":"Barry H, Mutua G, Kibuuka H, Anywaine Z, Sirima SB, Meda N, Anzala O, Eholie S, Betard C, Richert L, Lacabaratz C, McElrath MJ, De Rosa S, Cohen KW, Shukarev G, Robinson C, Gaddah A, Heerwegh D, Bockstal V, Luhn K, Leyssen M, Douoguih M, Thiebaut R; EBL2002 Study group. Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in healthy and HIV-infected adults: A randomised, placebo-controlled Phase II clinical trial in Africa. PLoS Med. 2021 Oct 29;18(10):e1003813. doi: 10.1371/journal.pmed.1003813. eCollection 2021 Oct."}]}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"A total of 1075 participants were enrolled. Among 1075 participants, 1 participant was enrolled twice and 1 participant was enrolled erroneously, but did not receive any study vaccination.","groups":[{"id":"FG000","title":"Cohort 1: Ad26.ZEBOV, MVA-BN-Filo, Ad26.ZEBOV, 28-Day Interval","description":"Participants (healthy adults and elderly) received intramuscular (IM) injection of Ad26.ZEBOV 5\\*10\\^10 viral particles (vp) on Day 1 followed by IM injection of MVA-BN-filo 1\\*10\\^8 infectious units (Inf.U) on Day 29. Subset of participants who earlier received Ad26.ZEBOV and MVA-BN-Filo (at selected sites), afterwards received IM injection of Ad26.ZEBOV 5\\*10\\^10 vp as a booster dose at 1 year post dose 1 (Day 365)."},{"id":"FG001","title":"Cohort 1: Placebo, Placebo, Placebo, 28-Day Interval","description":"Participants (healthy adults and elderly) received IM injection of Placebo 0.9 percent (%) saline on Day 1 followed by IM injection of placebo 0.9 % saline on Day 29. Subset of participants who earlier received placebo(at selected sites), afterwards received IM injection of placebo 0.9 % saline as a booster dose at 1 year post dose 1 (Day 365)."},{"id":"FG002","title":"Cohort 1: Ad26.ZEBOV, MVA-BN-Filo, Ad26.ZEBOV, 56-Day Interval","description":"Participants (healthy adults and elderly) received IM injection of Ad26.ZEBOV 5\\*10\\^10 vp on Day 1 followed by IM injection of MVA-BN-filo Inf.U on Day 57. Subset of participants who earlier received Ad26.ZEBOV and MVA-BN-Filo (at selected sites), afterwards received IM injection of Ad26.ZEBOV 5\\*10\\^10 vp as a booster dose at 1 year post dose 1 (Day 365)."},{"id":"FG003","title":"Cohort 1: Placebo, Placebo, Placebo, 56-Day Interval","description":"Participants (healthy adults and elderly) received placebo 0.9% saline on Day 1 followed by IM injection of placebo 0.9% saline on Day 57. Subset of participants who earlier received Placebo (at selected sites), afterwards received IM injection of Placebo 0.9 % saline as a booster dose at 1 year post dose 1 (Day 365)."},{"id":"FG004","title":"Cohort 1: Ad26.ZEBOV, MVA-BN-Filo, 84-Day Interval","description":"Participants (healthy adults and elderly) received IM injection of Ad26.ZEBOV 5\\*10\\^10 vp on Day 1 followed by IM injection of MVA-BN-filo 1\\*10\\^8 Inf.U on Day 85."},{"id":"FG005","title":"Cohort 1: Placebo, Placebo, 84-Day Interval","description":"Participants (healthy adults and elderly) received IM injection of Placebo 0.9 % saline on Day 1 followed by IM injection of Placebo 0.9 % saline on Day 85."},{"id":"FG006","title":"Cohort 2a: Ad26.ZEBOV, MVA-BN-Filo, 28-Day Interval","description":"Participants (human immunodeficiency virus \\[HIV\\]-infected adults) received IM injection of Ad26.ZEBOV 5\\*10\\^10 vp on Day 1 followed by IM injection of MVA-BN-filo 1\\*10\\^8 Inf.U on Day 29."},{"id":"FG007","title":"Cohort 2a: Placebo, Placebo, 28-Day Interval","description":"Participants (HIV-infected adults) received IM injection of Placebo 0.9 % saline on Day 1 followed by IM injection of Placebo 0.9 % saline on Day 29."},{"id":"FG008","title":"Cohort 2a: Ad26.ZEBOV, MVA-BN-Filo, 56-Day Interval","description":"Participants (HIV-infected adults) received IM injection of Ad26.ZEBOV 5\\*10\\^10 vp on Day 1 followed by IM injection of MVA-BN-filo 1\\*10\\^8 Inf.U on Day 57."},{"id":"FG009","title":"Cohort 2a: Placebo, Placebo, 56-Day Interval","description":"Participants (HIV-infected adults) received IM injection of Placebo 0.9 % saline on Day 1 followed by IM injection of Placebo 0.9 % saline on Day 57."},{"id":"FG010","title":"Cohort 2b: Ad26.ZEBOV, MVA-BN-Filo, 28-Day Interval","description":"Participants (Healthy Adolescents \\[12-17 years\\]) received IM injection of Ad26.ZEBOV 5\\*10\\^10 vp on Day 1 followed by IM injection of MVA-BN-filo 1\\*10\\^8 Inf.U on Day 29."},{"id":"FG011","title":"Cohort 2b: Placebo, Placebo, 28-Day Interval","description":"Participants (Healthy Adolescents \\[12-17 years\\]) received IM injection of Placebo 0.9 % saline on Day 1 followed by IM injection of Placebo 0.9 % saline on Day 29."},{"id":"FG012","title":"Cohort 2b: Ad26.ZEBOV, MVA-BN-Filo, 56-Day Interval","description":"Participants ((Healthy Adolescents \\[12-17 years\\]) received IM injection of Ad26.ZEBOV 5\\*10\\^10 vp on Day 1 followed by IM injection of MVA-BN-filo 1\\*10\\^8 Inf.U on Day 57."},{"id":"FG013","title":"Cohort 2b: Placebo, Placebo, 56-Day Interval","description":"Participants (Healthy Adolescents \\[12-17 years\\]) received IM injection of Placebo 0.9 % saline on Day 1 followed by IM injection of Placebo 0.9 % saline on Day 57."},{"id":"FG014","title":"Cohort 3: Ad26.ZEBOV, MVA-BN-Filo, 28-Day Interval","description":"Participants (Healthy Children \\[4-11 years\\]) received IM injection of Ad26.ZEBOV 5\\*10\\^10 vp on Day 1 followed by IM injection of MVA-BN-filo 1\\*10\\^8 Inf.U on Day 29."},{"id":"FG015","title":"Cohort 3: Placebo, Placebo, 28-Day Interval","description":"Participants (Healthy Children \\[4-11 years\\]) received IM injection of Placebo 0.9 % saline on Day 1 followed by IM injection of Placebo 0.9 % saline on Day 29."},{"id":"FG016","title":"Cohort 3: Ad26.ZEBOV, MVA-BN-Filo, 56-Day Interval","description":"Participants (Healthy Children \\[4-11 years\\]) received IM injection of Ad26.ZEBOV 5\\*10\\^10 vp on Day 1 followed by IM injection of MVA-BN-filo 1\\*10\\^8 Inf.U on Day 57."},{"id":"FG017","title":"Cohort 3: Placebo, Placebo, 56-Day Interval","description":"Participants (Healthy Children \\[4-11 years\\]) received IM injection of Placebo 0.9 % saline on Day 1 followed by IM injection of Placebo 0.9 % saline on Day 57."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"225"},{"groupId":"FG001","numSubjects":"43"},{"groupId":"FG002","numSubjects":"224"},{"groupId":"FG003","numSubjects":"44"},{"groupId":"FG004","numSubjects":"110"},{"groupId":"FG005","numSubjects":"22"},{"groupId":"FG006","numSubjects":"59"},{"groupId":"FG007","numSubjects":"12"},{"groupId":"FG008","numSubjects":"59"},{"groupId":"FG009","numSubjects":"12"},{"groupId":"FG010","numSubjects":"55"},{"groupId":"FG011","numSubjects":"11"},{"groupId":"FG012","numSubjects":"55"},{"groupId":"FG013","numSubjects":"10"},{"groupId":"FG014","numSubjects":"54"},{"groupId":"FG015","numSubjects":"12"},{"groupId":"FG016","numSubjects":"54"},{"groupId":"FG017","numSubjects":"12"}]},{"type":"Participants Who Received Booster Dose at 1 Year Post Dose 1 (on Day 365)","achievements":[{"groupId":"FG000","numSubjects":"34"},{"groupId":"FG001","numSubjects":"8"},{"groupId":"FG002","numSubjects":"39"},{"groupId":"FG003","numSubjects":"9"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"},{"groupId":"FG014","numSubjects":"0"},{"groupId":"FG015","numSubjects":"0"},{"groupId":"FG016","numSubjects":"0"},{"groupId":"FG017","numSubjects":"0"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"215"},{"groupId":"FG001","numSubjects":"40"},{"groupId":"FG002","numSubjects":"214"},{"groupId":"FG003","numSubjects":"43"},{"groupId":"FG004","numSubjects":"106"},{"groupId":"FG005","numSubjects":"22"},{"groupId":"FG006","numSubjects":"56"},{"groupId":"FG007","numSubjects":"12"},{"groupId":"FG008","numSubjects":"59"},{"groupId":"FG009","numSubjects":"12"},{"groupId":"FG010","numSubjects":"52"},{"groupId":"FG011","numSubjects":"10"},{"groupId":"FG012","numSubjects":"53"},{"groupId":"FG013","numSubjects":"10"},{"groupId":"FG014","numSubjects":"54"},{"groupId":"FG015","numSubjects":"12"},{"groupId":"FG016","numSubjects":"54"},{"groupId":"FG017","numSubjects":"11"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"10"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"10"},{"groupId":"FG003","numSubjects":"1"},{"groupId":"FG004","numSubjects":"4"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"3"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"3"},{"groupId":"FG011","numSubjects":"1"},{"groupId":"FG012","numSubjects":"2"},{"groupId":"FG013","numSubjects":"0"},{"groupId":"FG014","numSubjects":"0"},{"groupId":"FG015","numSubjects":"0"},{"groupId":"FG016","numSubjects":"0"},{"groupId":"FG017","numSubjects":"1"}]}],"dropWithdraws":[{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"1"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"1"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"1"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"1"},{"groupId":"FG013","numSubjects":"0"},{"groupId":"FG014","numSubjects":"0"},{"groupId":"FG015","numSubjects":"0"},{"groupId":"FG016","numSubjects":"0"},{"groupId":"FG017","numSubjects":"0"}]},{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"},{"groupId":"FG014","numSubjects":"0"},{"groupId":"FG015","numSubjects":"0"},{"groupId":"FG016","numSubjects":"0"},{"groupId":"FG017","numSubjects":"1"}]},{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"1"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"1"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"},{"groupId":"FG014","numSubjects":"0"},{"groupId":"FG015","numSubjects":"0"},{"groupId":"FG016","numSubjects":"0"},{"groupId":"FG017","numSubjects":"0"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"4"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"1"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"1"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"1"},{"groupId":"FG012","numSubjects":"1"},{"groupId":"FG013","numSubjects":"0"},{"groupId":"FG014","numSubjects":"0"},{"groupId":"FG015","numSubjects":"0"},{"groupId":"FG016","numSubjects":"0"},{"groupId":"FG017","numSubjects":"0"}]},{"type":"Physician Decision","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"1"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"1"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"},{"groupId":"FG014","numSubjects":"0"},{"groupId":"FG015","numSubjects":"0"},{"groupId":"FG016","numSubjects":"0"},{"groupId":"FG017","numSubjects":"0"}]},{"type":"Protocol Violation","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"5"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"1"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"},{"groupId":"FG014","numSubjects":"0"},{"groupId":"FG015","numSubjects":"0"},{"groupId":"FG016","numSubjects":"0"},{"groupId":"FG017","numSubjects":"0"}]},{"type":"Other","reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"1"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"},{"groupId":"FG014","numSubjects":"0"},{"groupId":"FG015","numSubjects":"0"},{"groupId":"FG016","numSubjects":"0"},{"groupId":"FG017","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Cohort 1: Ad26.ZEBOV, MVA-BN-Filo, Ad26.ZEBOV, 28-Day Interval","description":"Participants (healthy adults and elderly) received intramuscular (IM) injection of Ad26.ZEBOV 5\\*10\\^10 viral particles (vp) on Day 1 followed by IM injection of MVA-BN-filo 1\\*10\\^8 infectious units (Inf.U) on Day 29. Subset of participants who earlier received Ad26.ZEBOV and MVA-BN-Filo (at selected sites), afterwards received IM injection of Ad26.ZEBOV 5\\*10\\^10 vp as a booster dose at 1 year post dose 1 (Day 365)."},{"id":"BG001","title":"Cohort 1: Placebo, Placebo, Placebo, 28-Day Interval","description":"Participants (healthy adults and elderly) received IM injection of Placebo 0.9 percent (%) saline on Day 1 followed by IM injection of placebo 0.9 % saline on Day 29. Subset of participants who earlier received placebo(at selected sites), afterwards received IM injection of placebo 0.9 % saline as a booster dose at 1 year post dose 1 (Day 365)."},{"id":"BG002","title":"Cohort 1: Ad26.ZEBOV, MVA-BN-Filo, Ad26.ZEBOV, 56-Day Interval","description":"Participants (healthy adults and elderly) received IM injection of Ad26.ZEBOV 5\\*10\\^10 vp on Day 1 followed by IM injection of MVA-BN-filo Inf.U on Day 57. Subset of participants who earlier received Ad26.ZEBOV and MVA-BN-Filo (at selected sites), afterwards received IM injection of Ad26.ZEBOV 5\\*10\\^10 vp as a booster dose at 1 year post dose 1 (Day 365)."},{"id":"BG003","title":"Cohort 1: Placebo, Placebo, Placebo, 56-Day Interval","description":"Participants (healthy adults and elderly) received placebo 0.9% saline on Day 1 followed by IM injection of placebo 0.9% saline on Day 57. Subset of participants who earlier received Placebo (at selected sites), afterwards received IM injection of Placebo 0.9 % saline as a booster dose at 1 year post dose 1 (Day 365)."},{"id":"BG004","title":"Cohort 1: Ad26.ZEBOV, MVA-BN-Filo, 84-Day Interval","description":"Participants (healthy adults and elderly) received IM injection of Ad26.ZEBOV 5\\*10\\^10 vp on Day 1 followed by IM injection of MVA-BN-filo 1\\*10\\^8 Inf.U on Day 85."},{"id":"BG005","title":"Cohort 1: Placebo, Placebo, 84-Day Interval","description":"Participants (healthy adults and elderly) received IM injection of Placebo 0.9 % saline on Day 1 followed by IM injection of Placebo 0.9 % saline on Day 85."},{"id":"BG006","title":"Cohort 2a: Ad26.ZEBOV, MVA-BN-Filo, 28-Day Interval","description":"Participants (human immunodeficiency virus \\[HIV\\]-infected adults) received IM injection of Ad26.ZEBOV 5\\*10\\^10 vp on Day 1 followed by IM injection of MVA-BN-filo 1\\*10\\^8 Inf.U on Day 29."},{"id":"BG007","title":"Cohort 2a: Placebo, Placebo, 28-Day Interval","description":"Participants (HIV-infected adults) received IM injection of Placebo 0.9 % saline on Day 1 followed by IM injection of Placebo 0.9 % saline on Day 29."},{"id":"BG008","title":"Cohort 2a: Ad26.ZEBOV, MVA-BN-Filo, 56-Day Interval","description":"Participants (HIV-infected adults) received IM injection of Ad26.ZEBOV 5\\*10\\^10 vp on Day 1 followed by IM injection of MVA-BN-filo 1\\*10\\^8 Inf.U on Day 57."},{"id":"BG009","title":"Cohort 2a: Placebo, Placebo, 56-Day Interval","description":"Participants (HIV-infected adults) received IM injection of Placebo 0.9 % saline on Day 1 followed by IM injection of Placebo 0.9 % saline on Day 57."},{"id":"BG010","title":"Cohort 2b: Ad26.ZEBOV, MVA-BN-Filo, 28-Day Interval","description":"Participants (Healthy Adolescents \\[12-17 years\\]) received IM injection of Ad26.ZEBOV 5\\*10\\^10 vp on Day 1 followed by IM injection of MVA-BN-filo 1\\*10\\^8 Inf.U on Day 29."},{"id":"BG011","title":"Cohort 2b: Placebo, Placebo, 28-Day Interval","description":"Participants (Healthy Adolescents \\[12-17 years\\]) received IM injection of Placebo 0.9 % saline on Day 1 followed by IM injection of Placebo 0.9 % saline on Day 29."},{"id":"BG012","title":"Cohort 2b: Ad26.ZEBOV, MVA-BN-Filo, 56-Day Interval","description":"Participants ((Healthy Adolescents \\[12-17 years\\]) received IM injection of Ad26.ZEBOV 5\\*10\\^10 vp on Day 1 followed by IM injection of MVA-BN-filo 1\\*10\\^8 Inf.U on Day 57."},{"id":"BG013","title":"Cohort 2b: Placebo, Placebo, 56-Day Interval","description":"Participants (Healthy Adolescents \\[12-17 years\\]) received IM injection of Placebo 0.9 % saline on Day 1 followed by IM injection of Placebo 0.9 % saline on Day 57."},{"id":"BG014","title":"Cohort 3: Ad26.ZEBOV, MVA-BN-Filo, 28-Day Interval","description":"Participants (Healthy Children \\[4-11 years\\]) received IM injection of Ad26.ZEBOV 5\\*10\\^10 vp on Day 1 followed by IM injection of MVA-BN-filo 1\\*10\\^8 Inf.U on Day 29."},{"id":"BG015","title":"Cohort 3: Placebo, Placebo, 28-Day Interval","description":"Participants (Healthy Children \\[4-11 years\\]) received IM injection of Placebo 0.9 % saline on Day 1 followed by IM injection of Placebo 0.9 % saline on Day 29."},{"id":"BG016","title":"Cohort 3: Ad26.ZEBOV, MVA-BN-Filo, 56-Day Interval","description":"Participants (Healthy Children \\[4-11 years\\]) received IM injection of Ad26.ZEBOV 5\\*10\\^10 vp on Day 1 followed by IM injection of MVA-BN-filo 1\\*10\\^8 Inf.U on Day 57."},{"id":"BG017","title":"Cohort 3: Placebo, Placebo, 56-Day Interval","description":"Participants (Healthy Children \\[4-11 years\\]) received IM injection of Placebo 0.9 % saline on Day 1 followed by IM injection of Placebo 0.9 % saline on Day 57."},{"id":"BG018","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"225"},{"groupId":"BG001","value":"43"},{"groupId":"BG002","value":"224"},{"groupId":"BG003","value":"44"},{"groupId":"BG004","value":"110"},{"groupId":"BG005","value":"22"},{"groupId":"BG006","value":"59"},{"groupId":"BG007","value":"12"},{"groupId":"BG008","value":"59"},{"groupId":"BG009","value":"12"},{"groupId":"BG010","value":"55"},{"groupId":"BG011","value":"11"},{"groupId":"BG012","value":"55"},{"groupId":"BG013","value":"10"},{"groupId":"BG014","value":"54"},{"groupId":"BG015","value":"12"},{"groupId":"BG016","value":"54"},{"groupId":"BG017","value":"12"},{"groupId":"BG018","value":"1073"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"33.3","spread":"12.41"},{"groupId":"BG001","value":"32","spread":"10.43"},{"groupId":"BG002","value":"33.3","spread":"11.52"},{"groupId":"BG003","value":"33.3","spread":"11.57"},{"groupId":"BG004","value":"31.4","spread":"11.53"},{"groupId":"BG005","value":"33.7","spread":"12.31"},{"groupId":"BG006","value":"38.8","spread":"6.61"},{"groupId":"BG007","value":"34.3","spread":"7.66"},{"groupId":"BG008","value":"39","spread":"6.69"},{"groupId":"BG009","value":"42.1","spread":"4.96"},{"groupId":"BG010","value":"14.4","spread":"1.76"},{"groupId":"BG011","value":"14.5","spread":"1.86"},{"groupId":"BG012","value":"14.1","spread":"1.56"},{"groupId":"BG013","value":"14.2","spread":"1.81"},{"groupId":"BG014","value":"7.6","spread":"2.06"},{"groupId":"BG015","value":"7.1","spread":"2.07"},{"groupId":"BG016","value":"7.8","spread":"2.23"},{"groupId":"BG017","value":"7.3","spread":"2.09"},{"groupId":"BG018","value":"28.3","spread":"14.07"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"73"},{"groupId":"BG001","value":"15"},{"groupId":"BG002","value":"71"},{"groupId":"BG003","value":"16"},{"groupId":"BG004","value":"27"},{"groupId":"BG005","value":"8"},{"groupId":"BG006","value":"39"},{"groupId":"BG007","value":"8"},{"groupId":"BG008","value":"42"},{"groupId":"BG009","value":"10"},{"groupId":"BG010","value":"25"},{"groupId":"BG011","value":"5"},{"groupId":"BG012","value":"26"},{"groupId":"BG013","value":"4"},{"groupId":"BG014","value":"27"},{"groupId":"BG015","value":"5"},{"groupId":"BG016","value":"28"},{"groupId":"BG017","value":"5"},{"groupId":"BG018","value":"434"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"152"},{"groupId":"BG001","value":"28"},{"groupId":"BG002","value":"153"},{"groupId":"BG003","value":"28"},{"groupId":"BG004","value":"83"},{"groupId":"BG005","value":"14"},{"groupId":"BG006","value":"20"},{"groupId":"BG007","value":"4"},{"groupId":"BG008","value":"17"},{"groupId":"BG009","value":"2"},{"groupId":"BG010","value":"30"},{"groupId":"BG011","value":"6"},{"groupId":"BG012","value":"29"},{"groupId":"BG013","value":"6"},{"groupId":"BG014","value":"27"},{"groupId":"BG015","value":"7"},{"groupId":"BG016","value":"26"},{"groupId":"BG017","value":"7"},{"groupId":"BG018","value":"639"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"1"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"0"},{"groupId":"BG012","value":"0"},{"groupId":"BG013","value":"0"},{"groupId":"BG014","value":"1"},{"groupId":"BG015","value":"0"},{"groupId":"BG016","value":"1"},{"groupId":"BG017","value":"0"},{"groupId":"BG018","value":"9"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"222"},{"groupId":"BG001","value":"42"},{"groupId":"BG002","value":"222"},{"groupId":"BG003","value":"43"},{"groupId":"BG004","value":"110"},{"groupId":"BG005","value":"21"},{"groupId":"BG006","value":"59"},{"groupId":"BG007","value":"12"},{"groupId":"BG008","value":"59"},{"groupId":"BG009","value":"12"},{"groupId":"BG010","value":"55"},{"groupId":"BG011","value":"11"},{"groupId":"BG012","value":"55"},{"groupId":"BG013","value":"10"},{"groupId":"BG014","value":"53"},{"groupId":"BG015","value":"12"},{"groupId":"BG016","value":"53"},{"groupId":"BG017","value":"12"},{"groupId":"BG018","value":"1063"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"0"},{"groupId":"BG012","value":"0"},{"groupId":"BG013","value":"0"},{"groupId":"BG014","value":"0"},{"groupId":"BG015","value":"0"},{"groupId":"BG016","value":"0"},{"groupId":"BG017","value":"0"},{"groupId":"BG018","value":"1"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"0"},{"groupId":"BG012","value":"0"},{"groupId":"BG013","value":"0"},{"groupId":"BG014","value":"0"},{"groupId":"BG015","value":"0"},{"groupId":"BG016","value":"0"},{"groupId":"BG017","value":"0"},{"groupId":"BG018","value":"0"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"1"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"0"},{"groupId":"BG012","value":"0"},{"groupId":"BG013","value":"0"},{"groupId":"BG014","value":"0"},{"groupId":"BG015","value":"0"},{"groupId":"BG016","value":"0"},{"groupId":"BG017","value":"0"},{"groupId":"BG018","value":"4"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"0"},{"groupId":"BG012","value":"0"},{"groupId":"BG013","value":"0"},{"groupId":"BG014","value":"0"},{"groupId":"BG015","value":"0"},{"groupId":"BG016","value":"0"},{"groupId":"BG017","value":"0"},{"groupId":"BG018","value":"0"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"223"},{"groupId":"BG001","value":"42"},{"groupId":"BG002","value":"224"},{"groupId":"BG003","value":"43"},{"groupId":"BG004","value":"109"},{"groupId":"BG005","value":"22"},{"groupId":"BG006","value":"59"},{"groupId":"BG007","value":"12"},{"groupId":"BG008","value":"59"},{"groupId":"BG009","value":"12"},{"groupId":"BG010","value":"55"},{"groupId":"BG011","value":"11"},{"groupId":"BG012","value":"55"},{"groupId":"BG013","value":"10"},{"groupId":"BG014","value":"54"},{"groupId":"BG015","value":"12"},{"groupId":"BG016","value":"54"},{"groupId":"BG017","value":"12"},{"groupId":"BG018","value":"1068"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"0"},{"groupId":"BG012","value":"0"},{"groupId":"BG013","value":"0"},{"groupId":"BG014","value":"0"},{"groupId":"BG015","value":"0"},{"groupId":"BG016","value":"0"},{"groupId":"BG017","value":"0"},{"groupId":"BG018","value":"1"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"0"},{"groupId":"BG012","value":"0"},{"groupId":"BG013","value":"0"},{"groupId":"BG014","value":"0"},{"groupId":"BG015","value":"0"},{"groupId":"BG016","value":"0"},{"groupId":"BG017","value":"0"},{"groupId":"BG018","value":"0"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"0"},{"groupId":"BG012","value":"0"},{"groupId":"BG013","value":"0"},{"groupId":"BG014","value":"0"},{"groupId":"BG015","value":"0"},{"groupId":"BG016","value":"0"},{"groupId":"BG017","value":"0"},{"groupId":"BG018","value":"0"}]}]}]},{"title":"Region of Enrollment","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"title":"BURKINA FASO","categories":[{"measurements":[{"groupId":"BG000","value":"76"},{"groupId":"BG001","value":"16"},{"groupId":"BG002","value":"73"},{"groupId":"BG003","value":"16"},{"groupId":"BG004","value":"30"},{"groupId":"BG005","value":"1"},{"groupId":"BG006","value":"16"},{"groupId":"BG007","value":"4"},{"groupId":"BG008","value":"14"},{"groupId":"BG009","value":"2"},{"groupId":"BG010","value":"26"},{"groupId":"BG011","value":"5"},{"groupId":"BG012","value":"29"},{"groupId":"BG013","value":"4"},{"groupId":"BG014","value":"25"},{"groupId":"BG015","value":"5"},{"groupId":"BG016","value":"23"},{"groupId":"BG017","value":"4"},{"groupId":"BG018","value":"369"}]}]},{"title":"COTE D'IVOIRE","categories":[{"measurements":[{"groupId":"BG000","value":"38"},{"groupId":"BG001","value":"9"},{"groupId":"BG002","value":"44"},{"groupId":"BG003","value":"6"},{"groupId":"BG004","value":"22"},{"groupId":"BG005","value":"7"},{"groupId":"BG006","value":"8"},{"groupId":"BG007","value":"1"},{"groupId":"BG008","value":"11"},{"groupId":"BG009","value":"2"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"0"},{"groupId":"BG012","value":"0"},{"groupId":"BG013","value":"0"},{"groupId":"BG014","value":"12"},{"groupId":"BG015","value":"3"},{"groupId":"BG016","value":"12"},{"groupId":"BG017","value":"3"},{"groupId":"BG018","value":"178"}]}]},{"title":"KENYA","categories":[{"measurements":[{"groupId":"BG000","value":"28"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"27"},{"groupId":"BG003","value":"5"},{"groupId":"BG004","value":"16"},{"groupId":"BG005","value":"4"},{"groupId":"BG006","value":"14"},{"groupId":"BG007","value":"4"},{"groupId":"BG008","value":"12"},{"groupId":"BG009","value":"3"},{"groupId":"BG010","value":"12"},{"groupId":"BG011","value":"3"},{"groupId":"BG012","value":"13"},{"groupId":"BG013","value":"2"},{"groupId":"BG014","value":"5"},{"groupId":"BG015","value":"1"},{"groupId":"BG016","value":"5"},{"groupId":"BG017","value":"1"},{"groupId":"BG018","value":"158"}]}]},{"title":"UGANDA","categories":[{"measurements":[{"groupId":"BG000","value":"83"},{"groupId":"BG001","value":"15"},{"groupId":"BG002","value":"80"},{"groupId":"BG003","value":"17"},{"groupId":"BG004","value":"42"},{"groupId":"BG005","value":"10"},{"groupId":"BG006","value":"21"},{"groupId":"BG007","value":"3"},{"groupId":"BG008","value":"22"},{"groupId":"BG009","value":"5"},{"groupId":"BG010","value":"17"},{"groupId":"BG011","value":"3"},{"groupId":"BG012","value":"13"},{"groupId":"BG013","value":"4"},{"groupId":"BG014","value":"12"},{"groupId":"BG015","value":"3"},{"groupId":"BG016","value":"14"},{"groupId":"BG017","value":"4"},{"groupId":"BG018","value":"368"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Adverse Events (Day 29)","description":"An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product.","populationDescription":"Full analysis set included all participants who were randomized and received at least 1 dose of study vaccine (Ad26.ZEBOV, MVA-BN-Filo or placebo).","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up to 28 days post-dose 1 (Day 29)","groups":[{"id":"OG000","title":"Cohort 1: Ad26.ZEBOV, MVA-BN-Filo, Ad26.ZEBOV, 28-Day Interval","description":"Participants (healthy adults and elderly) received intramuscular (IM) injection of Ad26.ZEBOV 5\\*10\\^10 viral particles (vp) on Day 1 followed by IM injection of MVA-BN-filo 1\\*10\\^8 infectious units (Inf.U) on Day 29. Subset of participants who earlier received Ad26.ZEBOV and MVA-BN-Filo (at selected sites), afterwards received IM injection of Ad26.ZEBOV 5\\*10\\^10 vp as a booster dose at 1 year post dose 1 (Day 365)."},{"id":"OG001","title":"Cohort 1: Placebo, Placebo, Placebo, 28-Day Interval","description":"Participants (healthy adults and elderly) received IM injection of Placebo 0.9 percent (%) saline on Day 1 followed by IM injection of placebo 0.9 % saline on Day 29. Subset of participants who earlier received placebo(at selected sites), afterwards received IM injection of placebo 0.9 % saline as a booster dose at 1 year post dose 1 (Day 365)."},{"id":"OG002","title":"Cohort 1: Ad26.ZEBOV, MVA-BN-Filo, Ad26.ZEBOV, 56-Day Interval","description":"Participants (healthy adults and elderly) received IM injection of Ad26.ZEBOV 5\\*10\\^10 vp on Day 1 followed by IM injection of MVA-BN-filo Inf.U on Day 57. Subset of participants who earlier received Ad26.ZEBOV and MVA-BN-Filo (at selected sites), afterwards received IM injection of Ad26.ZEBOV 5\\*10\\^10 vp as a booster dose at 1 year post dose 1 (Day 365)."},{"id":"OG003","title":"Cohort 1: Placebo, Placebo, Placebo, 56-Day Interval","description":"Participants (healthy adults and elderly) received placebo 0.9% saline on Day 1 followed by IM injection of placebo 0.9% saline on Day 57. Subset of participants who earlier received Placebo (at selected sites), afterwards received IM injection of Placebo 0.9 % saline as a booster dose at 1 year post dose 1 (Day 365)."},{"id":"OG004","title":"Cohort 1: Ad26.ZEBOV, MVA-BN-Filo, 84-Day Interval","description":"Participants (healthy adults and elderly) received IM injection of Ad26.ZEBOV 5\\*10\\^10 vp on Day 1 followed by IM injection of MVA-BN-filo 1\\*10\\^8 Inf.U on Day 85."},{"id":"OG005","title":"Cohort 1: Placebo, Placebo, 84-Day Interval","description":"Participants (healthy adults and elderly) received IM injection of Placebo 0.9 % saline on Day 1 followed by IM injection of Placebo 0.9 % saline on Day 85."},{"id":"OG006","title":"Cohort 2a: Ad26.ZEBOV, MVA-BN-Filo, 28-Day Interval","description":"Participants (human immunodeficiency virus \\[HIV\\]-infected adults) received IM injection of Ad26.ZEBOV 5\\*10\\^10 vp on Day 1 followed by IM injection of MVA-BN-filo 1\\*10\\^8 Inf.U on Day 29."},{"id":"OG007","title":"Cohort 2a: Placebo, Placebo, 28-Day Interval","description":"Participants (HIV-infected adults) received IM injection of Placebo 0.9 % saline on Day 1 followed by IM injection of Placebo 0.9 % saline on Day 29."},{"id":"OG008","title":"Cohort 2a: Ad26.ZEBOV, MVA-BN-Filo, 56-Day Interval","description":"Participants (HIV-infected adults) received IM injection of Ad26.ZEBOV 5\\*10\\^10 vp on Day 1 followed by IM injection of MVA-BN-filo 1\\*10\\^8 Inf.U on Day 57."},{"id":"OG009","title":"Cohort 2a: Placebo, Placebo, 56-Day Interval","description":"Participants (HIV-infected adults) received IM injection of Placebo 0.9 % saline on Day 1 followed by IM injection of Placebo 0.9 % saline on Day 57."},{"id":"OG010","title":"Cohort 2b: Ad26.ZEBOV, MVA-BN-Filo, 28-Day Interval","description":"Participants (Healthy Adolescents \\[12-17 years\\]) received IM injection of Ad26.ZEBOV 5\\*10\\^10 vp on Day 1 followed by IM injection of MVA-BN-filo 1\\*10\\^8 Inf.U on Day 29."},{"id":"OG011","title":"Cohort 2b: Placebo, Placebo, 28-Day Interval","description":"Participants (Healthy Adolescents \\[12-17 years\\]) received IM injection of Placebo 0.9 % saline on Day 1 followed by IM injection of Placebo 0.9 % saline on Day 29."},{"id":"OG012","title":"Cohort 2b: Ad26.ZEBOV, MVA-BN-Filo, 56-Day Interval","description":"Participants ((Healthy Adolescents \\[12-17 years\\]) received IM injection of Ad26.ZEBOV 5\\*10\\^10 vp on Day 1 followed by IM injection of MVA-BN-filo 1\\*10\\^8 Inf.U on Day 57."},{"id":"OG013","title":"Cohort 2b: Placebo, Placebo, 56-Day Interval","description":"Participants (Healthy Adolescents \\[12-17 years\\]) received IM injection of Placebo 0.9 % saline on Day 1 followed by IM injection of Placebo 0.9 % saline on Day 57."},{"id":"OG014","title":"Cohort 3: Ad26.ZEBOV, MVA-BN-Filo, 28-Day Interval","description":"Participants (Healthy Children \\[4-11 years\\]) received IM injection of Ad26.ZEBOV 5\\*10\\^10 vp on Day 1 followed by IM injection of MVA-BN-filo 1\\*10\\^8 Inf.U on Day 29."},{"id":"OG015","title":"Cohort 3: Placebo, Placebo, 28-Day Interval","description":"Participants (Healthy Children \\[4-11 years\\]) received IM injection of Placebo 0.9 % saline on Day 1 followed by IM injection of Placebo 0.9 % saline on Day 29."},{"id":"OG016","title":"Cohort 3: Ad26.ZEBOV, MVA-BN-Filo, 56-Day Interval","description":"Participants (Healthy Children \\[4-11 years\\]) received IM injection of Ad26.ZEBOV 5\\*10\\^10 vp on Day 1 followed by IM injection of MVA-BN-filo 1\\*10\\^8 Inf.U on Day 57."},{"id":"OG017","title":"Cohort 3: Placebo, Placebo, 56-Day Interval","description":"Participants (Healthy Children \\[4-11 years\\]) received IM injection of Placebo 0.9 % saline on Day 1 followed by IM injection of Placebo 0.9 % saline on Day 57."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"225"},{"groupId":"OG001","value":"43"},{"groupId":"OG002","value":"224"},{"groupId":"OG003","value":"44"},{"groupId":"OG004","value":"110"},{"groupId":"OG005","value":"22"},{"groupId":"OG006","value":"59"},{"groupId":"OG007","value":"12"},{"groupId":"OG008","value":"59"},{"groupId":"OG009","value":"12"},{"groupId":"OG010","value":"55"},{"groupId":"OG011","value":"11"},{"groupId":"OG012","value":"55"},{"groupId":"OG013","value":"10"},{"groupId":"OG014","value":"54"},{"groupId":"OG015","value":"12"},{"groupId":"OG016","value":"54"},{"groupId":"OG017","value":"12"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"96"},{"groupId":"OG001","value":"17"},{"groupId":"OG002","value":"68"},{"groupId":"OG003","value":"17"},{"groupId":"OG004","value":"37"},{"groupId":"OG005","value":"6"},{"groupId":"OG006","value":"25"},{"groupId":"OG007","value":"7"},{"groupId":"OG008","value":"25"},{"groupId":"OG009","value":"3"},{"groupId":"OG010","value":"28"},{"groupId":"OG011","value":"4"},{"groupId":"OG012","value":"31"},{"groupId":"OG013","value":"5"},{"groupId":"OG014","value":"23"},{"groupId":"OG015","value":"4"},{"groupId":"OG016","value":"19"},{"groupId":"OG017","value":"4"}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Adverse Events (AEs) (28-Day Interval)","description":"An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product.","populationDescription":"Full analysis set included all participants who were randomized and received at least 1 dose of study vaccine (Ad26.ZEBOV, MVA-BN-Filo or placebo). Here, 'N' (number of participants analyzed) signifies those participants who were evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up to 28 days post-dose 2 (Day 57 for Cohorts 1, 2a, 2b and 3 [28-Day Interval])","groups":[{"id":"OG000","title":"Cohort 1: Ad26.ZEBOV, MVA-BN-Filo, Ad26.ZEBOV, 28-Day Interval","description":"Participants (healthy adults and elderly) received intramuscular (IM) injection of Ad26.ZEBOV 5\\*10\\^10 viral particles (vp) on Day 1 followed by IM injection of MVA-BN-filo 1\\*10\\^8 infectious units (Inf.U) on Day 29. Subset of participants who earlier received Ad26.ZEBOV and MVA-BN-Filo (at selected sites), afterwards received IM injection of Ad26.ZEBOV 5\\*10\\^10 vp as a booster dose at 1 year post dose 1 (Day 365)."},{"id":"OG001","title":"Cohort 1: Placebo, Placebo, Placebo, 28-Day Interval","description":"Participants (healthy adults and elderly) received IM injection of Placebo 0.9 percent (%) saline on Day 1 followed by IM injection of placebo 0.9 % saline on Day 29. Subset of participants who earlier received placebo(at selected sites), afterwards received IM injection of placebo 0.9 % saline as a booster dose at 1 year post dose 1 (Day 365)."},{"id":"OG002","title":"Cohort 2a: Ad26.ZEBOV, MVA-BN-Filo, 28-Day Interval","description":"Participants (human immunodeficiency virus \\[HIV\\]-infected adults) received IM injection of Ad26.ZEBOV 5\\*10\\^10 vp on Day 1 followed by IM injection of MVA-BN-filo 1\\*10\\^8 Inf.U on Day 29."},{"id":"OG003","title":"Cohort 2a: Placebo, Placebo, 28-Day Interval","description":"Participants (HIV-infected adults) received IM injection of Placebo 0.9 % saline on Day 1 followed by IM injection of Placebo 0.9 % saline on Day 29."},{"id":"OG004","title":"Cohort 2b: Ad26.ZEBOV, MVA-BN-Filo, 28-Day Interval","description":"Participants (Healthy Adolescents \\[12-17 years\\]) received IM injection of Ad26.ZEBOV 5\\*10\\^10 vp on Day 1 followed by IM injection of MVA-BN-filo 1\\*10\\^8 Inf.U on Day 29."},{"id":"OG005","title":"Cohort 2b: Placebo, Placebo, 28-Day Interval","description":"Participants (Healthy Adolescents \\[12-17 years\\]) received IM injection of Placebo 0.9 % saline on Day 1 followed by IM injection of Placebo 0.9 % saline on Day 29."},{"id":"OG006","title":"Cohort 3: Ad26.ZEBOV, MVA-BN-Filo, 28-Day Interval","description":"Participants (Healthy Children \\[4-11 years\\]) received IM injection of Ad26.ZEBOV 5\\*10\\^10 vp on Day 1 followed by IM injection of MVA-BN-filo 1\\*10\\^8 Inf.U on Day 29."},{"id":"OG007","title":"Cohort 3: Placebo, Placebo, 28-Day Interval","description":"Participants (Healthy Children \\[4-11 years\\]) received IM injection of Placebo 0.9 % saline on Day 1 followed by IM injection of Placebo 0.9 % saline on Day 29."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"219"},{"groupId":"OG001","value":"39"},{"groupId":"OG002","value":"58"},{"groupId":"OG003","value":"12"},{"groupId":"OG004","value":"55"},{"groupId":"OG005","value":"10"},{"groupId":"OG006","value":"54"},{"groupId":"OG007","value":"12"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"74"},{"groupId":"OG001","value":"15"},{"groupId":"OG002","value":"22"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"18"},{"groupId":"OG005","value":"4"},{"groupId":"OG006","value":"20"},{"groupId":"OG007","value":"7"}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Adverse Events (56-day Interval)","description":"An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product.","populationDescription":"Full analysis set included all participants who were randomized and received at least 1 dose of study vaccine (Ad26.ZEBOV, MVA-BN-Filo or placebo). Here, 'N' (number of participants analyzed) signifies those participants who were evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up 28 days post-dose 2 (Day 85 for Cohorts 1, 2a, 2b and 3 [56-Day Interval])","groups":[{"id":"OG000","title":"Cohort 1: Ad26.ZEBOV, MVA-BN-Filo, Ad26.ZEBOV, 56-Day Interval","description":"Participants (healthy adults and elderly) received IM injection of Ad26.ZEBOV 5\\*10\\^10 vp on Day 1 followed by IM injection of MVA-BN-filo Inf.U on Day 57. Subset of participants who earlier received Ad26.ZEBOV and MVA-BN-Filo (at selected sites), afterwards received IM injection of Ad26.ZEBOV 5\\*10\\^10 vp as a booster dose at 1 year post dose 1 (Day 365)."},{"id":"OG001","title":"Cohort 1: Placebo, Placebo, Placebo, 56-Day Interval","description":"Participants (healthy adults and elderly) received placebo 0.9% saline on Day 1 followed by IM injection of placebo 0.9% saline on Day 57. Subset of participants who earlier received Placebo (at selected sites), afterwards received IM injection of Placebo 0.9 % saline as a booster dose at 1 year post dose 1 (Day 365)."},{"id":"OG002","title":"Cohort 2a: Ad26.ZEBOV, MVA-BN-Filo, 56-Day Interval","description":"Participants (HIV-infected adults) received IM injection of Ad26.ZEBOV 5\\*10\\^10 vp on Day 1 followed by IM injection of MVA-BN-filo 1\\*10\\^8 Inf.U on Day 57."},{"id":"OG003","title":"Cohort 2a: Placebo, Placebo, 56-Day Interval","description":"Participants (HIV-infected adults) received IM injection of Placebo 0.9 % saline on Day 1 followed by IM injection of Placebo 0.9 % saline on Day 57."},{"id":"OG004","title":"Cohort 2b: Ad26.ZEBOV, MVA-BN-Filo, 56-Day Interval","description":"Participants ((Healthy Adolescents \\[12-17 years\\]) received IM injection of Ad26.ZEBOV 5\\*10\\^10 vp on Day 1 followed by IM injection of MVA-BN-filo 1\\*10\\^8 Inf.U on Day 57."},{"id":"OG005","title":"Cohort 2b: Placebo, Placebo, 56-Day Interval","description":"Participants (Healthy Adolescents \\[12-17 years\\]) received IM injection of Placebo 0.9 % saline on Day 1 followed by IM injection of Placebo 0.9 % saline on Day 57."},{"id":"OG006","title":"Cohort 3: Ad26.ZEBOV, MVA-BN-Filo, 56-Day Interval","description":"Participants (Healthy Children \\[4-11 years\\]) received IM injection of Ad26.ZEBOV 5\\*10\\^10 vp on Day 1 followed by IM injection of MVA-BN-filo 1\\*10\\^8 Inf.U on Day 57."},{"id":"OG007","title":"Cohort 3: Placebo, Placebo, 56-Day Interval","description":"Participants (Healthy Children \\[4-11 years\\]) received IM injection of Placebo 0.9 % saline on Day 1 followed by IM injection of Placebo 0.9 % saline on Day 57."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"200"},{"groupId":"OG001","value":"39"},{"groupId":"OG002","value":"59"},{"groupId":"OG003","value":"12"},{"groupId":"OG004","value":"54"},{"groupId":"OG005","value":"10"},{"groupId":"OG006","value":"54"},{"groupId":"OG007","value":"11"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"58"},{"groupId":"OG001","value":"13"},{"groupId":"OG002","value":"22"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"26"},{"groupId":"OG005","value":"4"},{"groupId":"OG006","value":"22"},{"groupId":"OG007","value":"8"}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Adverse Events (84-day Interval)","description":"An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product.","populationDescription":"Full analysis set included all participants who were randomized and received at least 1 dose of study vaccine (Ad26.ZEBOV, MVA-BN-Filo or placebo). Here, 'N' (number of participants analyzed) signifies those participants who were evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up to 28 days post-dose 2 (Day 113 for Cohort 1 [84-Day Interval])","groups":[{"id":"OG000","title":"Cohort 1: Ad26.ZEBOV, MVA-BN-Filo, 84-Day Interval","description":"Participants (healthy adults and elderly) received IM injection of Ad26.ZEBOV 5\\*10\\^10 vp on Day 1 followed by IM injection of MVA-BN-filo 1\\*10\\^8 Inf.U on Day 85."},{"id":"OG001","title":"Cohort 1: Placebo, Placebo, 84-Day Interval","description":"Participants (healthy adults and elderly) received IM injection of Placebo 0.9 % saline on Day 1 followed by IM injection of Placebo 0.9 % saline on Day 85."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"98"},{"groupId":"OG001","value":"21"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"7"}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Adverse Events Post-dose 3 (Day 393)","description":"An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product.","populationDescription":"Full analysis set included all participants who were randomized and received at least 1 dose of study vaccine (Ad26.ZEBOV, MVA-BN-Filo or placebo).","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up 28 days post-dose 3 (Day 393)","groups":[{"id":"OG000","title":"Cohort 1: Ad26.ZEBOV, MVA-BN-Filo, Ad26.ZEBOV, 28-Day Interval","description":"Participants (healthy adults and elderly) received intramuscular (IM) injection of Ad26.ZEBOV 5\\*10\\^10 viral particles (vp) on Day 1 followed by IM injection of MVA-BN-filo 1\\*10\\^8 infectious units (Inf.U) on Day 29. Subset of participants who earlier received Ad26.ZEBOV and MVA-BN-Filo (at selected sites), afterwards received IM injection of Ad26.ZEBOV 5\\*10\\^10 vp as a booster dose at 1 year post dose 1 (Day 365)."},{"id":"OG001","title":"Cohort 1: Placebo, Placebo, Placebo, 28-Day Interval","description":"Participants (healthy adults and elderly) received IM injection of Placebo 0.9 percent (%) saline on Day 1 followed by IM injection of placebo 0.9 % saline on Day 29. Subset of participants who earlier received placebo(at selected sites), afterwards received IM injection of placebo 0.9 % saline as a booster dose at 1 year post dose 1 (Day 365)."},{"id":"OG002","title":"Cohort 1: Ad26.ZEBOV, MVA-BN-Filo, Ad26.ZEBOV, 56-Day Interval","description":"Participants (healthy adults and elderly) received IM injection of Ad26.ZEBOV 5\\*10\\^10 vp on Day 1 followed by IM injection of MVA-BN-filo Inf.U on Day 57. Subset of participants who earlier received Ad26.ZEBOV and MVA-BN-Filo (at selected sites), afterwards received IM injection of Ad26.ZEBOV 5\\*10\\^10 vp as a booster dose at 1 year post dose 1 (Day 365)."},{"id":"OG003","title":"Cohort 1: Placebo, Placebo, Placebo, 56-Day Interval","description":"Participants (healthy adults and elderly) received placebo 0.9% saline on Day 1 followed by IM injection of placebo 0.9% saline on Day 57. Subset of participants who earlier received Placebo (at selected sites), afterwards received IM injection of Placebo 0.9 % saline as a booster dose at 1 year post dose 1 (Day 365)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"39"},{"groupId":"OG003","value":"9"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"14"},{"groupId":"OG003","value":"0"}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Serious Adverse Events","description":"A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.","populationDescription":"Full analysis set included all participants who were randomized and received at least 1 dose of study vaccine (Ad26.ZEBOV, MVA-BN-Filo or placebo).","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up to 3 years and 3 months","groups":[{"id":"OG000","title":"Cohort 1: Ad26.ZEBOV, MVA-BN-Filo, Ad26.ZEBOV, 28-Day Interval","description":"Participants (healthy adults and elderly) received intramuscular (IM) injection of Ad26.ZEBOV 5\\*10\\^10 viral particles (vp) on Day 1 followed by IM injection of MVA-BN-filo 1\\*10\\^8 infectious units (Inf.U) on Day 29. Subset of participants who earlier received Ad26.ZEBOV and MVA-BN-Filo (at selected sites), afterwards received IM injection of Ad26.ZEBOV 5\\*10\\^10 vp as a booster dose at 1 year post dose 1 (Day 365)."},{"id":"OG001","title":"Cohort 1: Placebo, Placebo, Placebo, 28-Day Interval","description":"Participants (healthy adults and elderly) received IM injection of Placebo 0.9 percent (%) saline on Day 1 followed by IM injection of placebo 0.9 % saline on Day 29. Subset of participants who earlier received placebo(at selected sites), afterwards received IM injection of placebo 0.9 % saline as a booster dose at 1 year post dose 1 (Day 365)."},{"id":"OG002","title":"Cohort 1: Ad26.ZEBOV, MVA-BN-Filo, Ad26.ZEBOV, 56-Day Interval","description":"Participants (healthy adults and elderly) received IM injection of Ad26.ZEBOV 5\\*10\\^10 vp on Day 1 followed by IM injection of MVA-BN-filo Inf.U on Day 57. Subset of participants who earlier received Ad26.ZEBOV and MVA-BN-Filo (at selected sites), afterwards received IM injection of Ad26.ZEBOV 5\\*10\\^10 vp as a booster dose at 1 year post dose 1 (Day 365)."},{"id":"OG003","title":"Cohort 1: Placebo, Placebo, Placebo, 56-Day Interval","description":"Participants (healthy adults and elderly) received placebo 0.9% saline on Day 1 followed by IM injection of placebo 0.9% saline on Day 57. Subset of participants who earlier received Placebo (at selected sites), afterwards received IM injection of Placebo 0.9 % saline as a booster dose at 1 year post dose 1 (Day 365)."},{"id":"OG004","title":"Cohort 1: Ad26.ZEBOV, MVA-BN-Filo, 84-Day Interval","description":"Participants (healthy adults and elderly) received IM injection of Ad26.ZEBOV 5\\*10\\^10 vp on Day 1 followed by IM injection of MVA-BN-filo 1\\*10\\^8 Inf.U on Day 85."},{"id":"OG005","title":"Cohort 1: Placebo, Placebo, 84-Day Interval","description":"Participants (healthy adults and elderly) received IM injection of Placebo 0.9 % saline on Day 1 followed by IM injection of Placebo 0.9 % saline on Day 85."},{"id":"OG006","title":"Cohort 2a: Ad26.ZEBOV, MVA-BN-Filo, 28-Day Interval","description":"Participants (human immunodeficiency virus \\[HIV\\]-infected adults) received IM injection of Ad26.ZEBOV 5\\*10\\^10 vp on Day 1 followed by IM injection of MVA-BN-filo 1\\*10\\^8 Inf.U on Day 29."},{"id":"OG007","title":"Cohort 2a: Placebo, Placebo, 28-Day Interval","description":"Participants (HIV-infected adults) received IM injection of Placebo 0.9 % saline on Day 1 followed by IM injection of Placebo 0.9 % saline on Day 29."},{"id":"OG008","title":"Cohort 2a: Ad26.ZEBOV, MVA-BN-Filo, 56-Day Interval","description":"Participants (HIV-infected adults) received IM injection of Ad26.ZEBOV 5\\*10\\^10 vp on Day 1 followed by IM injection of MVA-BN-filo 1\\*10\\^8 Inf.U on Day 57."},{"id":"OG009","title":"Cohort 2a: Placebo, Placebo, 56-Day Interval","description":"Participants (HIV-infected adults) received IM injection of Placebo 0.9 % saline on Day 1 followed by IM injection of Placebo 0.9 % saline on Day 57."},{"id":"OG010","title":"Cohort 2b: Ad26.ZEBOV, MVA-BN-Filo, 28-Day Interval","description":"Participants (Healthy Adolescents \\[12-17 years\\]) received IM injection of Ad26.ZEBOV 5\\*10\\^10 vp on Day 1 followed by IM injection of MVA-BN-filo 1\\*10\\^8 Inf.U on Day 29."},{"id":"OG011","title":"Cohort 2b: Placebo, Placebo, 28-Day Interval","description":"Participants (Healthy Adolescents \\[12-17 years\\]) received IM injection of Placebo 0.9 % saline on Day 1 followed by IM injection of Placebo 0.9 % saline on Day 29."},{"id":"OG012","title":"Cohort 2b: Ad26.ZEBOV, MVA-BN-Filo, 56-Day Interval","description":"Participants ((Healthy Adolescents \\[12-17 years\\]) received IM injection of Ad26.ZEBOV 5\\*10\\^10 vp on Day 1 followed by IM injection of MVA-BN-filo 1\\*10\\^8 Inf.U on Day 57."},{"id":"OG013","title":"Cohort 2b: Placebo, Placebo, 56-Day Interval","description":"Participants (Healthy Adolescents \\[12-17 years\\]) received IM injection of Placebo 0.9 % saline on Day 1 followed by IM injection of Placebo 0.9 % saline on Day 57."},{"id":"OG014","title":"Cohort 3: Ad26.ZEBOV, MVA-BN-Filo, 28-Day Interval","description":"Participants (Healthy Children \\[4-11 years\\]) received IM injection of Ad26.ZEBOV 5\\*10\\^10 vp on Day 1 followed by IM injection of MVA-BN-filo 1\\*10\\^8 Inf.U on Day 29."},{"id":"OG015","title":"Cohort 3: Placebo, Placebo, 28-Day Interval","description":"Participants (Healthy Children \\[4-11 years\\]) received IM injection of Placebo 0.9 % saline on Day 1 followed by IM injection of Placebo 0.9 % saline on Day 29."},{"id":"OG016","title":"Cohort 3: Ad26.ZEBOV, MVA-BN-Filo, 56-Day Interval","description":"Participants (Healthy Children \\[4-11 years\\]) received IM injection of Ad26.ZEBOV 5\\*10\\^10 vp on Day 1 followed by IM injection of MVA-BN-filo 1\\*10\\^8 Inf.U on Day 57."},{"id":"OG017","title":"Cohort 3: Placebo, Placebo, 56-Day Interval","description":"Participants (Healthy Children \\[4-11 years\\]) received IM injection of Placebo 0.9 % saline on Day 1 followed by IM injection of Placebo 0.9 % saline on Day 57."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"225"},{"groupId":"OG001","value":"43"},{"groupId":"OG002","value":"224"},{"groupId":"OG003","value":"44"},{"groupId":"OG004","value":"110"},{"groupId":"OG005","value":"22"},{"groupId":"OG006","value":"59"},{"groupId":"OG007","value":"12"},{"groupId":"OG008","value":"59"},{"groupId":"OG009","value":"12"},{"groupId":"OG010","value":"55"},{"groupId":"OG011","value":"11"},{"groupId":"OG012","value":"55"},{"groupId":"OG013","value":"10"},{"groupId":"OG014","value":"54"},{"groupId":"OG015","value":"12"},{"groupId":"OG016","value":"54"},{"groupId":"OG017","value":"12"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"6"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"1"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"1"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"1"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"1"}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Immediate Reportable Events (IREs)","description":"The following neuroinflammatory disorders were considered immediate reportable events which had to be reported to the sponsor within 24 hours of becoming aware of the event. Neuroinflammatory disorders included: cranial nerve disorders including paralyses/paresis (example: bell's palsy), optic neuritis, multiple sclerosis, transverse myelitis, guillain-barre syndrome including miller fisher syndrome, bickerstaff's encephalitis and other variants, acute disseminated encephalomyelitis, including site-specific variants (example: non-infectious encephalitis, encephalomyelitis, myelitis, myeloradiculomyelitis), myasthenia gravis and lambert-eaton myasthenic syndrome, immune-mediated peripheral neuropathies and plexopathies, including chronic inflammatory, demyelinating polyneuropathy, multifocal motor neuropathy, and polyneuropathies associated with monoclonal gammopathy, narcolepsy, isolated paresthesia of more than 7 days duration.","populationDescription":"Full analysis set included all participants who were randomized and received at least 1 dose of study vaccine (Ad26.ZEBOV, MVA-BN-Filo or placebo).","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up to 3 years and 3 months","groups":[{"id":"OG000","title":"Cohort 1: Ad26.ZEBOV, MVA-BN-Filo, Ad26.ZEBOV, 28-Day Interval","description":"Participants (healthy adults and elderly) received intramuscular (IM) injection of Ad26.ZEBOV 5\\*10\\^10 viral particles (vp) on Day 1 followed by IM injection of MVA-BN-filo 1\\*10\\^8 infectious units (Inf.U) on Day 29. Subset of participants who earlier received Ad26.ZEBOV and MVA-BN-Filo (at selected sites), afterwards received IM injection of Ad26.ZEBOV 5\\*10\\^10 vp as a booster dose at 1 year post dose 1 (Day 365)."},{"id":"OG001","title":"Cohort 1: Placebo, Placebo, Placebo, 28-Day Interval","description":"Participants (healthy adults and elderly) received IM injection of Placebo 0.9 percent (%) saline on Day 1 followed by IM injection of placebo 0.9 % saline on Day 29. Subset of participants who earlier received placebo(at selected sites), afterwards received IM injection of placebo 0.9 % saline as a booster dose at 1 year post dose 1 (Day 365)."},{"id":"OG002","title":"Cohort 1: Ad26.ZEBOV, MVA-BN-Filo, Ad26.ZEBOV, 56-Day Interval","description":"Participants (healthy adults and elderly) received IM injection of Ad26.ZEBOV 5\\*10\\^10 vp on Day 1 followed by IM injection of MVA-BN-filo Inf.U on Day 57. Subset of participants who earlier received Ad26.ZEBOV and MVA-BN-Filo (at selected sites), afterwards received IM injection of Ad26.ZEBOV 5\\*10\\^10 vp as a booster dose at 1 year post dose 1 (Day 365)."},{"id":"OG003","title":"Cohort 1: Placebo, Placebo, Placebo, 56-Day Interval","description":"Participants (healthy adults and elderly) received placebo 0.9% saline on Day 1 followed by IM injection of placebo 0.9% saline on Day 57. Subset of participants who earlier received Placebo (at selected sites), afterwards received IM injection of Placebo 0.9 % saline as a booster dose at 1 year post dose 1 (Day 365)."},{"id":"OG004","title":"Cohort 1: Ad26.ZEBOV, MVA-BN-Filo, 84-Day Interval","description":"Participants (healthy adults and elderly) received IM injection of Ad26.ZEBOV 5\\*10\\^10 vp on Day 1 followed by IM injection of MVA-BN-filo 1\\*10\\^8 Inf.U on Day 85."},{"id":"OG005","title":"Cohort 1: Placebo, Placebo, 84-Day Interval","description":"Participants (healthy adults and elderly) received IM injection of Placebo 0.9 % saline on Day 1 followed by IM injection of Placebo 0.9 % saline on Day 85."},{"id":"OG006","title":"Cohort 2a: Ad26.ZEBOV, MVA-BN-Filo, 28-Day Interval","description":"Participants (human immunodeficiency virus \\[HIV\\]-infected adults) received IM injection of Ad26.ZEBOV 5\\*10\\^10 vp on Day 1 followed by IM injection of MVA-BN-filo 1\\*10\\^8 Inf.U on Day 29."},{"id":"OG007","title":"Cohort 2a: Placebo, Placebo, 28-Day Interval","description":"Participants (HIV-infected adults) received IM injection of Placebo 0.9 % saline on Day 1 followed by IM injection of Placebo 0.9 % saline on Day 29."},{"id":"OG008","title":"Cohort 2a: Ad26.ZEBOV, MVA-BN-Filo, 56-Day Interval","description":"Participants (HIV-infected adults) received IM injection of Ad26.ZEBOV 5\\*10\\^10 vp on Day 1 followed by IM injection of MVA-BN-filo 1\\*10\\^8 Inf.U on Day 57."},{"id":"OG009","title":"Cohort 2a: Placebo, Placebo, 56-Day Interval","description":"Participants (HIV-infected adults) received IM injection of Placebo 0.9 % saline on Day 1 followed by IM injection of Placebo 0.9 % saline on Day 57."},{"id":"OG010","title":"Cohort 2b: Ad26.ZEBOV, MVA-BN-Filo, 28-Day Interval","description":"Participants (Healthy Adolescents \\[12-17 years\\]) received IM injection of Ad26.ZEBOV 5\\*10\\^10 vp on Day 1 followed by IM injection of MVA-BN-filo 1\\*10\\^8 Inf.U on Day 29."},{"id":"OG011","title":"Cohort 2b: Placebo, Placebo, 28-Day Interval","description":"Participants (Healthy Adolescents \\[12-17 years\\]) received IM injection of Placebo 0.9 % saline on Day 1 followed by IM injection of Placebo 0.9 % saline on Day 29."},{"id":"OG012","title":"Cohort 2b: Ad26.ZEBOV, MVA-BN-Filo, 56-Day Interval","description":"Participants ((Healthy Adolescents \\[12-17 years\\]) received IM injection of Ad26.ZEBOV 5\\*10\\^10 vp on Day 1 followed by IM injection of MVA-BN-filo 1\\*10\\^8 Inf.U on Day 57."},{"id":"OG013","title":"Cohort 2b: Placebo, Placebo, 56-Day Interval","description":"Participants (Healthy Adolescents \\[12-17 years\\]) received IM injection of Placebo 0.9 % saline on Day 1 followed by IM injection of Placebo 0.9 % saline on Day 57."},{"id":"OG014","title":"Cohort 3: Ad26.ZEBOV, MVA-BN-Filo, 28-Day Interval","description":"Participants (Healthy Children \\[4-11 years\\]) received IM injection of Ad26.ZEBOV 5\\*10\\^10 vp on Day 1 followed by IM injection of MVA-BN-filo 1\\*10\\^8 Inf.U on Day 29."},{"id":"OG015","title":"Cohort 3: Placebo, Placebo, 28-Day Interval","description":"Participants (Healthy Children \\[4-11 years\\]) received IM injection of Placebo 0.9 % saline on Day 1 followed by IM injection of Placebo 0.9 % saline on Day 29."},{"id":"OG016","title":"Cohort 3: Ad26.ZEBOV, MVA-BN-Filo, 56-Day Interval","description":"Participants (Healthy Children \\[4-11 years\\]) received IM injection of Ad26.ZEBOV 5\\*10\\^10 vp on Day 1 followed by IM injection of MVA-BN-filo 1\\*10\\^8 Inf.U on Day 57."},{"id":"OG017","title":"Cohort 3: Placebo, Placebo, 56-Day Interval","description":"Participants (Healthy Children \\[4-11 years\\]) received IM injection of Placebo 0.9 % saline on Day 1 followed by IM injection of Placebo 0.9 % saline on Day 57."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"225"},{"groupId":"OG001","value":"43"},{"groupId":"OG002","value":"224"},{"groupId":"OG003","value":"44"},{"groupId":"OG004","value":"110"},{"groupId":"OG005","value":"22"},{"groupId":"OG006","value":"59"},{"groupId":"OG007","value":"12"},{"groupId":"OG008","value":"59"},{"groupId":"OG009","value":"12"},{"groupId":"OG010","value":"55"},{"groupId":"OG011","value":"11"},{"groupId":"OG012","value":"55"},{"groupId":"OG013","value":"10"},{"groupId":"OG014","value":"54"},{"groupId":"OG015","value":"12"},{"groupId":"OG016","value":"54"},{"groupId":"OG017","value":"12"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"0"}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Solicited Local Adverse Events (Day 8)","description":"An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. Solicited local AEs were pre-defined local (at the injection site) AEs for which participants were specifically questioned and which were noted by participants in their diary for 7 days post vaccination. Solicited local AEs were: injection site pain/tenderness, erythema, induration/swelling, itching at the vaccination site.","populationDescription":"Full analysis set included all participants who were randomized and received at least 1 dose of study vaccine (Ad26.ZEBOV, MVA-BN-Filo or placebo).","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"7 days post-dose 1 (Day 8)","groups":[{"id":"OG000","title":"Cohort 1: Ad26.ZEBOV, MVA-BN-Filo, Ad26.ZEBOV, 28-Day Interval","description":"Participants (healthy adults and elderly) received intramuscular (IM) injection of Ad26.ZEBOV 5\\*10\\^10 viral particles (vp) on Day 1 followed by IM injection of MVA-BN-filo 1\\*10\\^8 infectious units (Inf.U) on Day 29. Subset of participants who earlier received Ad26.ZEBOV and MVA-BN-Filo (at selected sites), afterwards received IM injection of Ad26.ZEBOV 5\\*10\\^10 vp as a booster dose at 1 year post dose 1 (Day 365)."},{"id":"OG001","title":"Cohort 1: Placebo, Placebo, Placebo, 28-Day Interval","description":"Participants (healthy adults and elderly) received IM injection of Placebo 0.9 percent (%) saline on Day 1 followed by IM injection of placebo 0.9 % saline on Day 29. Subset of participants who earlier received placebo(at selected sites), afterwards received IM injection of placebo 0.9 % saline as a booster dose at 1 year post dose 1 (Day 365)."},{"id":"OG002","title":"Cohort 1: Ad26.ZEBOV, MVA-BN-Filo, Ad26.ZEBOV, 56-Day Interval","description":"Participants (healthy adults and elderly) received IM injection of Ad26.ZEBOV 5\\*10\\^10 vp on Day 1 followed by IM injection of MVA-BN-filo Inf.U on Day 57. Subset of participants who earlier received Ad26.ZEBOV and MVA-BN-Filo (at selected sites), afterwards received IM injection of Ad26.ZEBOV 5\\*10\\^10 vp as a booster dose at 1 year post dose 1 (Day 365)."},{"id":"OG003","title":"Cohort 1: Placebo, Placebo, Placebo, 56-Day Interval","description":"Participants (healthy adults and elderly) received placebo 0.9% saline on Day 1 followed by IM injection of placebo 0.9% saline on Day 57. Subset of participants who earlier received Placebo (at selected sites), afterwards received IM injection of Placebo 0.9 % saline as a booster dose at 1 year post dose 1 (Day 365)."},{"id":"OG004","title":"Cohort 1: Ad26.ZEBOV, MVA-BN-Filo, 84-Day Interval","description":"Participants (healthy adults and elderly) received IM injection of Ad26.ZEBOV 5\\*10\\^10 vp on Day 1 followed by IM injection of MVA-BN-filo 1\\*10\\^8 Inf.U on Day 85."},{"id":"OG005","title":"Cohort 1: Placebo, Placebo, 84-Day Interval","description":"Participants (healthy adults and elderly) received IM injection of Placebo 0.9 % saline on Day 1 followed by IM injection of Placebo 0.9 % saline on Day 85."},{"id":"OG006","title":"Cohort 2a: Ad26.ZEBOV, MVA-BN-Filo, 28-Day Interval","description":"Participants (human immunodeficiency virus \\[HIV\\]-infected adults) received IM injection of Ad26.ZEBOV 5\\*10\\^10 vp on Day 1 followed by IM injection of MVA-BN-filo 1\\*10\\^8 Inf.U on Day 29."},{"id":"OG007","title":"Cohort 2a: Placebo, Placebo, 28-Day Interval","description":"Participants (HIV-infected adults) received IM injection of Placebo 0.9 % saline on Day 1 followed by IM injection of Placebo 0.9 % saline on Day 29."},{"id":"OG008","title":"Cohort 2a: Ad26.ZEBOV, MVA-BN-Filo, 56-Day Interval","description":"Participants (HIV-infected adults) received IM injection of Ad26.ZEBOV 5\\*10\\^10 vp on Day 1 followed by IM injection of MVA-BN-filo 1\\*10\\^8 Inf.U on Day 57."},{"id":"OG009","title":"Cohort 2a: Placebo, Placebo, 56-Day Interval","description":"Participants (HIV-infected adults) received IM injection of Placebo 0.9 % saline on Day 1 followed by IM injection of Placebo 0.9 % saline on Day 57."},{"id":"OG010","title":"Cohort 2b: Ad26.ZEBOV, MVA-BN-Filo, 28-Day Interval","description":"Participants (Healthy Adolescents \\[12-17 years\\]) received IM injection of Ad26.ZEBOV 5\\*10\\^10 vp on Day 1 followed by IM injection of MVA-BN-filo 1\\*10\\^8 Inf.U on Day 29."},{"id":"OG011","title":"Cohort 2b: Placebo, Placebo, 28-Day Interval","description":"Participants (Healthy Adolescents \\[12-17 years\\]) received IM injection of Placebo 0.9 % saline on Day 1 followed by IM injection of Placebo 0.9 % saline on Day 29."},{"id":"OG012","title":"Cohort 2b: Ad26.ZEBOV, MVA-BN-Filo, 56-Day Interval","description":"Participants ((Healthy Adolescents \\[12-17 years\\]) received IM injection of Ad26.ZEBOV 5\\*10\\^10 vp on Day 1 followed by IM injection of MVA-BN-filo 1\\*10\\^8 Inf.U on Day 57."},{"id":"OG013","title":"Cohort 2b: Placebo, Placebo, 56-Day Interval","description":"Participants (Healthy Adolescents \\[12-17 years\\]) received IM injection of Placebo 0.9 % saline on Day 1 followed by IM injection of Placebo 0.9 % saline on Day 57."},{"id":"OG014","title":"Cohort 3: Ad26.ZEBOV, MVA-BN-Filo, 28-Day Interval","description":"Participants (Healthy Children \\[4-11 years\\]) received IM injection of Ad26.ZEBOV 5\\*10\\^10 vp on Day 1 followed by IM injection of MVA-BN-filo 1\\*10\\^8 Inf.U on Day 29."},{"id":"OG015","title":"Cohort 3: Placebo, Placebo, 28-Day Interval","description":"Participants (Healthy Children \\[4-11 years\\]) received IM injection of Placebo 0.9 % saline on Day 1 followed by IM injection of Placebo 0.9 % saline on Day 29."},{"id":"OG016","title":"Cohort 3: Ad26.ZEBOV, MVA-BN-Filo, 56-Day Interval","description":"Participants (Healthy Children \\[4-11 years\\]) received IM injection of Ad26.ZEBOV 5\\*10\\^10 vp on Day 1 followed by IM injection of MVA-BN-filo 1\\*10\\^8 Inf.U on Day 57."},{"id":"OG017","title":"Cohort 3: Placebo, Placebo, 56-Day Interval","description":"Participants (Healthy Children \\[4-11 years\\]) received IM injection of Placebo 0.9 % saline on Day 1 followed by IM injection of Placebo 0.9 % saline on Day 57."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"225"},{"groupId":"OG001","value":"43"},{"groupId":"OG002","value":"224"},{"groupId":"OG003","value":"44"},{"groupId":"OG004","value":"110"},{"groupId":"OG005","value":"22"},{"groupId":"OG006","value":"59"},{"groupId":"OG007","value":"12"},{"groupId":"OG008","value":"59"},{"groupId":"OG009","value":"12"},{"groupId":"OG010","value":"55"},{"groupId":"OG011","value":"11"},{"groupId":"OG012","value":"55"},{"groupId":"OG013","value":"10"},{"groupId":"OG014","value":"54"},{"groupId":"OG015","value":"12"},{"groupId":"OG016","value":"54"},{"groupId":"OG017","value":"12"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"123"},{"groupId":"OG001","value":"16"},{"groupId":"OG002","value":"121"},{"groupId":"OG003","value":"20"},{"groupId":"OG004","value":"63"},{"groupId":"OG005","value":"11"},{"groupId":"OG006","value":"34"},{"groupId":"OG007","value":"4"},{"groupId":"OG008","value":"35"},{"groupId":"OG009","value":"2"},{"groupId":"OG010","value":"26"},{"groupId":"OG011","value":"3"},{"groupId":"OG012","value":"30"},{"groupId":"OG013","value":"5"},{"groupId":"OG014","value":"26"},{"groupId":"OG015","value":"6"},{"groupId":"OG016","value":"29"},{"groupId":"OG017","value":"5"}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Solicited Local Adverse Events (28-day Interval)","description":"An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. Solicited local AEs were pre-defined local (at the injection site) AEs for which participants were specifically questioned and which were noted by participants in their diary for 7 days post vaccination. Solicited local AEs were: injection site pain/tenderness, erythema, induration/swelling, itching at the vaccination site.","populationDescription":"Full analysis set included all participants who were randomized and received at least 1 dose of study vaccine (Ad26.ZEBOV, MVA-BN-Filo or placebo). Here, 'N' (number of participants analyzed) signifies those participants who were evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up to 7 days post-dose 2 (Day 36 for Cohort 1, 2a, 2b and 3 [28-Day Interval])","groups":[{"id":"OG000","title":"Cohort 1: Ad26.ZEBOV, MVA-BN-Filo, Ad26.ZEBOV, 28-Day Interval","description":"Participants (healthy adults and elderly) received intramuscular (IM) injection of Ad26.ZEBOV 5\\*10\\^10 viral particles (vp) on Day 1 followed by IM injection of MVA-BN-filo 1\\*10\\^8 infectious units (Inf.U) on Day 29. Subset of participants who earlier received Ad26.ZEBOV and MVA-BN-Filo (at selected sites), afterwards received IM injection of Ad26.ZEBOV 5\\*10\\^10 vp as a booster dose at 1 year post dose 1 (Day 365)."},{"id":"OG001","title":"Cohort 1: Placebo, Placebo, Placebo, 28-Day Interval","description":"Participants (healthy adults and elderly) received IM injection of Placebo 0.9 percent (%) saline on Day 1 followed by IM injection of placebo 0.9 % saline on Day 29. Subset of participants who earlier received placebo(at selected sites), afterwards received IM injection of placebo 0.9 % saline as a booster dose at 1 year post dose 1 (Day 365)."},{"id":"OG002","title":"Cohort 2a: Ad26.ZEBOV, MVA-BN-Filo, 28-Day Interval","description":"Participants (human immunodeficiency virus \\[HIV\\]-infected adults) received IM injection of Ad26.ZEBOV 5\\*10\\^10 vp on Day 1 followed by IM injection of MVA-BN-filo 1\\*10\\^8 Inf.U on Day 29."},{"id":"OG003","title":"Cohort 2a: Placebo, Placebo, 28-Day Interval","description":"Participants (HIV-infected adults) received IM injection of Placebo 0.9 % saline on Day 1 followed by IM injection of Placebo 0.9 % saline on Day 29."},{"id":"OG004","title":"Cohort 2b: Ad26.ZEBOV, MVA-BN-Filo, 28-Day Interval","description":"Participants (Healthy Adolescents \\[12-17 years\\]) received IM injection of Ad26.ZEBOV 5\\*10\\^10 vp on Day 1 followed by IM injection of MVA-BN-filo 1\\*10\\^8 Inf.U on Day 29."},{"id":"OG005","title":"Cohort 2b: Placebo, Placebo, 28-Day Interval","description":"Participants (Healthy Adolescents \\[12-17 years\\]) received IM injection of Placebo 0.9 % saline on Day 1 followed by IM injection of Placebo 0.9 % saline on Day 29."},{"id":"OG006","title":"Cohort 3: Ad26.ZEBOV, MVA-BN-Filo, 28-Day Interval","description":"Participants (Healthy Children \\[4-11 years\\]) received IM injection of Ad26.ZEBOV 5\\*10\\^10 vp on Day 1 followed by IM injection of MVA-BN-filo 1\\*10\\^8 Inf.U on Day 29."},{"id":"OG007","title":"Cohort 3: Placebo, Placebo, 28-Day Interval","description":"Participants (Healthy Children \\[4-11 years\\]) received IM injection of Placebo 0.9 % saline on Day 1 followed by IM injection of Placebo 0.9 % saline on Day 29."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"219"},{"groupId":"OG001","value":"39"},{"groupId":"OG002","value":"58"},{"groupId":"OG003","value":"12"},{"groupId":"OG004","value":"55"},{"groupId":"OG005","value":"10"},{"groupId":"OG006","value":"54"},{"groupId":"OG007","value":"12"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"126"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"26"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"29"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"22"},{"groupId":"OG007","value":"2"}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Solicited Local Adverse Events Post-dose 2 (56-day Interval)","description":"An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. Solicited local AEs were pre-defined local (at the injection site) AEs for which participants were specifically questioned and which were noted by participants in their diary for 7 days post vaccination. Solicited local AEs were: injection site pain/tenderness, erythema, induration/swelling, itching at the vaccination site.","populationDescription":"Full analysis set included all participants who were randomized and received at least 1 dose of study vaccine (Ad26.ZEBOV, MVA-BN-Filo or placebo). Here, 'N' (number of participants analyzed) signifies those participants who were evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up to 7 days post-dose 2 (Day 64 for Cohort 1, 2a, 2b and 3 [56-Day Interval])","groups":[{"id":"OG000","title":"Cohort 1: Ad26.ZEBOV, MVA-BN-Filo, Ad26.ZEBOV, 56-Day Interval","description":"Participants (healthy adults and elderly) received IM injection of Ad26.ZEBOV 5\\*10\\^10 vp on Day 1 followed by IM injection of MVA-BN-filo Inf.U on Day 57. Subset of participants who earlier received Ad26.ZEBOV and MVA-BN-Filo (at selected sites), afterwards received IM injection of Ad26.ZEBOV 5\\*10\\^10 vp as a booster dose at 1 year post dose 1 (Day 365)."},{"id":"OG001","title":"Cohort 1: Placebo, Placebo, Placebo, 56-Day Interval","description":"Participants (healthy adults and elderly) received placebo 0.9% saline on Day 1 followed by IM injection of placebo 0.9% saline on Day 57. Subset of participants who earlier received Placebo (at selected sites), afterwards received IM injection of Placebo 0.9 % saline as a booster dose at 1 year post dose 1 (Day 365)."},{"id":"OG002","title":"Cohort 2a: Ad26.ZEBOV, MVA-BN-Filo, 56-Day Interval","description":"Participants (HIV-infected adults) received IM injection of Ad26.ZEBOV 5\\*10\\^10 vp on Day 1 followed by IM injection of MVA-BN-filo 1\\*10\\^8 Inf.U on Day 57."},{"id":"OG003","title":"Cohort 2a: Placebo, Placebo, 56-Day Interval","description":"Participants (HIV-infected adults) received IM injection of Placebo 0.9 % saline on Day 1 followed by IM injection of Placebo 0.9 % saline on Day 57."},{"id":"OG004","title":"Cohort 2b: Ad26.ZEBOV, MVA-BN-Filo, 56-Day Interval","description":"Participants ((Healthy Adolescents \\[12-17 years\\]) received IM injection of Ad26.ZEBOV 5\\*10\\^10 vp on Day 1 followed by IM injection of MVA-BN-filo 1\\*10\\^8 Inf.U on Day 57."},{"id":"OG005","title":"Cohort 2b: Placebo, Placebo, 56-Day Interval","description":"Participants (Healthy Adolescents \\[12-17 years\\]) received IM injection of Placebo 0.9 % saline on Day 1 followed by IM injection of Placebo 0.9 % saline on Day 57."},{"id":"OG006","title":"Cohort 3: Ad26.ZEBOV, MVA-BN-Filo, 56-Day Interval","description":"Participants (Healthy Children \\[4-11 years\\]) received IM injection of Ad26.ZEBOV 5\\*10\\^10 vp on Day 1 followed by IM injection of MVA-BN-filo 1\\*10\\^8 Inf.U on Day 57."},{"id":"OG007","title":"Cohort 3: Placebo, Placebo, 56-Day Interval","description":"Participants (Healthy Children \\[4-11 years\\]) received IM injection of Placebo 0.9 % saline on Day 1 followed by IM injection of Placebo 0.9 % saline on Day 57."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"200"},{"groupId":"OG001","value":"39"},{"groupId":"OG002","value":"59"},{"groupId":"OG003","value":"12"},{"groupId":"OG004","value":"54"},{"groupId":"OG005","value":"10"},{"groupId":"OG006","value":"54"},{"groupId":"OG007","value":"11"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"113"},{"groupId":"OG001","value":"16"},{"groupId":"OG002","value":"25"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"20"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"22"},{"groupId":"OG007","value":"2"}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Solicited Local Adverse Events (84-day Interval)","description":"An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. Solicited local AEs were pre-defined local (at the injection site) AEs for which participants were specifically questioned and which were noted by participants in their diary for 7 days post vaccination. Solicited local AEs were: injection site pain/tenderness, erythema, induration/swelling, itching at the vaccination site.","populationDescription":"Full analysis set included all participants who were randomized and received at least 1 dose of study vaccine (Ad26.ZEBOV, MVA-BN-Filo or placebo). Here, 'N' (number of participants analyzed) signifies those participants who were evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up to 7 days post-dose 2 (Day 92 for Cohort 1 [84-Day Interval])","groups":[{"id":"OG000","title":"Cohort 1: Ad26.ZEBOV, MVA-BN-Filo, 84-Day Interval","description":"Participants (healthy adults and elderly) received IM injection of Ad26.ZEBOV 5\\*10\\^10 vp on Day 1 followed by IM injection of MVA-BN-filo 1\\*10\\^8 Inf.U on Day 85."},{"id":"OG001","title":"Cohort 1: Placebo, Placebo, 84-Day Interval","description":"Participants (healthy adults and elderly) received IM injection of Placebo 0.9 % saline on Day 1 followed by IM injection of Placebo 0.9 % saline on Day 85."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"98"},{"groupId":"OG001","value":"21"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"57"},{"groupId":"OG001","value":"9"}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Solicited Local Adverse Events (Day 372)","description":"An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. Solicited local AEs were pre-defined local (at the injection site) AEs for which participants were specifically questioned and which were noted by participants in their diary for 7 days post vaccination. Solicited local AEs were: injection site pain/tenderness, erythema, induration/swelling, itching at the vaccination site.","populationDescription":"Full analysis set included all participants who were randomized and received at least 1 dose of study vaccine (Ad26.ZEBOV, MVA-BN-Filo or placebo).","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up 7 days post-dose 3 (Day 372)","groups":[{"id":"OG000","title":"Cohort 1: Ad26.ZEBOV, MVA-BN-Filo, Ad26.ZEBOV, 28-Day Interval","description":"Participants (healthy adults and elderly) received intramuscular (IM) injection of Ad26.ZEBOV 5\\*10\\^10 viral particles (vp) on Day 1 followed by IM injection of MVA-BN-filo 1\\*10\\^8 infectious units (Inf.U) on Day 29. Subset of participants who earlier received Ad26.ZEBOV and MVA-BN-Filo (at selected sites), afterwards received IM injection of Ad26.ZEBOV 5\\*10\\^10 vp as a booster dose at 1 year post dose 1 (Day 365)."},{"id":"OG001","title":"Cohort 1: Placebo, Placebo, Placebo, 28-Day Interval","description":"Participants (healthy adults and elderly) received IM injection of Placebo 0.9 percent (%) saline on Day 1 followed by IM injection of placebo 0.9 % saline on Day 29. Subset of participants who earlier received placebo(at selected sites), afterwards received IM injection of placebo 0.9 % saline as a booster dose at 1 year post dose 1 (Day 365)."},{"id":"OG002","title":"Cohort 1: Ad26.ZEBOV, MVA-BN-Filo, Ad26.ZEBOV, 56-Day Interval","description":"Participants (healthy adults and elderly) received IM injection of Ad26.ZEBOV 5\\*10\\^10 vp on Day 1 followed by IM injection of MVA-BN-filo Inf.U on Day 57. Subset of participants who earlier received Ad26.ZEBOV and MVA-BN-Filo (at selected sites), afterwards received IM injection of Ad26.ZEBOV 5\\*10\\^10 vp as a booster dose at 1 year post dose 1 (Day 365)."},{"id":"OG003","title":"Cohort 1: Placebo, Placebo, Placebo, 56-Day Interval","description":"Participants (healthy adults and elderly) received placebo 0.9% saline on Day 1 followed by IM injection of placebo 0.9% saline on Day 57. Subset of participants who earlier received Placebo (at selected sites), afterwards received IM injection of Placebo 0.9 % saline as a booster dose at 1 year post dose 1 (Day 365)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"39"},{"groupId":"OG003","value":"9"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"16"},{"groupId":"OG003","value":"3"}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Solicited Systemic Adverse Events (Day 8)","description":"An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. Participants were instructed on how to note signs and symptoms in the diary on a daily basis for 7 days post-vaccination (Day of vaccination and the subsequent 7 days) for solicited systemic AEs. Solicited systemic events included fever, headache, fatigue/malaise, myalgia, nausea/vomiting, arthralgia and chills.","populationDescription":"Full analysis set included all participants who were randomized and received at least 1 dose of study vaccine (Ad26.ZEBOV, MVA-BN-Filo or placebo).","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up to 7 days post-dose 1 (Day 8)","groups":[{"id":"OG000","title":"Cohort 1: Ad26.ZEBOV, MVA-BN-Filo, Ad26.ZEBOV, 28-Day Interval","description":"Participants (healthy adults and elderly) received intramuscular (IM) injection of Ad26.ZEBOV 5\\*10\\^10 viral particles (vp) on Day 1 followed by IM injection of MVA-BN-filo 1\\*10\\^8 infectious units (Inf.U) on Day 29. Subset of participants who earlier received Ad26.ZEBOV and MVA-BN-Filo (at selected sites), afterwards received IM injection of Ad26.ZEBOV 5\\*10\\^10 vp as a booster dose at 1 year post dose 1 (Day 365)."},{"id":"OG001","title":"Cohort 1: Placebo, Placebo, Placebo, 28-Day Interval","description":"Participants (healthy adults and elderly) received IM injection of Placebo 0.9 percent (%) saline on Day 1 followed by IM injection of placebo 0.9 % saline on Day 29. Subset of participants who earlier received placebo(at selected sites), afterwards received IM injection of placebo 0.9 % saline as a booster dose at 1 year post dose 1 (Day 365)."},{"id":"OG002","title":"Cohort 1: Ad26.ZEBOV, MVA-BN-Filo, Ad26.ZEBOV, 56-Day Interval","description":"Participants (healthy adults and elderly) received IM injection of Ad26.ZEBOV 5\\*10\\^10 vp on Day 1 followed by IM injection of MVA-BN-filo Inf.U on Day 57. Subset of participants who earlier received Ad26.ZEBOV and MVA-BN-Filo (at selected sites), afterwards received IM injection of Ad26.ZEBOV 5\\*10\\^10 vp as a booster dose at 1 year post dose 1 (Day 365)."},{"id":"OG003","title":"Cohort 1: Placebo, Placebo, Placebo, 56-Day Interval","description":"Participants (healthy adults and elderly) received placebo 0.9% saline on Day 1 followed by IM injection of placebo 0.9% saline on Day 57. Subset of participants who earlier received Placebo (at selected sites), afterwards received IM injection of Placebo 0.9 % saline as a booster dose at 1 year post dose 1 (Day 365)."},{"id":"OG004","title":"Cohort 1: Ad26.ZEBOV, MVA-BN-Filo, 84-Day Interval","description":"Participants (healthy adults and elderly) received IM injection of Ad26.ZEBOV 5\\*10\\^10 vp on Day 1 followed by IM injection of MVA-BN-filo 1\\*10\\^8 Inf.U on Day 85."},{"id":"OG005","title":"Cohort 1: Placebo, Placebo, 84-Day Interval","description":"Participants (healthy adults and elderly) received IM injection of Placebo 0.9 % saline on Day 1 followed by IM injection of Placebo 0.9 % saline on Day 85."},{"id":"OG006","title":"Cohort 2a: Ad26.ZEBOV, MVA-BN-Filo, 28-Day Interval","description":"Participants (human immunodeficiency virus \\[HIV\\]-infected adults) received IM injection of Ad26.ZEBOV 5\\*10\\^10 vp on Day 1 followed by IM injection of MVA-BN-filo 1\\*10\\^8 Inf.U on Day 29."},{"id":"OG007","title":"Cohort 2a: Placebo, Placebo, 28-Day Interval","description":"Participants (HIV-infected adults) received IM injection of Placebo 0.9 % saline on Day 1 followed by IM injection of Placebo 0.9 % saline on Day 29."},{"id":"OG008","title":"Cohort 2a: Ad26.ZEBOV, MVA-BN-Filo, 56-Day Interval","description":"Participants (HIV-infected adults) received IM injection of Ad26.ZEBOV 5\\*10\\^10 vp on Day 1 followed by IM injection of MVA-BN-filo 1\\*10\\^8 Inf.U on Day 57."},{"id":"OG009","title":"Cohort 2a: Placebo, Placebo, 56-Day Interval","description":"Participants (HIV-infected adults) received IM injection of Placebo 0.9 % saline on Day 1 followed by IM injection of Placebo 0.9 % saline on Day 57."},{"id":"OG010","title":"Cohort 2b: Ad26.ZEBOV, MVA-BN-Filo, 28-Day Interval","description":"Participants (Healthy Adolescents \\[12-17 years\\]) received IM injection of Ad26.ZEBOV 5\\*10\\^10 vp on Day 1 followed by IM injection of MVA-BN-filo 1\\*10\\^8 Inf.U on Day 29."},{"id":"OG011","title":"Cohort 2b: Placebo, Placebo, 28-Day Interval","description":"Participants (Healthy Adolescents \\[12-17 years\\]) received IM injection of Placebo 0.9 % saline on Day 1 followed by IM injection of Placebo 0.9 % saline on Day 29."},{"id":"OG012","title":"Cohort 2b: Ad26.ZEBOV, MVA-BN-Filo, 56-Day Interval","description":"Participants ((Healthy Adolescents \\[12-17 years\\]) received IM injection of Ad26.ZEBOV 5\\*10\\^10 vp on Day 1 followed by IM injection of MVA-BN-filo 1\\*10\\^8 Inf.U on Day 57."},{"id":"OG013","title":"Cohort 2b: Placebo, Placebo, 56-Day Interval","description":"Participants (Healthy Adolescents \\[12-17 years\\]) received IM injection of Placebo 0.9 % saline on Day 1 followed by IM injection of Placebo 0.9 % saline on Day 57."},{"id":"OG014","title":"Cohort 3: Ad26.ZEBOV, MVA-BN-Filo, 28-Day Interval","description":"Participants (Healthy Children \\[4-11 years\\]) received IM injection of Ad26.ZEBOV 5\\*10\\^10 vp on Day 1 followed by IM injection of MVA-BN-filo 1\\*10\\^8 Inf.U on Day 29."},{"id":"OG015","title":"Cohort 3: Placebo, Placebo, 28-Day Interval","description":"Participants (Healthy Children \\[4-11 years\\]) received IM injection of Placebo 0.9 % saline on Day 1 followed by IM injection of Placebo 0.9 % saline on Day 29."},{"id":"OG016","title":"Cohort 3: Ad26.ZEBOV, MVA-BN-Filo, 56-Day Interval","description":"Participants (Healthy Children \\[4-11 years\\]) received IM injection of Ad26.ZEBOV 5\\*10\\^10 vp on Day 1 followed by IM injection of MVA-BN-filo 1\\*10\\^8 Inf.U on Day 57."},{"id":"OG017","title":"Cohort 3: Placebo, Placebo, 56-Day Interval","description":"Participants (Healthy Children \\[4-11 years\\]) received IM injection of Placebo 0.9 % saline on Day 1 followed by IM injection of Placebo 0.9 % saline on Day 57."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"225"},{"groupId":"OG001","value":"43"},{"groupId":"OG002","value":"224"},{"groupId":"OG003","value":"44"},{"groupId":"OG004","value":"110"},{"groupId":"OG005","value":"22"},{"groupId":"OG006","value":"59"},{"groupId":"OG007","value":"12"},{"groupId":"OG008","value":"59"},{"groupId":"OG009","value":"12"},{"groupId":"OG010","value":"55"},{"groupId":"OG011","value":"11"},{"groupId":"OG012","value":"55"},{"groupId":"OG013","value":"10"},{"groupId":"OG014","value":"54"},{"groupId":"OG015","value":"12"},{"groupId":"OG016","value":"54"},{"groupId":"OG017","value":"12"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"146"},{"groupId":"OG001","value":"27"},{"groupId":"OG002","value":"140"},{"groupId":"OG003","value":"26"},{"groupId":"OG004","value":"75"},{"groupId":"OG005","value":"14"},{"groupId":"OG006","value":"44"},{"groupId":"OG007","value":"7"},{"groupId":"OG008","value":"36"},{"groupId":"OG009","value":"2"},{"groupId":"OG010","value":"29"},{"groupId":"OG011","value":"4"},{"groupId":"OG012","value":"30"},{"groupId":"OG013","value":"5"},{"groupId":"OG014","value":"24"},{"groupId":"OG015","value":"2"},{"groupId":"OG016","value":"23"},{"groupId":"OG017","value":"2"}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Solicited Systemic Adverse Events (28-Day Interval)","description":"An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. Participants were instructed on how to note signs and symptoms in the diary on a daily basis for 7 days post-vaccination (Day of vaccination and the subsequent 7 days) for solicited systemic AEs. Solicited systemic events included fever, headache, fatigue/malaise, myalgia, nausea/vomiting, arthralgia and chills.","populationDescription":"Full analysis set included all participants who were randomized and received at least 1 dose of study vaccine (Ad26.ZEBOV, MVA-BN-Filo or placebo). Here, 'N' (number of participants analyzed) signifies those participants who were evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up to 7 days post-dose 2 (Day 36 for Cohorts 1, 2a, 2b and 3 [28-Day Interval])","groups":[{"id":"OG000","title":"Cohort 1: Ad26.ZEBOV, MVA-BN-Filo, Ad26.ZEBOV, 28-Day Interval","description":"Participants (healthy adults and elderly) received intramuscular (IM) injection of Ad26.ZEBOV 5\\*10\\^10 viral particles (vp) on Day 1 followed by IM injection of MVA-BN-filo 1\\*10\\^8 infectious units (Inf.U) on Day 29. Subset of participants who earlier received Ad26.ZEBOV and MVA-BN-Filo (at selected sites), afterwards received IM injection of Ad26.ZEBOV 5\\*10\\^10 vp as a booster dose at 1 year post dose 1 (Day 365)."},{"id":"OG001","title":"Cohort 1: Placebo, Placebo, Placebo, 28-Day Interval","description":"Participants (healthy adults and elderly) received IM injection of Placebo 0.9 percent (%) saline on Day 1 followed by IM injection of placebo 0.9 % saline on Day 29. Subset of participants who earlier received placebo(at selected sites), afterwards received IM injection of placebo 0.9 % saline as a booster dose at 1 year post dose 1 (Day 365)."},{"id":"OG002","title":"Cohort 2a: Ad26.ZEBOV, MVA-BN-Filo, 28-Day Interval","description":"Participants (human immunodeficiency virus \\[HIV\\]-infected adults) received IM injection of Ad26.ZEBOV 5\\*10\\^10 vp on Day 1 followed by IM injection of MVA-BN-filo 1\\*10\\^8 Inf.U on Day 29."},{"id":"OG003","title":"Cohort 2a: Placebo, Placebo, 28-Day Interval","description":"Participants (HIV-infected adults) received IM injection of Placebo 0.9 % saline on Day 1 followed by IM injection of Placebo 0.9 % saline on Day 29."},{"id":"OG004","title":"Cohort 2b: Ad26.ZEBOV, MVA-BN-Filo, 28-Day Interval","description":"Participants (Healthy Adolescents \\[12-17 years\\]) received IM injection of Ad26.ZEBOV 5\\*10\\^10 vp on Day 1 followed by IM injection of MVA-BN-filo 1\\*10\\^8 Inf.U on Day 29."},{"id":"OG005","title":"Cohort 2b: Placebo, Placebo, 28-Day Interval","description":"Participants (Healthy Adolescents \\[12-17 years\\]) received IM injection of Placebo 0.9 % saline on Day 1 followed by IM injection of Placebo 0.9 % saline on Day 29."},{"id":"OG006","title":"Cohort 3: Ad26.ZEBOV, MVA-BN-Filo, 28-Day Interval","description":"Participants (Healthy Children \\[4-11 years\\]) received IM injection of Ad26.ZEBOV 5\\*10\\^10 vp on Day 1 followed by IM injection of MVA-BN-filo 1\\*10\\^8 Inf.U on Day 29."},{"id":"OG007","title":"Cohort 3: Placebo, Placebo, 28-Day Interval","description":"Participants (Healthy Children \\[4-11 years\\]) received IM injection of Placebo 0.9 % saline on Day 1 followed by IM injection of Placebo 0.9 % saline on Day 29."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"219"},{"groupId":"OG001","value":"39"},{"groupId":"OG002","value":"58"},{"groupId":"OG003","value":"12"},{"groupId":"OG004","value":"55"},{"groupId":"OG005","value":"10"},{"groupId":"OG006","value":"54"},{"groupId":"OG007","value":"12"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"121"},{"groupId":"OG001","value":"14"},{"groupId":"OG002","value":"32"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"27"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"10"},{"groupId":"OG007","value":"3"}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Solicited Systemic Adverse Events (56-Day Interval)","description":"An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. Participants were instructed on how to note signs and symptoms in the diary on a daily basis for 7 days post-vaccination (Day of vaccination and the subsequent 7 days) for solicited systemic AEs. Solicited systemic events included fever, headache, fatigue/malaise, myalgia, nausea/vomiting, arthralgia and chills.","populationDescription":"Full analysis set included all participants who were randomized and received at least 1 dose of study vaccine (Ad26.ZEBOV, MVA-BN-Filo or placebo). Here, 'N' (number of participants analyzed) signifies those participants who were evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up 7 days post-dose 2 (Day 64 for Cohort 1, 2a, 2b and 3 [56-Day Interval])","groups":[{"id":"OG000","title":"Cohort 1: Ad26.ZEBOV, MVA-BN-Filo, Ad26.ZEBOV, 56-Day Interval","description":"Participants (healthy adults and elderly) received IM injection of Ad26.ZEBOV 5\\*10\\^10 vp on Day 1 followed by IM injection of MVA-BN-filo Inf.U on Day 57. Subset of participants who earlier received Ad26.ZEBOV and MVA-BN-Filo (at selected sites), afterwards received IM injection of Ad26.ZEBOV 5\\*10\\^10 vp as a booster dose at 1 year post dose 1 (Day 365)."},{"id":"OG001","title":"Cohort 1: Placebo, Placebo, Placebo, 56-Day Interval","description":"Participants (healthy adults and elderly) received placebo 0.9% saline on Day 1 followed by IM injection of placebo 0.9% saline on Day 57. Subset of participants who earlier received Placebo (at selected sites), afterwards received IM injection of Placebo 0.9 % saline as a booster dose at 1 year post dose 1 (Day 365)."},{"id":"OG002","title":"Cohort 2a: Ad26.ZEBOV, MVA-BN-Filo, 56-Day Interval","description":"Participants (HIV-infected adults) received IM injection of Ad26.ZEBOV 5\\*10\\^10 vp on Day 1 followed by IM injection of MVA-BN-filo 1\\*10\\^8 Inf.U on Day 57."},{"id":"OG003","title":"Cohort 2a: Placebo, Placebo, 56-Day Interval","description":"Participants (HIV-infected adults) received IM injection of Placebo 0.9 % saline on Day 1 followed by IM injection of Placebo 0.9 % saline on Day 57."},{"id":"OG004","title":"Cohort 2b: Ad26.ZEBOV, MVA-BN-Filo, 56-Day Interval","description":"Participants ((Healthy Adolescents \\[12-17 years\\]) received IM injection of Ad26.ZEBOV 5\\*10\\^10 vp on Day 1 followed by IM injection of MVA-BN-filo 1\\*10\\^8 Inf.U on Day 57."},{"id":"OG005","title":"Cohort 2b: Placebo, Placebo, 56-Day Interval","description":"Participants (Healthy Adolescents \\[12-17 years\\]) received IM injection of Placebo 0.9 % saline on Day 1 followed by IM injection of Placebo 0.9 % saline on Day 57."},{"id":"OG006","title":"Cohort 3: Ad26.ZEBOV, MVA-BN-Filo, 56-Day Interval","description":"Participants (Healthy Children \\[4-11 years\\]) received IM injection of Ad26.ZEBOV 5\\*10\\^10 vp on Day 1 followed by IM injection of MVA-BN-filo 1\\*10\\^8 Inf.U on Day 57."},{"id":"OG007","title":"Cohort 3: Placebo, Placebo, 56-Day Interval","description":"Participants (Healthy Children \\[4-11 years\\]) received IM injection of Placebo 0.9 % saline on Day 1 followed by IM injection of Placebo 0.9 % saline on Day 57."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"200"},{"groupId":"OG001","value":"39"},{"groupId":"OG002","value":"59"},{"groupId":"OG003","value":"12"},{"groupId":"OG004","value":"54"},{"groupId":"OG005","value":"10"},{"groupId":"OG006","value":"54"},{"groupId":"OG007","value":"11"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"121"},{"groupId":"OG001","value":"21"},{"groupId":"OG002","value":"26"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"25"},{"groupId":"OG005","value":"6"},{"groupId":"OG006","value":"10"},{"groupId":"OG007","value":"4"}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Solicited Systemic Adverse Events (84-Day Interval)","description":"An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. Participants were instructed on how to note signs and symptoms in the diary on a daily basis for 7 days post-vaccination (Day of vaccination and the subsequent 7 days) for solicited systemic AEs. Solicited systemic events included fever, headache, fatigue/malaise, myalgia, nausea/vomiting, arthralgia and chills.","populationDescription":"Full analysis set included all participants who were randomized and received at least 1 dose of study vaccine (Ad26.ZEBOV, MVA-BN-Filo or placebo). Here, 'N' (number of participants analyzed) signifies those participants who were evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up 7 days post-dose 2 (Day 92 for Cohort 1 [84-Day Interval])","groups":[{"id":"OG000","title":"Cohort 1: Ad26.ZEBOV, MVA-BN-Filo, 84-Day Interval","description":"Participants (healthy adults and elderly) received IM injection of Ad26.ZEBOV 5\\*10\\^10 vp on Day 1 followed by IM injection of MVA-BN-filo 1\\*10\\^8 Inf.U on Day 85."},{"id":"OG001","title":"Cohort 1: Placebo, Placebo, 84-Day Interval","description":"Participants (healthy adults and elderly) received IM injection of Placebo 0.9 % saline on Day 1 followed by IM injection of Placebo 0.9 % saline on Day 85."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"98"},{"groupId":"OG001","value":"21"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"64"},{"groupId":"OG001","value":"14"}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Solicited Systemic Adverse Events (Day 372)","description":"An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. Participants were instructed on how to note signs and symptoms in the diary on a daily basis for 7 days post-vaccination (Day of vaccination and the subsequent 7 days) for solicited systemic AEs. Solicited systemic events included fever, headache, fatigue/malaise, myalgia, nausea/vomiting, arthralgia and chills.","populationDescription":"Full analysis set included all participants who were randomized and received at least 1 dose of study vaccine (Ad26.ZEBOV, MVA-BN-Filo or placebo).","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up to 7 days post-dose 3 (Day 372)","groups":[{"id":"OG000","title":"Cohort 1: Ad26.ZEBOV, MVA-BN-Filo, Ad26.ZEBOV, 28-Day Interval","description":"Participants (healthy adults and elderly) received intramuscular (IM) injection of Ad26.ZEBOV 5\\*10\\^10 viral particles (vp) on Day 1 followed by IM injection of MVA-BN-filo 1\\*10\\^8 infectious units (Inf.U) on Day 29. Subset of participants who earlier received Ad26.ZEBOV and MVA-BN-Filo (at selected sites), afterwards received IM injection of Ad26.ZEBOV 5\\*10\\^10 vp as a booster dose at 1 year post dose 1 (Day 365)."},{"id":"OG001","title":"Cohort 1: Placebo, Placebo, Placebo, 28-Day Interval","description":"Participants (healthy adults and elderly) received IM injection of Placebo 0.9 percent (%) saline on Day 1 followed by IM injection of placebo 0.9 % saline on Day 29. Subset of participants who earlier received placebo(at selected sites), afterwards received IM injection of placebo 0.9 % saline as a booster dose at 1 year post dose 1 (Day 365)."},{"id":"OG002","title":"Cohort 1: Ad26.ZEBOV, MVA-BN-Filo, Ad26.ZEBOV, 56-Day Interval","description":"Participants (healthy adults and elderly) received IM injection of Ad26.ZEBOV 5\\*10\\^10 vp on Day 1 followed by IM injection of MVA-BN-filo Inf.U on Day 57. Subset of participants who earlier received Ad26.ZEBOV and MVA-BN-Filo (at selected sites), afterwards received IM injection of Ad26.ZEBOV 5\\*10\\^10 vp as a booster dose at 1 year post dose 1 (Day 365)."},{"id":"OG003","title":"Cohort 1: Placebo, Placebo, Placebo, 56-Day Interval","description":"Participants (healthy adults and elderly) received placebo 0.9% saline on Day 1 followed by IM injection of placebo 0.9% saline on Day 57. Subset of participants who earlier received Placebo (at selected sites), afterwards received IM injection of Placebo 0.9 % saline as a booster dose at 1 year post dose 1 (Day 365)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"39"},{"groupId":"OG003","value":"9"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"18"},{"groupId":"OG003","value":"4"}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Concentrations (GMCs) of Binding Antibody Levels Against Ebola Virus Glycoprotein (EBOV GP) Measured Using Filovirus Animal Non-Clinical Group (FANG) Enzyme-linked Immunosorbent Assay","description":"GMCs of antibodies binding to EBOV GP using FANG ELISA were reported and were measured in ELISA unit per milliliter (EU/mL). Serum samples were collected for analysis of binding antibodies against EBOV GP using FANG ELISA to determine humoral responses following vaccination. For ELISA binding antibody responses, values below the lower limit of quantification (LLOQ) (36.11 ELISA units/mL).","populationDescription":"The per protocol analysis set included all randomized and vaccinated participants, who received both the prime and boost vaccinations (administered not more than 10 days outside the visit window), have immunogenicity data, from baseline and at least one post-vaccination evaluable immunogenicity sample, and have no major protocol violations influencing the immune response.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"ELISA units/mL","timeFrame":"21-days post-dose 2 (Day 50 for Cohorts 1, 2a, 2b, 3 [28-day interval] , Day 78 for Cohort 1, 2a, 2b, 3 [56-day interval] and Day 106 Cohort 1 [84-day interval]","groups":[{"id":"OG000","title":"Cohort 1: Ad26.ZEBOV, MVA-BN-Filo, Ad26.ZEBOV, 28-Day Interval","description":"Participants (healthy adults and elderly) received intramuscular (IM) injection of Ad26.ZEBOV 5\\*10\\^10 viral particles (vp) on Day 1 followed by IM injection of MVA-BN-filo 1\\*10\\^8 infectious units (Inf.U) on Day 29. Subset of participants who earlier received Ad26.ZEBOV and MVA-BN-Filo (at selected sites), afterwards received IM injection of Ad26.ZEBOV 5\\*10\\^10 vp as a booster dose at 1 year post dose 1 (Day 365)."},{"id":"OG001","title":"Cohort 1: Placebo, Placebo, Placebo, 28-Day Interval","description":"Participants (healthy adults and elderly) received IM injection of Placebo 0.9 percent (%) saline on Day 1 followed by IM injection of placebo 0.9 % saline on Day 29. Subset of participants who earlier received placebo(at selected sites), afterwards received IM injection of placebo 0.9 % saline as a booster dose at 1 year post dose 1 (Day 365)."},{"id":"OG002","title":"Cohort 1: Ad26.ZEBOV, MVA-BN-Filo, Ad26.ZEBOV, 56-Day Interval","description":"Participants (healthy adults and elderly) received IM injection of Ad26.ZEBOV 5\\*10\\^10 vp on Day 1 followed by IM injection of MVA-BN-filo Inf.U on Day 57. Subset of participants who earlier received Ad26.ZEBOV and MVA-BN-Filo (at selected sites), afterwards received IM injection of Ad26.ZEBOV 5\\*10\\^10 vp as a booster dose at 1 year post dose 1 (Day 365)."},{"id":"OG003","title":"Cohort 1: Placebo, Placebo, Placebo, 56-Day Interval","description":"Participants (healthy adults and elderly) received placebo 0.9% saline on Day 1 followed by IM injection of placebo 0.9% saline on Day 57. Subset of participants who earlier received Placebo (at selected sites), afterwards received IM injection of Placebo 0.9 % saline as a booster dose at 1 year post dose 1 (Day 365)."},{"id":"OG004","title":"Cohort 1: Ad26.ZEBOV, MVA-BN-Filo, 84-Day Interval","description":"Participants (healthy adults and elderly) received IM injection of Ad26.ZEBOV 5\\*10\\^10 vp on Day 1 followed by IM injection of MVA-BN-filo 1\\*10\\^8 Inf.U on Day 85."},{"id":"OG005","title":"Cohort 1: Placebo, Placebo, 84-Day Interval","description":"Participants (healthy adults and elderly) received IM injection of Placebo 0.9 % saline on Day 1 followed by IM injection of Placebo 0.9 % saline on Day 85."},{"id":"OG006","title":"Cohort 2a: Ad26.ZEBOV, MVA-BN-Filo, 28-Day Interval","description":"Participants (human immunodeficiency virus \\[HIV\\]-infected adults) received IM injection of Ad26.ZEBOV 5\\*10\\^10 vp on Day 1 followed by IM injection of MVA-BN-filo 1\\*10\\^8 Inf.U on Day 29."},{"id":"OG007","title":"Cohort 2a: Placebo, Placebo, 28-Day Interval","description":"Participants (HIV-infected adults) received IM injection of Placebo 0.9 % saline on Day 1 followed by IM injection of Placebo 0.9 % saline on Day 29."},{"id":"OG008","title":"Cohort 2a: Ad26.ZEBOV, MVA-BN-Filo, 56-Day Interval","description":"Participants (HIV-infected adults) received IM injection of Ad26.ZEBOV 5\\*10\\^10 vp on Day 1 followed by IM injection of MVA-BN-filo 1\\*10\\^8 Inf.U on Day 57."},{"id":"OG009","title":"Cohort 2a: Placebo, Placebo, 56-Day Interval","description":"Participants (HIV-infected adults) received IM injection of Placebo 0.9 % saline on Day 1 followed by IM injection of Placebo 0.9 % saline on Day 57."},{"id":"OG010","title":"Cohort 2b: Ad26.ZEBOV, MVA-BN-Filo, 28-Day Interval","description":"Participants (Healthy Adolescents \\[12-17 years\\]) received IM injection of Ad26.ZEBOV 5\\*10\\^10 vp on Day 1 followed by IM injection of MVA-BN-filo 1\\*10\\^8 Inf.U on Day 29."},{"id":"OG011","title":"Cohort 2b: Placebo, Placebo, 28-Day Interval","description":"Participants (Healthy Adolescents \\[12-17 years\\]) received IM injection of Placebo 0.9 % saline on Day 1 followed by IM injection of Placebo 0.9 % saline on Day 29."},{"id":"OG012","title":"Cohort 2b: Ad26.ZEBOV, MVA-BN-Filo, 56-Day Interval","description":"Participants ((Healthy Adolescents \\[12-17 years\\]) received IM injection of Ad26.ZEBOV 5\\*10\\^10 vp on Day 1 followed by IM injection of MVA-BN-filo 1\\*10\\^8 Inf.U on Day 57."},{"id":"OG013","title":"Cohort 2b: Placebo, Placebo, 56-Day Interval","description":"Participants (Healthy Adolescents \\[12-17 years\\]) received IM injection of Placebo 0.9 % saline on Day 1 followed by IM injection of Placebo 0.9 % saline on Day 57."},{"id":"OG014","title":"Cohort 3: Ad26.ZEBOV, MVA-BN-Filo, 28-Day Interval","description":"Participants (Healthy Children \\[4-11 years\\]) received IM injection of Ad26.ZEBOV 5\\*10\\^10 vp on Day 1 followed by IM injection of MVA-BN-filo 1\\*10\\^8 Inf.U on Day 29."},{"id":"OG015","title":"Cohort 3: Placebo, Placebo, 28-Day Interval","description":"Participants (Healthy Children \\[4-11 years\\]) received IM injection of Placebo 0.9 % saline on Day 1 followed by IM injection of Placebo 0.9 % saline on Day 29."},{"id":"OG016","title":"Cohort 3: Ad26.ZEBOV, MVA-BN-Filo, 56-Day Interval","description":"Participants (Healthy Children \\[4-11 years\\]) received IM injection of Ad26.ZEBOV 5\\*10\\^10 vp on Day 1 followed by IM injection of MVA-BN-filo 1\\*10\\^8 Inf.U on Day 57."},{"id":"OG017","title":"Cohort 3: Placebo, Placebo, 56-Day Interval","description":"Participants (Healthy Children \\[4-11 years\\]) received IM injection of Placebo 0.9 % saline on Day 1 followed by IM injection of Placebo 0.9 % saline on Day 57."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"225"},{"groupId":"OG001","value":"43"},{"groupId":"OG002","value":"224"},{"groupId":"OG003","value":"44"},{"groupId":"OG004","value":"110"},{"groupId":"OG005","value":"22"},{"groupId":"OG006","value":"59"},{"groupId":"OG007","value":"12"},{"groupId":"OG008","value":"59"},{"groupId":"OG009","value":"12"},{"groupId":"OG010","value":"55"},{"groupId":"OG011","value":"11"},{"groupId":"OG012","value":"55"},{"groupId":"OG013","value":"10"},{"groupId":"OG014","value":"54"},{"groupId":"OG015","value":"12"},{"groupId":"OG016","value":"54"},{"groupId":"OG017","value":"12"}]}],"classes":[{"title":"Day 50 (21 days post-dose 2)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"171"},{"groupId":"OG001","value":"30"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"58"},{"groupId":"OG007","value":"11"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"53"},{"groupId":"OG011","value":"10"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"53"},{"groupId":"OG015","value":"12"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3085","lowerLimit":"2648","upperLimit":"3594"},{"groupId":"OG001","value":"NA","lowerLimit":"NA","upperLimit":"NA","comment":"Here, \"NA\" signifies that the calculated Geometric mean and its 95% CI were less than LLOQ 36.11 ELISA units/mL)."},{"groupId":"OG006","value":"4207","lowerLimit":"3233","upperLimit":"5474"},{"groupId":"OG007","value":"NA","lowerLimit":"NA","upperLimit":"39","comment":"Here, \"NA\" signifies that the calculated Geometric mean and its lower limit of 95% CI were less than LLOQ 36.11 ELISA units/mL)."},{"groupId":"OG010","value":"6993","lowerLimit":"5256","upperLimit":"9303"},{"groupId":"OG011","value":"NA","lowerLimit":"NA","upperLimit":"74","comment":"Here, \"NA\" signifies that the calculated Geometric mean and its lower limit of 95% CI were less than LLOQ 36.11 ELISA units/mL)."},{"groupId":"OG014","value":"8007","lowerLimit":"6321","upperLimit":"10142"},{"groupId":"OG015","value":"NA","lowerLimit":"NA","upperLimit":"82","comment":"Here, \"NA\" signifies that the calculated Geometric mean and its lower limit of 95% CI were less than LLOQ 36.11 ELISA units/mL)."}]}]},{"title":"Day 78 (21 days post-dose 2)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"136"},{"groupId":"OG003","value":"24"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"59"},{"groupId":"OG009","value":"12"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"53"},{"groupId":"OG013","value":"10"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"53"},{"groupId":"OG017","value":"11"}]}],"categories":[{"measurements":[{"groupId":"OG002","value":"7518","lowerLimit":"6468","upperLimit":"8740"},{"groupId":"OG003","value":"NA","lowerLimit":"NA","upperLimit":"53","comment":"Here, \"NA\" signifies that the calculated Geometric mean and its lower limit of 95% CI were less than LLOQ 36.11 ELISA units/mL)"},{"groupId":"OG008","value":"5283","lowerLimit":"4094","upperLimit":"6817"},{"groupId":"OG009","value":"NA","lowerLimit":"NA","upperLimit":"NA","comment":"Here, \"NA\" signifies that the calculated Geometric mean and its 95% CI were less than LLOQ 36.11 ELISA units/mL)."},{"groupId":"OG012","value":"13532","lowerLimit":"10732","upperLimit":"17061"},{"groupId":"OG013","value":"37","lowerLimit":"NA","upperLimit":"89","comment":"Here, \"NA\" signifies that the calculated Geometric mean and its lower limit of 95% CI were less than LLOQ 36.11 ELISA units/mL)."},{"groupId":"OG016","value":"17388","lowerLimit":"12973","upperLimit":"23306"},{"groupId":"OG017","value":"NA","lowerLimit":"NA","upperLimit":"NA","comment":"Here, \"NA\" signifies that the calculated Geometric mean and its 95% CI were less than LLOQ 36.11 ELISA units/mL)."}]}]},{"title":"Day 106 (21 days post-dose 2)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"27"},{"groupId":"OG005","value":"7"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG004","value":"7300","lowerLimit":"5116","upperLimit":"10417"},{"groupId":"OG005","value":"NA","lowerLimit":"NA","upperLimit":"NA","comment":"Here, \"NA\" signifies that the calculated Geometric mean and its 95% CI were less than LLOQ 36.11 ELISA units/mL)."}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Serious Adverse Events Post-dose 3","description":"A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.","populationDescription":"Full analysis set included all participants who were randomized and received at least 1 dose of study vaccine (Ad26.ZEBOV, MVA-BN-Filo or placebo).","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up 28 days post-dose 3 (Day 393)","groups":[{"id":"OG000","title":"Cohort 1: Ad26.ZEBOV, MVA-BN-Filo, Ad26.ZEBOV, 28-Day Interval","description":"Participants (healthy adults and elderly) received intramuscular (IM) injection of Ad26.ZEBOV 5\\*10\\^10 viral particles (vp) on Day 1 followed by IM injection of MVA-BN-filo 1\\*10\\^8 infectious units (Inf.U) on Day 29. Subset of participants who earlier received Ad26.ZEBOV and MVA-BN-Filo (at selected sites), afterwards received IM injection of Ad26.ZEBOV 5\\*10\\^10 vp as a booster dose at 1 year post dose 1 (Day 365)."},{"id":"OG001","title":"Cohort 1: Placebo, Placebo, Placebo, 28-Day Interval","description":"Participants (healthy adults and elderly) received IM injection of Placebo 0.9 percent (%) saline on Day 1 followed by IM injection of placebo 0.9 % saline on Day 29. Subset of participants who earlier received placebo(at selected sites), afterwards received IM injection of placebo 0.9 % saline as a booster dose at 1 year post dose 1 (Day 365)."},{"id":"OG002","title":"Cohort 1: Ad26.ZEBOV, MVA-BN-Filo, Ad26.ZEBOV, 56-Day Interval","description":"Participants (healthy adults and elderly) received IM injection of Ad26.ZEBOV 5\\*10\\^10 vp on Day 1 followed by IM injection of MVA-BN-filo Inf.U on Day 57. Subset of participants who earlier received Ad26.ZEBOV and MVA-BN-Filo (at selected sites), afterwards received IM injection of Ad26.ZEBOV 5\\*10\\^10 vp as a booster dose at 1 year post dose 1 (Day 365)."},{"id":"OG003","title":"Cohort 1: Placebo, Placebo, Placebo, 56-Day Interval","description":"Participants (healthy adults and elderly) received placebo 0.9% saline on Day 1 followed by IM injection of placebo 0.9% saline on Day 57. Subset of participants who earlier received Placebo (at selected sites), afterwards received IM injection of Placebo 0.9 % saline as a booster dose at 1 year post dose 1 (Day 365)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"39"},{"groupId":"OG003","value":"9"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"Up to 3 years and 3 months","description":"Full analysis set included all participants who were randomized and received at least 1 dose of study vaccine (Ad26.ZEBOV, MVA-BN-Filo or placebo).","eventGroups":[{"id":"EG000","title":"Cohort 1: Ad26.ZEBOV, MVA-BN-Filo, Ad26.ZEBOV, 28-Day Interval","description":"Participants (healthy adults and elderly) received intramuscular (IM) injection of Ad26.ZEBOV 5\\*10\\^10 viral particles (vp) on Day 1 followed by IM injection of MVA-BN-filo 1\\*10\\^8 infectious units (Inf.U) on Day 29. Subset of participants who earlier received Ad26.ZEBOV and MVA-BN-Filo (at selected sites), afterwards received IM injection of Ad26.ZEBOV 5\\*10\\^10 vp as a booster dose at 1 year post dose 1 (Day 365).","deathsNumAffected":0,"deathsNumAtRisk":225,"seriousNumAffected":7,"seriousNumAtRisk":225,"otherNumAffected":94,"otherNumAtRisk":225},{"id":"EG001","title":"Cohort 1: Placebo, Placebo, Placebo, 28-Day Interval","description":"Participants (healthy adults and elderly) received IM injection of Placebo 0.9 percent (%) saline on Day 1 followed by IM injection of placebo 0.9 % saline on Day 29. Subset of participants who earlier received placebo(at selected sites), afterwards received IM injection of placebo 0.9 % saline as a booster dose at 1 year post dose 1 (Day 365).","deathsNumAffected":0,"deathsNumAtRisk":43,"seriousNumAffected":1,"seriousNumAtRisk":43,"otherNumAffected":17,"otherNumAtRisk":43},{"id":"EG002","title":"Cohort 1: Ad26.ZEBOV, MVA-BN-Filo, Ad26.ZEBOV, 56-Day Interval","description":"Participants (healthy adults and elderly) received IM injection of Ad26.ZEBOV 5\\*10\\^10 vp on Day 1 followed by IM injection of MVA-BN-filo Inf.U on Day 57. Subset of participants who earlier received Ad26.ZEBOV and MVA-BN-Filo (at selected sites), afterwards received IM injection of Ad26.ZEBOV 5\\*10\\^10 vp as a booster dose at 1 year post dose 1 (Day 365).","deathsNumAffected":0,"deathsNumAtRisk":224,"seriousNumAffected":7,"seriousNumAtRisk":224,"otherNumAffected":80,"otherNumAtRisk":224},{"id":"EG003","title":"Cohort 1: Placebo, Placebo, Placebo, 56-Day Interval","description":"Participants (healthy adults and elderly) received placebo 0.9% saline on Day 1 followed by IM injection of placebo 0.9% saline on Day 57. Subset of participants who earlier received Placebo (at selected sites), afterwards received IM injection of Placebo 0.9 % saline as a booster dose at 1 year post dose 1 (Day 365).","deathsNumAffected":0,"deathsNumAtRisk":44,"seriousNumAffected":0,"seriousNumAtRisk":44,"otherNumAffected":21,"otherNumAtRisk":44},{"id":"EG004","title":"Cohort 1: Ad26.ZEBOV, MVA-BN-Filo, 84-Day Interval","description":"Participants (healthy adults and elderly) received IM injection of Ad26.ZEBOV 5\\*10\\^10 vp on Day 1 followed by IM injection of MVA-BN-filo 1\\*10\\^8 Inf.U on Day 85.","deathsNumAffected":0,"deathsNumAtRisk":110,"seriousNumAffected":6,"seriousNumAtRisk":110,"otherNumAffected":43,"otherNumAtRisk":110},{"id":"EG005","title":"Cohort 1: Placebo, Placebo, 84-Day Interval","description":"Participants (healthy adults and elderly) received IM injection of Placebo 0.9 % saline on Day 1 followed by IM injection of Placebo 0.9 % saline on Day 85.","deathsNumAffected":0,"deathsNumAtRisk":22,"seriousNumAffected":0,"seriousNumAtRisk":22,"otherNumAffected":12,"otherNumAtRisk":22},{"id":"EG006","title":"Cohort 2a: Ad26.ZEBOV, MVA-BN-Filo, 28-Day Interval","description":"Participants (human immunodeficiency virus \\[HIV\\]-infected adults) received IM injection of Ad26.ZEBOV 5\\*10\\^10 vp on Day 1 followed by IM injection of MVA-BN-filo 1\\*10\\^8 Inf.U on Day 29.","deathsNumAffected":1,"deathsNumAtRisk":59,"seriousNumAffected":1,"seriousNumAtRisk":59,"otherNumAffected":24,"otherNumAtRisk":59},{"id":"EG007","title":"Cohort 2a: Placebo, Placebo, 28-Day Interval","description":"Participants (HIV-infected adults) received IM injection of Placebo 0.9 % saline on Day 1 followed by IM injection of Placebo 0.9 % saline on Day 29.","deathsNumAffected":0,"deathsNumAtRisk":12,"seriousNumAffected":0,"seriousNumAtRisk":12,"otherNumAffected":9,"otherNumAtRisk":12},{"id":"EG008","title":"Cohort 2a: Ad26.ZEBOV, MVA-BN-Filo, 56-Day Interval","description":"Participants (HIV-infected adults) received IM injection of Ad26.ZEBOV 5\\*10\\^10 vp on Day 1 followed by IM injection of MVA-BN-filo 1\\*10\\^8 Inf.U on Day 57.","deathsNumAffected":0,"deathsNumAtRisk":59,"seriousNumAffected":1,"seriousNumAtRisk":59,"otherNumAffected":28,"otherNumAtRisk":59},{"id":"EG009","title":"Cohort 2a: Placebo, Placebo, 56-Day Interval","description":"Participants (HIV-infected adults) received IM injection of Placebo 0.9 % saline on Day 1 followed by IM injection of Placebo 0.9 % saline on Day 57.","deathsNumAffected":0,"deathsNumAtRisk":12,"seriousNumAffected":0,"seriousNumAtRisk":12,"otherNumAffected":5,"otherNumAtRisk":12},{"id":"EG010","title":"Cohort 2b: Ad26.ZEBOV, MVA-BN-Filo, 28-Day Interval","description":"Participants (Healthy Adolescents \\[12-17 years\\]) received IM injection of Ad26.ZEBOV 5\\*10\\^10 vp on Day 1 followed by IM injection of MVA-BN-filo 1\\*10\\^8 Inf.U on Day 29.","deathsNumAffected":1,"deathsNumAtRisk":55,"seriousNumAffected":1,"seriousNumAtRisk":55,"otherNumAffected":29,"otherNumAtRisk":55},{"id":"EG011","title":"Cohort 2b: Placebo, Placebo, 28-Day Interval","description":"Participants (Healthy Adolescents \\[12-17 years\\]) received IM injection of Placebo 0.9 % saline on Day 1 followed by IM injection of Placebo 0.9 % saline on Day 29.","deathsNumAffected":0,"deathsNumAtRisk":11,"seriousNumAffected":0,"seriousNumAtRisk":11,"otherNumAffected":5,"otherNumAtRisk":11},{"id":"EG012","title":"Cohort 2b: Ad26.ZEBOV, MVA-BN-Filo, 56-Day Interval","description":"Participants ((Healthy Adolescents \\[12-17 years\\]) received IM injection of Ad26.ZEBOV 5\\*10\\^10 vp on Day 1 followed by IM injection of MVA-BN-filo 1\\*10\\^8 Inf.U on Day 57.","deathsNumAffected":0,"deathsNumAtRisk":55,"seriousNumAffected":0,"seriousNumAtRisk":55,"otherNumAffected":33,"otherNumAtRisk":55},{"id":"EG013","title":"Cohort 2b: Placebo, Placebo, 56-Day Interval","description":"Participants (Healthy Adolescents \\[12-17 years\\]) received IM injection of Placebo 0.9 % saline on Day 1 followed by IM injection of Placebo 0.9 % saline on Day 57.","deathsNumAffected":0,"deathsNumAtRisk":10,"seriousNumAffected":0,"seriousNumAtRisk":10,"otherNumAffected":6,"otherNumAtRisk":10},{"id":"EG014","title":"Cohort 3: Ad26.ZEBOV, MVA-BN-Filo, 28-Day Interval","description":"Participants (Healthy Children \\[4-11 years\\]) received IM injection of Ad26.ZEBOV 5\\*10\\^10 vp on Day 1 followed by IM injection of MVA-BN-filo 1\\*10\\^8 Inf.U on Day 29.","deathsNumAffected":0,"deathsNumAtRisk":54,"seriousNumAffected":1,"seriousNumAtRisk":54,"otherNumAffected":27,"otherNumAtRisk":54},{"id":"EG015","title":"Cohort 3: Placebo, Placebo, 28-Day Interval","description":"Participants (Healthy Children \\[4-11 years\\]) received IM injection of Placebo 0.9 % saline on Day 1 followed by IM injection of Placebo 0.9 % saline on Day 29.","deathsNumAffected":0,"deathsNumAtRisk":12,"seriousNumAffected":0,"seriousNumAtRisk":12,"otherNumAffected":9,"otherNumAtRisk":12},{"id":"EG016","title":"Cohort 3: Ad26.ZEBOV, MVA-BN-Filo, 56-Day Interval","description":"Participants (Healthy Children \\[4-11 years\\]) received IM injection of Ad26.ZEBOV 5\\*10\\^10 vp on Day 1 followed by IM injection of MVA-BN-filo 1\\*10\\^8 Inf.U on Day 57.","deathsNumAffected":0,"deathsNumAtRisk":54,"seriousNumAffected":0,"seriousNumAtRisk":54,"otherNumAffected":22,"otherNumAtRisk":54},{"id":"EG017","title":"Cohort 3: Placebo, Placebo, 56-Day Interval","description":"Participants (Healthy Children \\[4-11 years\\]) received IM injection of Placebo 0.9 % saline on Day 1 followed by IM injection of Placebo 0.9 % saline on Day 57.","deathsNumAffected":0,"deathsNumAtRisk":12,"seriousNumAffected":1,"seriousNumAtRisk":12,"otherNumAffected":9,"otherNumAtRisk":12}],"seriousEvents":[{"term":"Dolichocolon","organSystem":"Congenital, familial and genetic disorders","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":225},{"groupId":"EG001","numAffected":0,"numAtRisk":43},{"groupId":"EG002","numAffected":0,"numAtRisk":224},{"groupId":"EG003","numAffected":0,"numAtRisk":44},{"groupId":"EG004","numAffected":0,"numAtRisk":110},{"groupId":"EG005","numAffected":0,"numAtRisk":22},{"groupId":"EG006","numAffected":0,"numAtRisk":59},{"groupId":"EG007","numAffected":0,"numAtRisk":12},{"groupId":"EG008","numAffected":0,"numAtRisk":59},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":55},{"groupId":"EG011","numAffected":0,"numAtRisk":11},{"groupId":"EG012","numAffected":0,"numAtRisk":55},{"groupId":"EG013","numAffected":0,"numAtRisk":10},{"groupId":"EG014","numAffected":0,"numAtRisk":54},{"groupId":"EG015","numAffected":0,"numAtRisk":12},{"groupId":"EG016","numAffected":0,"numAtRisk":54},{"groupId":"EG017","numAffected":0,"numAtRisk":12}]},{"term":"Meniere's Disease","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":225},{"groupId":"EG001","numAffected":1,"numAtRisk":43},{"groupId":"EG002","numAffected":0,"numAtRisk":224},{"groupId":"EG003","numAffected":0,"numAtRisk":44},{"groupId":"EG004","numAffected":0,"numAtRisk":110},{"groupId":"EG005","numAffected":0,"numAtRisk":22},{"groupId":"EG006","numAffected":0,"numAtRisk":59},{"groupId":"EG007","numAffected":0,"numAtRisk":12},{"groupId":"EG008","numAffected":0,"numAtRisk":59},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":55},{"groupId":"EG011","numAffected":0,"numAtRisk":11},{"groupId":"EG012","numAffected":0,"numAtRisk":55},{"groupId":"EG013","numAffected":0,"numAtRisk":10},{"groupId":"EG014","numAffected":0,"numAtRisk":54},{"groupId":"EG015","numAffected":0,"numAtRisk":12},{"groupId":"EG016","numAffected":0,"numAtRisk":54},{"groupId":"EG017","numAffected":0,"numAtRisk":12}]},{"term":"Cataract","organSystem":"Eye disorders","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":225},{"groupId":"EG001","numAffected":0,"numAtRisk":43},{"groupId":"EG002","numAffected":1,"numAtRisk":224},{"groupId":"EG003","numAffected":0,"numAtRisk":44},{"groupId":"EG004","numAffected":0,"numAtRisk":110},{"groupId":"EG005","numAffected":0,"numAtRisk":22},{"groupId":"EG006","numAffected":0,"numAtRisk":59},{"groupId":"EG007","numAffected":0,"numAtRisk":12},{"groupId":"EG008","numAffected":0,"numAtRisk":59},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":55},{"groupId":"EG011","numAffected":0,"numAtRisk":11},{"groupId":"EG012","numAffected":0,"numAtRisk":55},{"groupId":"EG013","numAffected":0,"numAtRisk":10},{"groupId":"EG014","numAffected":0,"numAtRisk":54},{"groupId":"EG015","numAffected":0,"numAtRisk":12},{"groupId":"EG016","numAffected":0,"numAtRisk":54},{"groupId":"EG017","numAffected":0,"numAtRisk":12}]},{"term":"Glaucoma","organSystem":"Eye disorders","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":225},{"groupId":"EG001","numAffected":0,"numAtRisk":43},{"groupId":"EG002","numAffected":0,"numAtRisk":224},{"groupId":"EG003","numAffected":0,"numAtRisk":44},{"groupId":"EG004","numAffected":0,"numAtRisk":110},{"groupId":"EG005","numAffected":0,"numAtRisk":22},{"groupId":"EG006","numAffected":0,"numAtRisk":59},{"groupId":"EG007","numAffected":0,"numAtRisk":12},{"groupId":"EG008","numAffected":0,"numAtRisk":59},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":55},{"groupId":"EG011","numAffected":0,"numAtRisk":11},{"groupId":"EG012","numAffected":0,"numAtRisk":55},{"groupId":"EG013","numAffected":0,"numAtRisk":10},{"groupId":"EG014","numAffected":0,"numAtRisk":54},{"groupId":"EG015","numAffected":0,"numAtRisk":12},{"groupId":"EG016","numAffected":0,"numAtRisk":54},{"groupId":"EG017","numAffected":0,"numAtRisk":12}]},{"term":"Inguinal Hernia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":225},{"groupId":"EG001","numAffected":0,"numAtRisk":43},{"groupId":"EG002","numAffected":1,"numAtRisk":224},{"groupId":"EG003","numAffected":0,"numAtRisk":44},{"groupId":"EG004","numAffected":1,"numAtRisk":110},{"groupId":"EG005","numAffected":0,"numAtRisk":22},{"groupId":"EG006","numAffected":0,"numAtRisk":59},{"groupId":"EG007","numAffected":0,"numAtRisk":12},{"groupId":"EG008","numAffected":0,"numAtRisk":59},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":55},{"groupId":"EG011","numAffected":0,"numAtRisk":11},{"groupId":"EG012","numAffected":0,"numAtRisk":55},{"groupId":"EG013","numAffected":0,"numAtRisk":10},{"groupId":"EG014","numAffected":0,"numAtRisk":54},{"groupId":"EG015","numAffected":0,"numAtRisk":12},{"groupId":"EG016","numAffected":0,"numAtRisk":54},{"groupId":"EG017","numAffected":0,"numAtRisk":12}]},{"term":"Obstruction Gastric","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":225},{"groupId":"EG001","numAffected":0,"numAtRisk":43},{"groupId":"EG002","numAffected":1,"numAtRisk":224},{"groupId":"EG003","numAffected":0,"numAtRisk":44},{"groupId":"EG004","numAffected":0,"numAtRisk":110},{"groupId":"EG005","numAffected":0,"numAtRisk":22},{"groupId":"EG006","numAffected":0,"numAtRisk":59},{"groupId":"EG007","numAffected":0,"numAtRisk":12},{"groupId":"EG008","numAffected":0,"numAtRisk":59},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":55},{"groupId":"EG011","numAffected":0,"numAtRisk":11},{"groupId":"EG012","numAffected":0,"numAtRisk":55},{"groupId":"EG013","numAffected":0,"numAtRisk":10},{"groupId":"EG014","numAffected":0,"numAtRisk":54},{"groupId":"EG015","numAffected":0,"numAtRisk":12},{"groupId":"EG016","numAffected":0,"numAtRisk":54},{"groupId":"EG017","numAffected":0,"numAtRisk":12}]},{"term":"Cellulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":225},{"groupId":"EG001","numAffected":0,"numAtRisk":43},{"groupId":"EG002","numAffected":0,"numAtRisk":224},{"groupId":"EG003","numAffected":0,"numAtRisk":44},{"groupId":"EG004","numAffected":0,"numAtRisk":110},{"groupId":"EG005","numAffected":0,"numAtRisk":22},{"groupId":"EG006","numAffected":0,"numAtRisk":59},{"groupId":"EG007","numAffected":0,"numAtRisk":12},{"groupId":"EG008","numAffected":0,"numAtRisk":59},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":55},{"groupId":"EG011","numAffected":0,"numAtRisk":11},{"groupId":"EG012","numAffected":0,"numAtRisk":55},{"groupId":"EG013","numAffected":0,"numAtRisk":10},{"groupId":"EG014","numAffected":0,"numAtRisk":54},{"groupId":"EG015","numAffected":0,"numAtRisk":12},{"groupId":"EG016","numAffected":0,"numAtRisk":54},{"groupId":"EG017","numAffected":0,"numAtRisk":12}]},{"term":"Malaria","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":225},{"groupId":"EG001","numAffected":1,"numAtRisk":43},{"groupId":"EG002","numAffected":3,"numAtRisk":224},{"groupId":"EG003","numAffected":0,"numAtRisk":44},{"groupId":"EG004","numAffected":3,"numAtRisk":110},{"groupId":"EG005","numAffected":0,"numAtRisk":22},{"groupId":"EG006","numAffected":0,"numAtRisk":59},{"groupId":"EG007","numAffected":0,"numAtRisk":12},{"groupId":"EG008","numAffected":0,"numAtRisk":59},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":1,"numAtRisk":55},{"groupId":"EG011","numAffected":0,"numAtRisk":11},{"groupId":"EG012","numAffected":0,"numAtRisk":55},{"groupId":"EG013","numAffected":0,"numAtRisk":10},{"groupId":"EG014","numAffected":1,"numAtRisk":54},{"groupId":"EG015","numAffected":0,"numAtRisk":12},{"groupId":"EG016","numAffected":0,"numAtRisk":54},{"groupId":"EG017","numAffected":0,"numAtRisk":12}]},{"term":"Pulmonary Tuberculosis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":225},{"groupId":"EG001","numAffected":0,"numAtRisk":43},{"groupId":"EG002","numAffected":0,"numAtRisk":224},{"groupId":"EG003","numAffected":0,"numAtRisk":44},{"groupId":"EG004","numAffected":1,"numAtRisk":110},{"groupId":"EG005","numAffected":0,"numAtRisk":22},{"groupId":"EG006","numAffected":0,"numAtRisk":59},{"groupId":"EG007","numAffected":0,"numAtRisk":12},{"groupId":"EG008","numAffected":0,"numAtRisk":59},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":55},{"groupId":"EG011","numAffected":0,"numAtRisk":11},{"groupId":"EG012","numAffected":0,"numAtRisk":55},{"groupId":"EG013","numAffected":0,"numAtRisk":10},{"groupId":"EG014","numAffected":0,"numAtRisk":54},{"groupId":"EG015","numAffected":0,"numAtRisk":12},{"groupId":"EG016","numAffected":0,"numAtRisk":54},{"groupId":"EG017","numAffected":0,"numAtRisk":12}]},{"term":"Typhoid Fever","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":225},{"groupId":"EG001","numAffected":0,"numAtRisk":43},{"groupId":"EG002","numAffected":0,"numAtRisk":224},{"groupId":"EG003","numAffected":0,"numAtRisk":44},{"groupId":"EG004","numAffected":0,"numAtRisk":110},{"groupId":"EG005","numAffected":0,"numAtRisk":22},{"groupId":"EG006","numAffected":0,"numAtRisk":59},{"groupId":"EG007","numAffected":0,"numAtRisk":12},{"groupId":"EG008","numAffected":0,"numAtRisk":59},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":1,"numAtRisk":55},{"groupId":"EG011","numAffected":0,"numAtRisk":11},{"groupId":"EG012","numAffected":0,"numAtRisk":55},{"groupId":"EG013","numAffected":0,"numAtRisk":10},{"groupId":"EG014","numAffected":0,"numAtRisk":54},{"groupId":"EG015","numAffected":0,"numAtRisk":12},{"groupId":"EG016","numAffected":0,"numAtRisk":54},{"groupId":"EG017","numAffected":0,"numAtRisk":12}]},{"term":"Alcohol Poisoning","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":225},{"groupId":"EG001","numAffected":0,"numAtRisk":43},{"groupId":"EG002","numAffected":0,"numAtRisk":224},{"groupId":"EG003","numAffected":0,"numAtRisk":44},{"groupId":"EG004","numAffected":0,"numAtRisk":110},{"groupId":"EG005","numAffected":0,"numAtRisk":22},{"groupId":"EG006","numAffected":1,"numAtRisk":59},{"groupId":"EG007","numAffected":0,"numAtRisk":12},{"groupId":"EG008","numAffected":0,"numAtRisk":59},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":55},{"groupId":"EG011","numAffected":0,"numAtRisk":11},{"groupId":"EG012","numAffected":0,"numAtRisk":55},{"groupId":"EG013","numAffected":0,"numAtRisk":10},{"groupId":"EG014","numAffected":0,"numAtRisk":54},{"groupId":"EG015","numAffected":0,"numAtRisk":12},{"groupId":"EG016","numAffected":0,"numAtRisk":54},{"groupId":"EG017","numAffected":0,"numAtRisk":12}]},{"term":"Burns Second Degree","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":225},{"groupId":"EG001","numAffected":0,"numAtRisk":43},{"groupId":"EG002","numAffected":0,"numAtRisk":224},{"groupId":"EG003","numAffected":0,"numAtRisk":44},{"groupId":"EG004","numAffected":0,"numAtRisk":110},{"groupId":"EG005","numAffected":0,"numAtRisk":22},{"groupId":"EG006","numAffected":0,"numAtRisk":59},{"groupId":"EG007","numAffected":0,"numAtRisk":12},{"groupId":"EG008","numAffected":0,"numAtRisk":59},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":55},{"groupId":"EG011","numAffected":0,"numAtRisk":11},{"groupId":"EG012","numAffected":0,"numAtRisk":55},{"groupId":"EG013","numAffected":0,"numAtRisk":10},{"groupId":"EG014","numAffected":0,"numAtRisk":54},{"groupId":"EG015","numAffected":0,"numAtRisk":12},{"groupId":"EG016","numAffected":0,"numAtRisk":54},{"groupId":"EG017","numAffected":1,"numAtRisk":12}]},{"term":"Ligament Sprain","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":225},{"groupId":"EG001","numAffected":0,"numAtRisk":43},{"groupId":"EG002","numAffected":0,"numAtRisk":224},{"groupId":"EG003","numAffected":0,"numAtRisk":44},{"groupId":"EG004","numAffected":0,"numAtRisk":110},{"groupId":"EG005","numAffected":0,"numAtRisk":22},{"groupId":"EG006","numAffected":0,"numAtRisk":59},{"groupId":"EG007","numAffected":0,"numAtRisk":12},{"groupId":"EG008","numAffected":0,"numAtRisk":59},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":55},{"groupId":"EG011","numAffected":0,"numAtRisk":11},{"groupId":"EG012","numAffected":0,"numAtRisk":55},{"groupId":"EG013","numAffected":0,"numAtRisk":10},{"groupId":"EG014","numAffected":0,"numAtRisk":54},{"groupId":"EG015","numAffected":0,"numAtRisk":12},{"groupId":"EG016","numAffected":0,"numAtRisk":54},{"groupId":"EG017","numAffected":0,"numAtRisk":12}]},{"term":"Electrolyte Imbalance","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":225},{"groupId":"EG001","numAffected":0,"numAtRisk":43},{"groupId":"EG002","numAffected":1,"numAtRisk":224},{"groupId":"EG003","numAffected":0,"numAtRisk":44},{"groupId":"EG004","numAffected":0,"numAtRisk":110},{"groupId":"EG005","numAffected":0,"numAtRisk":22},{"groupId":"EG006","numAffected":0,"numAtRisk":59},{"groupId":"EG007","numAffected":0,"numAtRisk":12},{"groupId":"EG008","numAffected":0,"numAtRisk":59},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":55},{"groupId":"EG011","numAffected":0,"numAtRisk":11},{"groupId":"EG012","numAffected":0,"numAtRisk":55},{"groupId":"EG013","numAffected":0,"numAtRisk":10},{"groupId":"EG014","numAffected":0,"numAtRisk":54},{"groupId":"EG015","numAffected":0,"numAtRisk":12},{"groupId":"EG016","numAffected":0,"numAtRisk":54},{"groupId":"EG017","numAffected":0,"numAtRisk":12}]},{"term":"Abortion Spontaneous","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":225},{"groupId":"EG001","numAffected":0,"numAtRisk":43},{"groupId":"EG002","numAffected":1,"numAtRisk":224},{"groupId":"EG003","numAffected":0,"numAtRisk":44},{"groupId":"EG004","numAffected":0,"numAtRisk":110},{"groupId":"EG005","numAffected":0,"numAtRisk":22},{"groupId":"EG006","numAffected":0,"numAtRisk":59},{"groupId":"EG007","numAffected":0,"numAtRisk":12},{"groupId":"EG008","numAffected":0,"numAtRisk":59},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":55},{"groupId":"EG011","numAffected":0,"numAtRisk":11},{"groupId":"EG012","numAffected":0,"numAtRisk":55},{"groupId":"EG013","numAffected":0,"numAtRisk":10},{"groupId":"EG014","numAffected":0,"numAtRisk":54},{"groupId":"EG015","numAffected":0,"numAtRisk":12},{"groupId":"EG016","numAffected":0,"numAtRisk":54},{"groupId":"EG017","numAffected":0,"numAtRisk":12}]},{"term":"Anembryonic Gestation","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":225},{"groupId":"EG001","numAffected":0,"numAtRisk":43},{"groupId":"EG002","numAffected":0,"numAtRisk":224},{"groupId":"EG003","numAffected":0,"numAtRisk":44},{"groupId":"EG004","numAffected":1,"numAtRisk":110},{"groupId":"EG005","numAffected":0,"numAtRisk":22},{"groupId":"EG006","numAffected":0,"numAtRisk":59},{"groupId":"EG007","numAffected":0,"numAtRisk":12},{"groupId":"EG008","numAffected":0,"numAtRisk":59},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":55},{"groupId":"EG011","numAffected":0,"numAtRisk":11},{"groupId":"EG012","numAffected":0,"numAtRisk":55},{"groupId":"EG013","numAffected":0,"numAtRisk":10},{"groupId":"EG014","numAffected":0,"numAtRisk":54},{"groupId":"EG015","numAffected":0,"numAtRisk":12},{"groupId":"EG016","numAffected":0,"numAtRisk":54},{"groupId":"EG017","numAffected":0,"numAtRisk":12}]},{"term":"Acute Kidney Injury","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":225},{"groupId":"EG001","numAffected":0,"numAtRisk":43},{"groupId":"EG002","numAffected":1,"numAtRisk":224},{"groupId":"EG003","numAffected":0,"numAtRisk":44},{"groupId":"EG004","numAffected":0,"numAtRisk":110},{"groupId":"EG005","numAffected":0,"numAtRisk":22},{"groupId":"EG006","numAffected":0,"numAtRisk":59},{"groupId":"EG007","numAffected":0,"numAtRisk":12},{"groupId":"EG008","numAffected":0,"numAtRisk":59},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":55},{"groupId":"EG011","numAffected":0,"numAtRisk":11},{"groupId":"EG012","numAffected":0,"numAtRisk":55},{"groupId":"EG013","numAffected":0,"numAtRisk":10},{"groupId":"EG014","numAffected":0,"numAtRisk":54},{"groupId":"EG015","numAffected":0,"numAtRisk":12},{"groupId":"EG016","numAffected":0,"numAtRisk":54},{"groupId":"EG017","numAffected":0,"numAtRisk":12}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":225},{"groupId":"EG001","numAffected":0,"numAtRisk":43},{"groupId":"EG002","numAffected":0,"numAtRisk":224},{"groupId":"EG003","numAffected":0,"numAtRisk":44},{"groupId":"EG004","numAffected":0,"numAtRisk":110},{"groupId":"EG005","numAffected":0,"numAtRisk":22},{"groupId":"EG006","numAffected":0,"numAtRisk":59},{"groupId":"EG007","numAffected":0,"numAtRisk":12},{"groupId":"EG008","numAffected":1,"numAtRisk":59},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":55},{"groupId":"EG011","numAffected":0,"numAtRisk":11},{"groupId":"EG012","numAffected":0,"numAtRisk":55},{"groupId":"EG013","numAffected":0,"numAtRisk":10},{"groupId":"EG014","numAffected":0,"numAtRisk":54},{"groupId":"EG015","numAffected":0,"numAtRisk":12},{"groupId":"EG016","numAffected":0,"numAtRisk":54},{"groupId":"EG017","numAffected":0,"numAtRisk":12}]}],"otherEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":225},{"groupId":"EG001","numAffected":0,"numAtRisk":43},{"groupId":"EG002","numAffected":1,"numAtRisk":224},{"groupId":"EG003","numAffected":0,"numAtRisk":44},{"groupId":"EG004","numAffected":0,"numAtRisk":110},{"groupId":"EG005","numAffected":0,"numAtRisk":22},{"groupId":"EG006","numAffected":0,"numAtRisk":59},{"groupId":"EG007","numAffected":1,"numAtRisk":12},{"groupId":"EG008","numAffected":1,"numAtRisk":59},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":1,"numAtRisk":55},{"groupId":"EG011","numAffected":0,"numAtRisk":11},{"groupId":"EG012","numAffected":1,"numAtRisk":55},{"groupId":"EG013","numAffected":0,"numAtRisk":10},{"groupId":"EG014","numAffected":3,"numAtRisk":54},{"groupId":"EG015","numAffected":1,"numAtRisk":12},{"groupId":"EG016","numAffected":1,"numAtRisk":54},{"groupId":"EG017","numAffected":1,"numAtRisk":12}]},{"term":"Leukopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":225},{"groupId":"EG001","numAffected":1,"numAtRisk":43},{"groupId":"EG002","numAffected":4,"numAtRisk":224},{"groupId":"EG003","numAffected":1,"numAtRisk":44},{"groupId":"EG004","numAffected":0,"numAtRisk":110},{"groupId":"EG005","numAffected":0,"numAtRisk":22},{"groupId":"EG006","numAffected":1,"numAtRisk":59},{"groupId":"EG007","numAffected":1,"numAtRisk":12},{"groupId":"EG008","numAffected":3,"numAtRisk":59},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":55},{"groupId":"EG011","numAffected":2,"numAtRisk":11},{"groupId":"EG012","numAffected":0,"numAtRisk":55},{"groupId":"EG013","numAffected":0,"numAtRisk":10},{"groupId":"EG014","numAffected":2,"numAtRisk":54},{"groupId":"EG015","numAffected":0,"numAtRisk":12},{"groupId":"EG016","numAffected":1,"numAtRisk":54},{"groupId":"EG017","numAffected":1,"numAtRisk":12}]},{"term":"Microcytic Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":225},{"groupId":"EG001","numAffected":0,"numAtRisk":43},{"groupId":"EG002","numAffected":0,"numAtRisk":224},{"groupId":"EG003","numAffected":0,"numAtRisk":44},{"groupId":"EG004","numAffected":0,"numAtRisk":110},{"groupId":"EG005","numAffected":0,"numAtRisk":22},{"groupId":"EG006","numAffected":0,"numAtRisk":59},{"groupId":"EG007","numAffected":0,"numAtRisk":12},{"groupId":"EG008","numAffected":0,"numAtRisk":59},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":1,"numAtRisk":55},{"groupId":"EG011","numAffected":0,"numAtRisk":11},{"groupId":"EG012","numAffected":0,"numAtRisk":55},{"groupId":"EG013","numAffected":1,"numAtRisk":10},{"groupId":"EG014","numAffected":0,"numAtRisk":54},{"groupId":"EG015","numAffected":0,"numAtRisk":12},{"groupId":"EG016","numAffected":0,"numAtRisk":54},{"groupId":"EG017","numAffected":0,"numAtRisk":12}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":14,"numAtRisk":225},{"groupId":"EG001","numAffected":1,"numAtRisk":43},{"groupId":"EG002","numAffected":8,"numAtRisk":224},{"groupId":"EG003","numAffected":4,"numAtRisk":44},{"groupId":"EG004","numAffected":2,"numAtRisk":110},{"groupId":"EG005","numAffected":2,"numAtRisk":22},{"groupId":"EG006","numAffected":2,"numAtRisk":59},{"groupId":"EG007","numAffected":2,"numAtRisk":12},{"groupId":"EG008","numAffected":6,"numAtRisk":59},{"groupId":"EG009","numAffected":1,"numAtRisk":12},{"groupId":"EG010","numAffected":2,"numAtRisk":55},{"groupId":"EG011","numAffected":0,"numAtRisk":11},{"groupId":"EG012","numAffected":3,"numAtRisk":55},{"groupId":"EG013","numAffected":1,"numAtRisk":10},{"groupId":"EG014","numAffected":1,"numAtRisk":54},{"groupId":"EG015","numAffected":1,"numAtRisk":12},{"groupId":"EG016","numAffected":1,"numAtRisk":54},{"groupId":"EG017","numAffected":1,"numAtRisk":12}]},{"term":"Bradycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":225},{"groupId":"EG001","numAffected":0,"numAtRisk":43},{"groupId":"EG002","numAffected":0,"numAtRisk":224},{"groupId":"EG003","numAffected":0,"numAtRisk":44},{"groupId":"EG004","numAffected":0,"numAtRisk":110},{"groupId":"EG005","numAffected":0,"numAtRisk":22},{"groupId":"EG006","numAffected":0,"numAtRisk":59},{"groupId":"EG007","numAffected":0,"numAtRisk":12},{"groupId":"EG008","numAffected":0,"numAtRisk":59},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":1,"numAtRisk":55},{"groupId":"EG011","numAffected":0,"numAtRisk":11},{"groupId":"EG012","numAffected":0,"numAtRisk":55},{"groupId":"EG013","numAffected":1,"numAtRisk":10},{"groupId":"EG014","numAffected":0,"numAtRisk":54},{"groupId":"EG015","numAffected":0,"numAtRisk":12},{"groupId":"EG016","numAffected":0,"numAtRisk":54},{"groupId":"EG017","numAffected":0,"numAtRisk":12}]},{"term":"Blepharitis","organSystem":"Eye disorders","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":225},{"groupId":"EG001","numAffected":0,"numAtRisk":43},{"groupId":"EG002","numAffected":0,"numAtRisk":224},{"groupId":"EG003","numAffected":0,"numAtRisk":44},{"groupId":"EG004","numAffected":0,"numAtRisk":110},{"groupId":"EG005","numAffected":0,"numAtRisk":22},{"groupId":"EG006","numAffected":0,"numAtRisk":59},{"groupId":"EG007","numAffected":0,"numAtRisk":12},{"groupId":"EG008","numAffected":0,"numAtRisk":59},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":55},{"groupId":"EG011","numAffected":1,"numAtRisk":11},{"groupId":"EG012","numAffected":0,"numAtRisk":55},{"groupId":"EG013","numAffected":0,"numAtRisk":10},{"groupId":"EG014","numAffected":0,"numAtRisk":54},{"groupId":"EG015","numAffected":0,"numAtRisk":12},{"groupId":"EG016","numAffected":0,"numAtRisk":54},{"groupId":"EG017","numAffected":0,"numAtRisk":12}]},{"term":"Conjunctivitis Allergic","organSystem":"Eye disorders","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":225},{"groupId":"EG001","numAffected":0,"numAtRisk":43},{"groupId":"EG002","numAffected":0,"numAtRisk":224},{"groupId":"EG003","numAffected":0,"numAtRisk":44},{"groupId":"EG004","numAffected":0,"numAtRisk":110},{"groupId":"EG005","numAffected":0,"numAtRisk":22},{"groupId":"EG006","numAffected":0,"numAtRisk":59},{"groupId":"EG007","numAffected":0,"numAtRisk":12},{"groupId":"EG008","numAffected":0,"numAtRisk":59},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":55},{"groupId":"EG011","numAffected":1,"numAtRisk":11},{"groupId":"EG012","numAffected":0,"numAtRisk":55},{"groupId":"EG013","numAffected":1,"numAtRisk":10},{"groupId":"EG014","numAffected":0,"numAtRisk":54},{"groupId":"EG015","numAffected":0,"numAtRisk":12},{"groupId":"EG016","numAffected":0,"numAtRisk":54},{"groupId":"EG017","numAffected":0,"numAtRisk":12}]},{"term":"Eye Pruritus","organSystem":"Eye disorders","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":225},{"groupId":"EG001","numAffected":0,"numAtRisk":43},{"groupId":"EG002","numAffected":0,"numAtRisk":224},{"groupId":"EG003","numAffected":0,"numAtRisk":44},{"groupId":"EG004","numAffected":0,"numAtRisk":110},{"groupId":"EG005","numAffected":0,"numAtRisk":22},{"groupId":"EG006","numAffected":0,"numAtRisk":59},{"groupId":"EG007","numAffected":0,"numAtRisk":12},{"groupId":"EG008","numAffected":0,"numAtRisk":59},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":55},{"groupId":"EG011","numAffected":0,"numAtRisk":11},{"groupId":"EG012","numAffected":0,"numAtRisk":55},{"groupId":"EG013","numAffected":0,"numAtRisk":10},{"groupId":"EG014","numAffected":0,"numAtRisk":54},{"groupId":"EG015","numAffected":0,"numAtRisk":12},{"groupId":"EG016","numAffected":0,"numAtRisk":54},{"groupId":"EG017","numAffected":1,"numAtRisk":12}]},{"term":"Abdominal Pain Lower","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":225},{"groupId":"EG001","numAffected":0,"numAtRisk":43},{"groupId":"EG002","numAffected":0,"numAtRisk":224},{"groupId":"EG003","numAffected":0,"numAtRisk":44},{"groupId":"EG004","numAffected":0,"numAtRisk":110},{"groupId":"EG005","numAffected":0,"numAtRisk":22},{"groupId":"EG006","numAffected":0,"numAtRisk":59},{"groupId":"EG007","numAffected":1,"numAtRisk":12},{"groupId":"EG008","numAffected":0,"numAtRisk":59},{"groupId":"EG009","numAffected":1,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":55},{"groupId":"EG011","numAffected":0,"numAtRisk":11},{"groupId":"EG012","numAffected":0,"numAtRisk":55},{"groupId":"EG013","numAffected":0,"numAtRisk":10},{"groupId":"EG014","numAffected":0,"numAtRisk":54},{"groupId":"EG015","numAffected":0,"numAtRisk":12},{"groupId":"EG016","numAffected":0,"numAtRisk":54},{"groupId":"EG017","numAffected":0,"numAtRisk":12}]},{"term":"Dental Caries","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":225},{"groupId":"EG001","numAffected":1,"numAtRisk":43},{"groupId":"EG002","numAffected":2,"numAtRisk":224},{"groupId":"EG003","numAffected":1,"numAtRisk":44},{"groupId":"EG004","numAffected":0,"numAtRisk":110},{"groupId":"EG005","numAffected":1,"numAtRisk":22},{"groupId":"EG006","numAffected":0,"numAtRisk":59},{"groupId":"EG007","numAffected":0,"numAtRisk":12},{"groupId":"EG008","numAffected":0,"numAtRisk":59},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":55},{"groupId":"EG011","numAffected":0,"numAtRisk":11},{"groupId":"EG012","numAffected":1,"numAtRisk":55},{"groupId":"EG013","numAffected":0,"numAtRisk":10},{"groupId":"EG014","numAffected":0,"numAtRisk":54},{"groupId":"EG015","numAffected":1,"numAtRisk":12},{"groupId":"EG016","numAffected":0,"numAtRisk":54},{"groupId":"EG017","numAffected":0,"numAtRisk":12}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":225},{"groupId":"EG001","numAffected":0,"numAtRisk":43},{"groupId":"EG002","numAffected":3,"numAtRisk":224},{"groupId":"EG003","numAffected":1,"numAtRisk":44},{"groupId":"EG004","numAffected":3,"numAtRisk":110},{"groupId":"EG005","numAffected":1,"numAtRisk":22},{"groupId":"EG006","numAffected":0,"numAtRisk":59},{"groupId":"EG007","numAffected":0,"numAtRisk":12},{"groupId":"EG008","numAffected":1,"numAtRisk":59},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":1,"numAtRisk":55},{"groupId":"EG011","numAffected":0,"numAtRisk":11},{"groupId":"EG012","numAffected":0,"numAtRisk":55},{"groupId":"EG013","numAffected":1,"numAtRisk":10},{"groupId":"EG014","numAffected":1,"numAtRisk":54},{"groupId":"EG015","numAffected":0,"numAtRisk":12},{"groupId":"EG016","numAffected":1,"numAtRisk":54},{"groupId":"EG017","numAffected":0,"numAtRisk":12}]},{"term":"Food Poisoning","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":225},{"groupId":"EG001","numAffected":0,"numAtRisk":43},{"groupId":"EG002","numAffected":0,"numAtRisk":224},{"groupId":"EG003","numAffected":0,"numAtRisk":44},{"groupId":"EG004","numAffected":0,"numAtRisk":110},{"groupId":"EG005","numAffected":0,"numAtRisk":22},{"groupId":"EG006","numAffected":0,"numAtRisk":59},{"groupId":"EG007","numAffected":0,"numAtRisk":12},{"groupId":"EG008","numAffected":0,"numAtRisk":59},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":55},{"groupId":"EG011","numAffected":0,"numAtRisk":11},{"groupId":"EG012","numAffected":0,"numAtRisk":55},{"groupId":"EG013","numAffected":0,"numAtRisk":10},{"groupId":"EG014","numAffected":0,"numAtRisk":54},{"groupId":"EG015","numAffected":1,"numAtRisk":12},{"groupId":"EG016","numAffected":0,"numAtRisk":54},{"groupId":"EG017","numAffected":0,"numAtRisk":12}]},{"term":"Chest Pain","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":225},{"groupId":"EG001","numAffected":0,"numAtRisk":43},{"groupId":"EG002","numAffected":2,"numAtRisk":224},{"groupId":"EG003","numAffected":1,"numAtRisk":44},{"groupId":"EG004","numAffected":0,"numAtRisk":110},{"groupId":"EG005","numAffected":0,"numAtRisk":22},{"groupId":"EG006","numAffected":0,"numAtRisk":59},{"groupId":"EG007","numAffected":0,"numAtRisk":12},{"groupId":"EG008","numAffected":1,"numAtRisk":59},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":1,"numAtRisk":55},{"groupId":"EG011","numAffected":0,"numAtRisk":11},{"groupId":"EG012","numAffected":1,"numAtRisk":55},{"groupId":"EG013","numAffected":1,"numAtRisk":10},{"groupId":"EG014","numAffected":0,"numAtRisk":54},{"groupId":"EG015","numAffected":0,"numAtRisk":12},{"groupId":"EG016","numAffected":0,"numAtRisk":54},{"groupId":"EG017","numAffected":0,"numAtRisk":12}]},{"term":"Hypersensitivity","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":225},{"groupId":"EG001","numAffected":0,"numAtRisk":43},{"groupId":"EG002","numAffected":0,"numAtRisk":224},{"groupId":"EG003","numAffected":0,"numAtRisk":44},{"groupId":"EG004","numAffected":0,"numAtRisk":110},{"groupId":"EG005","numAffected":0,"numAtRisk":22},{"groupId":"EG006","numAffected":0,"numAtRisk":59},{"groupId":"EG007","numAffected":0,"numAtRisk":12},{"groupId":"EG008","numAffected":0,"numAtRisk":59},{"groupId":"EG009","numAffected":1,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":55},{"groupId":"EG011","numAffected":0,"numAtRisk":11},{"groupId":"EG012","numAffected":0,"numAtRisk":55},{"groupId":"EG013","numAffected":0,"numAtRisk":10},{"groupId":"EG014","numAffected":0,"numAtRisk":54},{"groupId":"EG015","numAffected":0,"numAtRisk":12},{"groupId":"EG016","numAffected":0,"numAtRisk":54},{"groupId":"EG017","numAffected":0,"numAtRisk":12}]},{"term":"Bronchitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":225},{"groupId":"EG001","numAffected":2,"numAtRisk":43},{"groupId":"EG002","numAffected":4,"numAtRisk":224},{"groupId":"EG003","numAffected":0,"numAtRisk":44},{"groupId":"EG004","numAffected":0,"numAtRisk":110},{"groupId":"EG005","numAffected":0,"numAtRisk":22},{"groupId":"EG006","numAffected":0,"numAtRisk":59},{"groupId":"EG007","numAffected":0,"numAtRisk":12},{"groupId":"EG008","numAffected":1,"numAtRisk":59},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":55},{"groupId":"EG011","numAffected":0,"numAtRisk":11},{"groupId":"EG012","numAffected":0,"numAtRisk":55},{"groupId":"EG013","numAffected":0,"numAtRisk":10},{"groupId":"EG014","numAffected":4,"numAtRisk":54},{"groupId":"EG015","numAffected":1,"numAtRisk":12},{"groupId":"EG016","numAffected":2,"numAtRisk":54},{"groupId":"EG017","numAffected":2,"numAtRisk":12}]},{"term":"Conjunctivitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":225},{"groupId":"EG001","numAffected":0,"numAtRisk":43},{"groupId":"EG002","numAffected":2,"numAtRisk":224},{"groupId":"EG003","numAffected":0,"numAtRisk":44},{"groupId":"EG004","numAffected":3,"numAtRisk":110},{"groupId":"EG005","numAffected":0,"numAtRisk":22},{"groupId":"EG006","numAffected":1,"numAtRisk":59},{"groupId":"EG007","numAffected":0,"numAtRisk":12},{"groupId":"EG008","numAffected":0,"numAtRisk":59},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":55},{"groupId":"EG011","numAffected":0,"numAtRisk":11},{"groupId":"EG012","numAffected":3,"numAtRisk":55},{"groupId":"EG013","numAffected":0,"numAtRisk":10},{"groupId":"EG014","numAffected":0,"numAtRisk":54},{"groupId":"EG015","numAffected":0,"numAtRisk":12},{"groupId":"EG016","numAffected":0,"numAtRisk":54},{"groupId":"EG017","numAffected":0,"numAtRisk":12}]},{"term":"Infection Parasitic","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":225},{"groupId":"EG001","numAffected":0,"numAtRisk":43},{"groupId":"EG002","numAffected":0,"numAtRisk":224},{"groupId":"EG003","numAffected":0,"numAtRisk":44},{"groupId":"EG004","numAffected":0,"numAtRisk":110},{"groupId":"EG005","numAffected":0,"numAtRisk":22},{"groupId":"EG006","numAffected":0,"numAtRisk":59},{"groupId":"EG007","numAffected":0,"numAtRisk":12},{"groupId":"EG008","numAffected":0,"numAtRisk":59},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":55},{"groupId":"EG011","numAffected":0,"numAtRisk":11},{"groupId":"EG012","numAffected":0,"numAtRisk":55},{"groupId":"EG013","numAffected":0,"numAtRisk":10},{"groupId":"EG014","numAffected":0,"numAtRisk":54},{"groupId":"EG015","numAffected":1,"numAtRisk":12},{"groupId":"EG016","numAffected":0,"numAtRisk":54},{"groupId":"EG017","numAffected":0,"numAtRisk":12}]},{"term":"Influenza","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":225},{"groupId":"EG001","numAffected":1,"numAtRisk":43},{"groupId":"EG002","numAffected":4,"numAtRisk":224},{"groupId":"EG003","numAffected":1,"numAtRisk":44},{"groupId":"EG004","numAffected":0,"numAtRisk":110},{"groupId":"EG005","numAffected":0,"numAtRisk":22},{"groupId":"EG006","numAffected":1,"numAtRisk":59},{"groupId":"EG007","numAffected":0,"numAtRisk":12},{"groupId":"EG008","numAffected":0,"numAtRisk":59},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":55},{"groupId":"EG011","numAffected":0,"numAtRisk":11},{"groupId":"EG012","numAffected":1,"numAtRisk":55},{"groupId":"EG013","numAffected":0,"numAtRisk":10},{"groupId":"EG014","numAffected":2,"numAtRisk":54},{"groupId":"EG015","numAffected":1,"numAtRisk":12},{"groupId":"EG016","numAffected":3,"numAtRisk":54},{"groupId":"EG017","numAffected":0,"numAtRisk":12}]},{"term":"Malaria","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":16,"numAtRisk":225},{"groupId":"EG001","numAffected":2,"numAtRisk":43},{"groupId":"EG002","numAffected":12,"numAtRisk":224},{"groupId":"EG003","numAffected":5,"numAtRisk":44},{"groupId":"EG004","numAffected":6,"numAtRisk":110},{"groupId":"EG005","numAffected":2,"numAtRisk":22},{"groupId":"EG006","numAffected":1,"numAtRisk":59},{"groupId":"EG007","numAffected":0,"numAtRisk":12},{"groupId":"EG008","numAffected":3,"numAtRisk":59},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":3,"numAtRisk":55},{"groupId":"EG011","numAffected":1,"numAtRisk":11},{"groupId":"EG012","numAffected":8,"numAtRisk":55},{"groupId":"EG013","numAffected":1,"numAtRisk":10},{"groupId":"EG014","numAffected":7,"numAtRisk":54},{"groupId":"EG015","numAffected":2,"numAtRisk":12},{"groupId":"EG016","numAffected":4,"numAtRisk":54},{"groupId":"EG017","numAffected":0,"numAtRisk":12}]},{"term":"Nasopharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":225},{"groupId":"EG001","numAffected":4,"numAtRisk":43},{"groupId":"EG002","numAffected":11,"numAtRisk":224},{"groupId":"EG003","numAffected":1,"numAtRisk":44},{"groupId":"EG004","numAffected":2,"numAtRisk":110},{"groupId":"EG005","numAffected":1,"numAtRisk":22},{"groupId":"EG006","numAffected":1,"numAtRisk":59},{"groupId":"EG007","numAffected":0,"numAtRisk":12},{"groupId":"EG008","numAffected":0,"numAtRisk":59},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":3,"numAtRisk":55},{"groupId":"EG011","numAffected":0,"numAtRisk":11},{"groupId":"EG012","numAffected":4,"numAtRisk":55},{"groupId":"EG013","numAffected":2,"numAtRisk":10},{"groupId":"EG014","numAffected":1,"numAtRisk":54},{"groupId":"EG015","numAffected":0,"numAtRisk":12},{"groupId":"EG016","numAffected":2,"numAtRisk":54},{"groupId":"EG017","numAffected":0,"numAtRisk":12}]},{"term":"Pharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":225},{"groupId":"EG001","numAffected":0,"numAtRisk":43},{"groupId":"EG002","numAffected":0,"numAtRisk":224},{"groupId":"EG003","numAffected":0,"numAtRisk":44},{"groupId":"EG004","numAffected":1,"numAtRisk":110},{"groupId":"EG005","numAffected":0,"numAtRisk":22},{"groupId":"EG006","numAffected":0,"numAtRisk":59},{"groupId":"EG007","numAffected":1,"numAtRisk":12},{"groupId":"EG008","numAffected":0,"numAtRisk":59},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":55},{"groupId":"EG011","numAffected":0,"numAtRisk":11},{"groupId":"EG012","numAffected":0,"numAtRisk":55},{"groupId":"EG013","numAffected":0,"numAtRisk":10},{"groupId":"EG014","numAffected":0,"numAtRisk":54},{"groupId":"EG015","numAffected":0,"numAtRisk":12},{"groupId":"EG016","numAffected":0,"numAtRisk":54},{"groupId":"EG017","numAffected":0,"numAtRisk":12}]},{"term":"Respiratory Tract Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":225},{"groupId":"EG001","numAffected":1,"numAtRisk":43},{"groupId":"EG002","numAffected":1,"numAtRisk":224},{"groupId":"EG003","numAffected":0,"numAtRisk":44},{"groupId":"EG004","numAffected":0,"numAtRisk":110},{"groupId":"EG005","numAffected":0,"numAtRisk":22},{"groupId":"EG006","numAffected":0,"numAtRisk":59},{"groupId":"EG007","numAffected":0,"numAtRisk":12},{"groupId":"EG008","numAffected":0,"numAtRisk":59},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":55},{"groupId":"EG011","numAffected":0,"numAtRisk":11},{"groupId":"EG012","numAffected":0,"numAtRisk":55},{"groupId":"EG013","numAffected":0,"numAtRisk":10},{"groupId":"EG014","numAffected":0,"numAtRisk":54},{"groupId":"EG015","numAffected":0,"numAtRisk":12},{"groupId":"EG016","numAffected":0,"numAtRisk":54},{"groupId":"EG017","numAffected":1,"numAtRisk":12}]},{"term":"Rhinitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":225},{"groupId":"EG001","numAffected":0,"numAtRisk":43},{"groupId":"EG002","numAffected":2,"numAtRisk":224},{"groupId":"EG003","numAffected":1,"numAtRisk":44},{"groupId":"EG004","numAffected":4,"numAtRisk":110},{"groupId":"EG005","numAffected":2,"numAtRisk":22},{"groupId":"EG006","numAffected":0,"numAtRisk":59},{"groupId":"EG007","numAffected":0,"numAtRisk":12},{"groupId":"EG008","numAffected":2,"numAtRisk":59},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":55},{"groupId":"EG011","numAffected":0,"numAtRisk":11},{"groupId":"EG012","numAffected":0,"numAtRisk":55},{"groupId":"EG013","numAffected":0,"numAtRisk":10},{"groupId":"EG014","numAffected":4,"numAtRisk":54},{"groupId":"EG015","numAffected":0,"numAtRisk":12},{"groupId":"EG016","numAffected":6,"numAtRisk":54},{"groupId":"EG017","numAffected":1,"numAtRisk":12}]},{"term":"Sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":225},{"groupId":"EG001","numAffected":0,"numAtRisk":43},{"groupId":"EG002","numAffected":0,"numAtRisk":224},{"groupId":"EG003","numAffected":0,"numAtRisk":44},{"groupId":"EG004","numAffected":0,"numAtRisk":110},{"groupId":"EG005","numAffected":0,"numAtRisk":22},{"groupId":"EG006","numAffected":1,"numAtRisk":59},{"groupId":"EG007","numAffected":0,"numAtRisk":12},{"groupId":"EG008","numAffected":2,"numAtRisk":59},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":55},{"groupId":"EG011","numAffected":0,"numAtRisk":11},{"groupId":"EG012","numAffected":0,"numAtRisk":55},{"groupId":"EG013","numAffected":0,"numAtRisk":10},{"groupId":"EG014","numAffected":0,"numAtRisk":54},{"groupId":"EG015","numAffected":0,"numAtRisk":12},{"groupId":"EG016","numAffected":0,"numAtRisk":54},{"groupId":"EG017","numAffected":1,"numAtRisk":12}]},{"term":"Tonsillitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":225},{"groupId":"EG001","numAffected":0,"numAtRisk":43},{"groupId":"EG002","numAffected":0,"numAtRisk":224},{"groupId":"EG003","numAffected":1,"numAtRisk":44},{"groupId":"EG004","numAffected":0,"numAtRisk":110},{"groupId":"EG005","numAffected":0,"numAtRisk":22},{"groupId":"EG006","numAffected":1,"numAtRisk":59},{"groupId":"EG007","numAffected":0,"numAtRisk":12},{"groupId":"EG008","numAffected":0,"numAtRisk":59},{"groupId":"EG009","numAffected":1,"numAtRisk":12},{"groupId":"EG010","numAffected":1,"numAtRisk":55},{"groupId":"EG011","numAffected":0,"numAtRisk":11},{"groupId":"EG012","numAffected":1,"numAtRisk":55},{"groupId":"EG013","numAffected":0,"numAtRisk":10},{"groupId":"EG014","numAffected":1,"numAtRisk":54},{"groupId":"EG015","numAffected":0,"numAtRisk":12},{"groupId":"EG016","numAffected":0,"numAtRisk":54},{"groupId":"EG017","numAffected":0,"numAtRisk":12}]},{"term":"Upper Respiratory Tract Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":17,"numAtRisk":225},{"groupId":"EG001","numAffected":1,"numAtRisk":43},{"groupId":"EG002","numAffected":18,"numAtRisk":224},{"groupId":"EG003","numAffected":3,"numAtRisk":44},{"groupId":"EG004","numAffected":9,"numAtRisk":110},{"groupId":"EG005","numAffected":3,"numAtRisk":22},{"groupId":"EG006","numAffected":7,"numAtRisk":59},{"groupId":"EG007","numAffected":1,"numAtRisk":12},{"groupId":"EG008","numAffected":3,"numAtRisk":59},{"groupId":"EG009","numAffected":1,"numAtRisk":12},{"groupId":"EG010","numAffected":6,"numAtRisk":55},{"groupId":"EG011","numAffected":0,"numAtRisk":11},{"groupId":"EG012","numAffected":3,"numAtRisk":55},{"groupId":"EG013","numAffected":2,"numAtRisk":10},{"groupId":"EG014","numAffected":0,"numAtRisk":54},{"groupId":"EG015","numAffected":1,"numAtRisk":12},{"groupId":"EG016","numAffected":4,"numAtRisk":54},{"groupId":"EG017","numAffected":0,"numAtRisk":12}]},{"term":"Vulvovaginal Candidiasis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":225},{"groupId":"EG001","numAffected":0,"numAtRisk":43},{"groupId":"EG002","numAffected":0,"numAtRisk":224},{"groupId":"EG003","numAffected":0,"numAtRisk":44},{"groupId":"EG004","numAffected":1,"numAtRisk":110},{"groupId":"EG005","numAffected":0,"numAtRisk":22},{"groupId":"EG006","numAffected":0,"numAtRisk":59},{"groupId":"EG007","numAffected":1,"numAtRisk":12},{"groupId":"EG008","numAffected":0,"numAtRisk":59},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":55},{"groupId":"EG011","numAffected":0,"numAtRisk":11},{"groupId":"EG012","numAffected":0,"numAtRisk":55},{"groupId":"EG013","numAffected":0,"numAtRisk":10},{"groupId":"EG014","numAffected":0,"numAtRisk":54},{"groupId":"EG015","numAffected":0,"numAtRisk":12},{"groupId":"EG016","numAffected":0,"numAtRisk":54},{"groupId":"EG017","numAffected":0,"numAtRisk":12}]},{"term":"Foot Fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":225},{"groupId":"EG001","numAffected":0,"numAtRisk":43},{"groupId":"EG002","numAffected":0,"numAtRisk":224},{"groupId":"EG003","numAffected":0,"numAtRisk":44},{"groupId":"EG004","numAffected":0,"numAtRisk":110},{"groupId":"EG005","numAffected":0,"numAtRisk":22},{"groupId":"EG006","numAffected":0,"numAtRisk":59},{"groupId":"EG007","numAffected":1,"numAtRisk":12},{"groupId":"EG008","numAffected":0,"numAtRisk":59},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":55},{"groupId":"EG011","numAffected":0,"numAtRisk":11},{"groupId":"EG012","numAffected":0,"numAtRisk":55},{"groupId":"EG013","numAffected":0,"numAtRisk":10},{"groupId":"EG014","numAffected":0,"numAtRisk":54},{"groupId":"EG015","numAffected":0,"numAtRisk":12},{"groupId":"EG016","numAffected":0,"numAtRisk":54},{"groupId":"EG017","numAffected":0,"numAtRisk":12}]},{"term":"Ligament Sprain","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":225},{"groupId":"EG001","numAffected":0,"numAtRisk":43},{"groupId":"EG002","numAffected":0,"numAtRisk":224},{"groupId":"EG003","numAffected":0,"numAtRisk":44},{"groupId":"EG004","numAffected":0,"numAtRisk":110},{"groupId":"EG005","numAffected":0,"numAtRisk":22},{"groupId":"EG006","numAffected":0,"numAtRisk":59},{"groupId":"EG007","numAffected":1,"numAtRisk":12},{"groupId":"EG008","numAffected":0,"numAtRisk":59},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":55},{"groupId":"EG011","numAffected":0,"numAtRisk":11},{"groupId":"EG012","numAffected":0,"numAtRisk":55},{"groupId":"EG013","numAffected":0,"numAtRisk":10},{"groupId":"EG014","numAffected":0,"numAtRisk":54},{"groupId":"EG015","numAffected":0,"numAtRisk":12},{"groupId":"EG016","numAffected":0,"numAtRisk":54},{"groupId":"EG017","numAffected":0,"numAtRisk":12}]},{"term":"Alanine Aminotransferase Increased","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":225},{"groupId":"EG001","numAffected":1,"numAtRisk":43},{"groupId":"EG002","numAffected":1,"numAtRisk":224},{"groupId":"EG003","numAffected":0,"numAtRisk":44},{"groupId":"EG004","numAffected":1,"numAtRisk":110},{"groupId":"EG005","numAffected":0,"numAtRisk":22},{"groupId":"EG006","numAffected":0,"numAtRisk":59},{"groupId":"EG007","numAffected":1,"numAtRisk":12},{"groupId":"EG008","numAffected":4,"numAtRisk":59},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":55},{"groupId":"EG011","numAffected":0,"numAtRisk":11},{"groupId":"EG012","numAffected":0,"numAtRisk":55},{"groupId":"EG013","numAffected":0,"numAtRisk":10},{"groupId":"EG014","numAffected":0,"numAtRisk":54},{"groupId":"EG015","numAffected":0,"numAtRisk":12},{"groupId":"EG016","numAffected":0,"numAtRisk":54},{"groupId":"EG017","numAffected":0,"numAtRisk":12}]},{"term":"Aspartate Aminotransferase Increased","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":225},{"groupId":"EG001","numAffected":2,"numAtRisk":43},{"groupId":"EG002","numAffected":2,"numAtRisk":224},{"groupId":"EG003","numAffected":0,"numAtRisk":44},{"groupId":"EG004","numAffected":1,"numAtRisk":110},{"groupId":"EG005","numAffected":0,"numAtRisk":22},{"groupId":"EG006","numAffected":0,"numAtRisk":59},{"groupId":"EG007","numAffected":0,"numAtRisk":12},{"groupId":"EG008","numAffected":2,"numAtRisk":59},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":1,"numAtRisk":55},{"groupId":"EG011","numAffected":1,"numAtRisk":11},{"groupId":"EG012","numAffected":1,"numAtRisk":55},{"groupId":"EG013","numAffected":0,"numAtRisk":10},{"groupId":"EG014","numAffected":1,"numAtRisk":54},{"groupId":"EG015","numAffected":0,"numAtRisk":12},{"groupId":"EG016","numAffected":1,"numAtRisk":54},{"groupId":"EG017","numAffected":0,"numAtRisk":12}]},{"term":"Blood Potassium Decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":225},{"groupId":"EG001","numAffected":0,"numAtRisk":43},{"groupId":"EG002","numAffected":3,"numAtRisk":224},{"groupId":"EG003","numAffected":0,"numAtRisk":44},{"groupId":"EG004","numAffected":0,"numAtRisk":110},{"groupId":"EG005","numAffected":0,"numAtRisk":22},{"groupId":"EG006","numAffected":0,"numAtRisk":59},{"groupId":"EG007","numAffected":1,"numAtRisk":12},{"groupId":"EG008","numAffected":0,"numAtRisk":59},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":55},{"groupId":"EG011","numAffected":0,"numAtRisk":11},{"groupId":"EG012","numAffected":0,"numAtRisk":55},{"groupId":"EG013","numAffected":0,"numAtRisk":10},{"groupId":"EG014","numAffected":0,"numAtRisk":54},{"groupId":"EG015","numAffected":0,"numAtRisk":12},{"groupId":"EG016","numAffected":0,"numAtRisk":54},{"groupId":"EG017","numAffected":0,"numAtRisk":12}]},{"term":"Blood Pressure Increased","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":225},{"groupId":"EG001","numAffected":0,"numAtRisk":43},{"groupId":"EG002","numAffected":0,"numAtRisk":224},{"groupId":"EG003","numAffected":0,"numAtRisk":44},{"groupId":"EG004","numAffected":0,"numAtRisk":110},{"groupId":"EG005","numAffected":0,"numAtRisk":22},{"groupId":"EG006","numAffected":0,"numAtRisk":59},{"groupId":"EG007","numAffected":0,"numAtRisk":12},{"groupId":"EG008","numAffected":1,"numAtRisk":59},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":55},{"groupId":"EG011","numAffected":1,"numAtRisk":11},{"groupId":"EG012","numAffected":0,"numAtRisk":55},{"groupId":"EG013","numAffected":0,"numAtRisk":10},{"groupId":"EG014","numAffected":0,"numAtRisk":54},{"groupId":"EG015","numAffected":0,"numAtRisk":12},{"groupId":"EG016","numAffected":0,"numAtRisk":54},{"groupId":"EG017","numAffected":0,"numAtRisk":12}]},{"term":"Blood Sodium Decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":9,"numAtRisk":225},{"groupId":"EG001","numAffected":0,"numAtRisk":43},{"groupId":"EG002","numAffected":4,"numAtRisk":224},{"groupId":"EG003","numAffected":0,"numAtRisk":44},{"groupId":"EG004","numAffected":0,"numAtRisk":110},{"groupId":"EG005","numAffected":0,"numAtRisk":22},{"groupId":"EG006","numAffected":0,"numAtRisk":59},{"groupId":"EG007","numAffected":0,"numAtRisk":12},{"groupId":"EG008","numAffected":1,"numAtRisk":59},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":1,"numAtRisk":55},{"groupId":"EG011","numAffected":0,"numAtRisk":11},{"groupId":"EG012","numAffected":3,"numAtRisk":55},{"groupId":"EG013","numAffected":1,"numAtRisk":10},{"groupId":"EG014","numAffected":0,"numAtRisk":54},{"groupId":"EG015","numAffected":0,"numAtRisk":12},{"groupId":"EG016","numAffected":0,"numAtRisk":54},{"groupId":"EG017","numAffected":0,"numAtRisk":12}]},{"term":"Blood Urea Decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":225},{"groupId":"EG001","numAffected":0,"numAtRisk":43},{"groupId":"EG002","numAffected":2,"numAtRisk":224},{"groupId":"EG003","numAffected":0,"numAtRisk":44},{"groupId":"EG004","numAffected":1,"numAtRisk":110},{"groupId":"EG005","numAffected":0,"numAtRisk":22},{"groupId":"EG006","numAffected":1,"numAtRisk":59},{"groupId":"EG007","numAffected":0,"numAtRisk":12},{"groupId":"EG008","numAffected":1,"numAtRisk":59},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":5,"numAtRisk":55},{"groupId":"EG011","numAffected":0,"numAtRisk":11},{"groupId":"EG012","numAffected":1,"numAtRisk":55},{"groupId":"EG013","numAffected":1,"numAtRisk":10},{"groupId":"EG014","numAffected":0,"numAtRisk":54},{"groupId":"EG015","numAffected":0,"numAtRisk":12},{"groupId":"EG016","numAffected":1,"numAtRisk":54},{"groupId":"EG017","numAffected":0,"numAtRisk":12}]},{"term":"Monocyte Count Decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":225},{"groupId":"EG001","numAffected":0,"numAtRisk":43},{"groupId":"EG002","numAffected":0,"numAtRisk":224},{"groupId":"EG003","numAffected":0,"numAtRisk":44},{"groupId":"EG004","numAffected":1,"numAtRisk":110},{"groupId":"EG005","numAffected":0,"numAtRisk":22},{"groupId":"EG006","numAffected":1,"numAtRisk":59},{"groupId":"EG007","numAffected":0,"numAtRisk":12},{"groupId":"EG008","numAffected":0,"numAtRisk":59},{"groupId":"EG009","numAffected":1,"numAtRisk":12},{"groupId":"EG010","numAffected":1,"numAtRisk":55},{"groupId":"EG011","numAffected":0,"numAtRisk":11},{"groupId":"EG012","numAffected":0,"numAtRisk":55},{"groupId":"EG013","numAffected":0,"numAtRisk":10},{"groupId":"EG014","numAffected":0,"numAtRisk":54},{"groupId":"EG015","numAffected":0,"numAtRisk":12},{"groupId":"EG016","numAffected":0,"numAtRisk":54},{"groupId":"EG017","numAffected":0,"numAtRisk":12}]},{"term":"Neutrophil Count Decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":225},{"groupId":"EG001","numAffected":0,"numAtRisk":43},{"groupId":"EG002","numAffected":1,"numAtRisk":224},{"groupId":"EG003","numAffected":1,"numAtRisk":44},{"groupId":"EG004","numAffected":0,"numAtRisk":110},{"groupId":"EG005","numAffected":0,"numAtRisk":22},{"groupId":"EG006","numAffected":0,"numAtRisk":59},{"groupId":"EG007","numAffected":0,"numAtRisk":12},{"groupId":"EG008","numAffected":0,"numAtRisk":59},{"groupId":"EG009","numAffected":1,"numAtRisk":12},{"groupId":"EG010","numAffected":2,"numAtRisk":55},{"groupId":"EG011","numAffected":0,"numAtRisk":11},{"groupId":"EG012","numAffected":0,"numAtRisk":55},{"groupId":"EG013","numAffected":0,"numAtRisk":10},{"groupId":"EG014","numAffected":0,"numAtRisk":54},{"groupId":"EG015","numAffected":0,"numAtRisk":12},{"groupId":"EG016","numAffected":0,"numAtRisk":54},{"groupId":"EG017","numAffected":1,"numAtRisk":12}]},{"term":"Transaminases Increased","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":225},{"groupId":"EG001","numAffected":0,"numAtRisk":43},{"groupId":"EG002","numAffected":1,"numAtRisk":224},{"groupId":"EG003","numAffected":0,"numAtRisk":44},{"groupId":"EG004","numAffected":0,"numAtRisk":110},{"groupId":"EG005","numAffected":0,"numAtRisk":22},{"groupId":"EG006","numAffected":0,"numAtRisk":59},{"groupId":"EG007","numAffected":1,"numAtRisk":12},{"groupId":"EG008","numAffected":1,"numAtRisk":59},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":55},{"groupId":"EG011","numAffected":0,"numAtRisk":11},{"groupId":"EG012","numAffected":0,"numAtRisk":55},{"groupId":"EG013","numAffected":0,"numAtRisk":10},{"groupId":"EG014","numAffected":0,"numAtRisk":54},{"groupId":"EG015","numAffected":0,"numAtRisk":12},{"groupId":"EG016","numAffected":1,"numAtRisk":54},{"groupId":"EG017","numAffected":0,"numAtRisk":12}]},{"term":"Hypercreatininaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":225},{"groupId":"EG001","numAffected":0,"numAtRisk":43},{"groupId":"EG002","numAffected":0,"numAtRisk":224},{"groupId":"EG003","numAffected":0,"numAtRisk":44},{"groupId":"EG004","numAffected":1,"numAtRisk":110},{"groupId":"EG005","numAffected":0,"numAtRisk":22},{"groupId":"EG006","numAffected":0,"numAtRisk":59},{"groupId":"EG007","numAffected":0,"numAtRisk":12},{"groupId":"EG008","numAffected":0,"numAtRisk":59},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":2,"numAtRisk":55},{"groupId":"EG011","numAffected":1,"numAtRisk":11},{"groupId":"EG012","numAffected":5,"numAtRisk":55},{"groupId":"EG013","numAffected":0,"numAtRisk":10},{"groupId":"EG014","numAffected":0,"numAtRisk":54},{"groupId":"EG015","numAffected":0,"numAtRisk":12},{"groupId":"EG016","numAffected":0,"numAtRisk":54},{"groupId":"EG017","numAffected":0,"numAtRisk":12}]},{"term":"Hypernatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":225},{"groupId":"EG001","numAffected":2,"numAtRisk":43},{"groupId":"EG002","numAffected":0,"numAtRisk":224},{"groupId":"EG003","numAffected":0,"numAtRisk":44},{"groupId":"EG004","numAffected":2,"numAtRisk":110},{"groupId":"EG005","numAffected":1,"numAtRisk":22},{"groupId":"EG006","numAffected":3,"numAtRisk":59},{"groupId":"EG007","numAffected":0,"numAtRisk":12},{"groupId":"EG008","numAffected":0,"numAtRisk":59},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":6,"numAtRisk":55},{"groupId":"EG011","numAffected":1,"numAtRisk":11},{"groupId":"EG012","numAffected":7,"numAtRisk":55},{"groupId":"EG013","numAffected":0,"numAtRisk":10},{"groupId":"EG014","numAffected":4,"numAtRisk":54},{"groupId":"EG015","numAffected":1,"numAtRisk":12},{"groupId":"EG016","numAffected":3,"numAtRisk":54},{"groupId":"EG017","numAffected":1,"numAtRisk":12}]},{"term":"Hypokalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":225},{"groupId":"EG001","numAffected":0,"numAtRisk":43},{"groupId":"EG002","numAffected":0,"numAtRisk":224},{"groupId":"EG003","numAffected":0,"numAtRisk":44},{"groupId":"EG004","numAffected":1,"numAtRisk":110},{"groupId":"EG005","numAffected":0,"numAtRisk":22},{"groupId":"EG006","numAffected":2,"numAtRisk":59},{"groupId":"EG007","numAffected":0,"numAtRisk":12},{"groupId":"EG008","numAffected":3,"numAtRisk":59},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":55},{"groupId":"EG011","numAffected":0,"numAtRisk":11},{"groupId":"EG012","numAffected":1,"numAtRisk":55},{"groupId":"EG013","numAffected":0,"numAtRisk":10},{"groupId":"EG014","numAffected":0,"numAtRisk":54},{"groupId":"EG015","numAffected":0,"numAtRisk":12},{"groupId":"EG016","numAffected":0,"numAtRisk":54},{"groupId":"EG017","numAffected":0,"numAtRisk":12}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":225},{"groupId":"EG001","numAffected":0,"numAtRisk":43},{"groupId":"EG002","numAffected":0,"numAtRisk":224},{"groupId":"EG003","numAffected":0,"numAtRisk":44},{"groupId":"EG004","numAffected":0,"numAtRisk":110},{"groupId":"EG005","numAffected":0,"numAtRisk":22},{"groupId":"EG006","numAffected":1,"numAtRisk":59},{"groupId":"EG007","numAffected":1,"numAtRisk":12},{"groupId":"EG008","numAffected":1,"numAtRisk":59},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":55},{"groupId":"EG011","numAffected":0,"numAtRisk":11},{"groupId":"EG012","numAffected":0,"numAtRisk":55},{"groupId":"EG013","numAffected":0,"numAtRisk":10},{"groupId":"EG014","numAffected":1,"numAtRisk":54},{"groupId":"EG015","numAffected":0,"numAtRisk":12},{"groupId":"EG016","numAffected":0,"numAtRisk":54},{"groupId":"EG017","numAffected":0,"numAtRisk":12}]},{"term":"Back Pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":225},{"groupId":"EG001","numAffected":1,"numAtRisk":43},{"groupId":"EG002","numAffected":5,"numAtRisk":224},{"groupId":"EG003","numAffected":3,"numAtRisk":44},{"groupId":"EG004","numAffected":3,"numAtRisk":110},{"groupId":"EG005","numAffected":0,"numAtRisk":22},{"groupId":"EG006","numAffected":1,"numAtRisk":59},{"groupId":"EG007","numAffected":0,"numAtRisk":12},{"groupId":"EG008","numAffected":5,"numAtRisk":59},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":55},{"groupId":"EG011","numAffected":0,"numAtRisk":11},{"groupId":"EG012","numAffected":0,"numAtRisk":55},{"groupId":"EG013","numAffected":0,"numAtRisk":10},{"groupId":"EG014","numAffected":0,"numAtRisk":54},{"groupId":"EG015","numAffected":0,"numAtRisk":12},{"groupId":"EG016","numAffected":0,"numAtRisk":54},{"groupId":"EG017","numAffected":0,"numAtRisk":12}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":225},{"groupId":"EG001","numAffected":0,"numAtRisk":43},{"groupId":"EG002","numAffected":5,"numAtRisk":224},{"groupId":"EG003","numAffected":0,"numAtRisk":44},{"groupId":"EG004","numAffected":2,"numAtRisk":110},{"groupId":"EG005","numAffected":0,"numAtRisk":22},{"groupId":"EG006","numAffected":3,"numAtRisk":59},{"groupId":"EG007","numAffected":1,"numAtRisk":12},{"groupId":"EG008","numAffected":1,"numAtRisk":59},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":55},{"groupId":"EG011","numAffected":0,"numAtRisk":11},{"groupId":"EG012","numAffected":0,"numAtRisk":55},{"groupId":"EG013","numAffected":0,"numAtRisk":10},{"groupId":"EG014","numAffected":0,"numAtRisk":54},{"groupId":"EG015","numAffected":0,"numAtRisk":12},{"groupId":"EG016","numAffected":0,"numAtRisk":54},{"groupId":"EG017","numAffected":0,"numAtRisk":12}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":15,"numAtRisk":225},{"groupId":"EG001","numAffected":4,"numAtRisk":43},{"groupId":"EG002","numAffected":8,"numAtRisk":224},{"groupId":"EG003","numAffected":3,"numAtRisk":44},{"groupId":"EG004","numAffected":7,"numAtRisk":110},{"groupId":"EG005","numAffected":2,"numAtRisk":22},{"groupId":"EG006","numAffected":3,"numAtRisk":59},{"groupId":"EG007","numAffected":0,"numAtRisk":12},{"groupId":"EG008","numAffected":2,"numAtRisk":59},{"groupId":"EG009","numAffected":1,"numAtRisk":12},{"groupId":"EG010","numAffected":1,"numAtRisk":55},{"groupId":"EG011","numAffected":0,"numAtRisk":11},{"groupId":"EG012","numAffected":4,"numAtRisk":55},{"groupId":"EG013","numAffected":0,"numAtRisk":10},{"groupId":"EG014","numAffected":0,"numAtRisk":54},{"groupId":"EG015","numAffected":0,"numAtRisk":12},{"groupId":"EG016","numAffected":1,"numAtRisk":54},{"groupId":"EG017","numAffected":1,"numAtRisk":12}]},{"term":"Paraesthesia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":225},{"groupId":"EG001","numAffected":0,"numAtRisk":43},{"groupId":"EG002","numAffected":0,"numAtRisk":224},{"groupId":"EG003","numAffected":0,"numAtRisk":44},{"groupId":"EG004","numAffected":1,"numAtRisk":110},{"groupId":"EG005","numAffected":0,"numAtRisk":22},{"groupId":"EG006","numAffected":0,"numAtRisk":59},{"groupId":"EG007","numAffected":1,"numAtRisk":12},{"groupId":"EG008","numAffected":0,"numAtRisk":59},{"groupId":"EG009","numAffected":1,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":55},{"groupId":"EG011","numAffected":0,"numAtRisk":11},{"groupId":"EG012","numAffected":0,"numAtRisk":55},{"groupId":"EG013","numAffected":0,"numAtRisk":10},{"groupId":"EG014","numAffected":0,"numAtRisk":54},{"groupId":"EG015","numAffected":0,"numAtRisk":12},{"groupId":"EG016","numAffected":0,"numAtRisk":54},{"groupId":"EG017","numAffected":0,"numAtRisk":12}]},{"term":"Sciatica","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":225},{"groupId":"EG001","numAffected":0,"numAtRisk":43},{"groupId":"EG002","numAffected":0,"numAtRisk":224},{"groupId":"EG003","numAffected":0,"numAtRisk":44},{"groupId":"EG004","numAffected":0,"numAtRisk":110},{"groupId":"EG005","numAffected":0,"numAtRisk":22},{"groupId":"EG006","numAffected":0,"numAtRisk":59},{"groupId":"EG007","numAffected":1,"numAtRisk":12},{"groupId":"EG008","numAffected":1,"numAtRisk":59},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":55},{"groupId":"EG011","numAffected":0,"numAtRisk":11},{"groupId":"EG012","numAffected":0,"numAtRisk":55},{"groupId":"EG013","numAffected":0,"numAtRisk":10},{"groupId":"EG014","numAffected":0,"numAtRisk":54},{"groupId":"EG015","numAffected":0,"numAtRisk":12},{"groupId":"EG016","numAffected":0,"numAtRisk":54},{"groupId":"EG017","numAffected":0,"numAtRisk":12}]},{"term":"Menorrhagia","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":225},{"groupId":"EG001","numAffected":1,"numAtRisk":43},{"groupId":"EG002","numAffected":1,"numAtRisk":224},{"groupId":"EG003","numAffected":3,"numAtRisk":44},{"groupId":"EG004","numAffected":2,"numAtRisk":110},{"groupId":"EG005","numAffected":0,"numAtRisk":22},{"groupId":"EG006","numAffected":1,"numAtRisk":59},{"groupId":"EG007","numAffected":0,"numAtRisk":12},{"groupId":"EG008","numAffected":1,"numAtRisk":59},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":1,"numAtRisk":55},{"groupId":"EG011","numAffected":0,"numAtRisk":11},{"groupId":"EG012","numAffected":0,"numAtRisk":55},{"groupId":"EG013","numAffected":0,"numAtRisk":10},{"groupId":"EG014","numAffected":0,"numAtRisk":54},{"groupId":"EG015","numAffected":0,"numAtRisk":12},{"groupId":"EG016","numAffected":0,"numAtRisk":54},{"groupId":"EG017","numAffected":0,"numAtRisk":12}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":225},{"groupId":"EG001","numAffected":2,"numAtRisk":43},{"groupId":"EG002","numAffected":4,"numAtRisk":224},{"groupId":"EG003","numAffected":0,"numAtRisk":44},{"groupId":"EG004","numAffected":1,"numAtRisk":110},{"groupId":"EG005","numAffected":0,"numAtRisk":22},{"groupId":"EG006","numAffected":0,"numAtRisk":59},{"groupId":"EG007","numAffected":0,"numAtRisk":12},{"groupId":"EG008","numAffected":2,"numAtRisk":59},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":1,"numAtRisk":55},{"groupId":"EG011","numAffected":1,"numAtRisk":11},{"groupId":"EG012","numAffected":0,"numAtRisk":55},{"groupId":"EG013","numAffected":1,"numAtRisk":10},{"groupId":"EG014","numAffected":2,"numAtRisk":54},{"groupId":"EG015","numAffected":3,"numAtRisk":12},{"groupId":"EG016","numAffected":2,"numAtRisk":54},{"groupId":"EG017","numAffected":1,"numAtRisk":12}]},{"term":"Productive Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":225},{"groupId":"EG001","numAffected":0,"numAtRisk":43},{"groupId":"EG002","numAffected":1,"numAtRisk":224},{"groupId":"EG003","numAffected":0,"numAtRisk":44},{"groupId":"EG004","numAffected":0,"numAtRisk":110},{"groupId":"EG005","numAffected":0,"numAtRisk":22},{"groupId":"EG006","numAffected":0,"numAtRisk":59},{"groupId":"EG007","numAffected":0,"numAtRisk":12},{"groupId":"EG008","numAffected":0,"numAtRisk":59},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":55},{"groupId":"EG011","numAffected":0,"numAtRisk":11},{"groupId":"EG012","numAffected":1,"numAtRisk":55},{"groupId":"EG013","numAffected":0,"numAtRisk":10},{"groupId":"EG014","numAffected":3,"numAtRisk":54},{"groupId":"EG015","numAffected":0,"numAtRisk":12},{"groupId":"EG016","numAffected":0,"numAtRisk":54},{"groupId":"EG017","numAffected":1,"numAtRisk":12}]},{"term":"Dry Skin","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA Version 21.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":225},{"groupId":"EG001","numAffected":0,"numAtRisk":43},{"groupId":"EG002","numAffected":0,"numAtRisk":224},{"groupId":"EG003","numAffected":0,"numAtRisk":44},{"groupId":"EG004","numAffected":0,"numAtRisk":110},{"groupId":"EG005","numAffected":0,"numAtRisk":22},{"groupId":"EG006","numAffected":0,"numAtRisk":59},{"groupId":"EG007","numAffected":1,"numAtRisk":12},{"groupId":"EG008","numAffected":0,"numAtRisk":59},{"groupId":"EG009","numAffected":0,"numAtRisk":12},{"groupId":"EG010","numAffected":0,"numAtRisk":55},{"groupId":"EG011","numAffected":0,"numAtRisk":11},{"groupId":"EG012","numAffected":0,"numAtRisk":55},{"groupId":"EG013","numAffected":0,"numAtRisk":10},{"groupId":"EG014","numAffected":0,"numAtRisk":54},{"groupId":"EG015","numAffected":0,"numAtRisk":12},{"groupId":"EG016","numAffected":0,"numAtRisk":54},{"groupId":"EG017","numAffected":0,"numAtRisk":12}]}]},"moreInfoModule":{"limitationsAndCaveats":{"description":"A total of 259 participants in Cohort 1 either did not receive dose 2 (N=52) or received dose 2 outside of their protocol-defined interval (N=207), mainly due to the study pause resulting in a reduced precision for the immunogenicity estimates in the Per Protocol Analysis Set."},"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation."},"pointOfContact":{"title":"Executive Medical Director","organization":"Janssen Vaccines & Prevention B.V","email":"ClinicalTrialDisclosure@its.jnj.com","phone":"844-434-4210"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot","hasProtocol":true,"hasSap":false,"hasIcf":false,"label":"Study Protocol","date":"2017-05-04","uploadDate":"2022-02-09T11:33","filename":"Prot_000.pdf","size":1211004},{"typeAbbrev":"SAP","hasProtocol":false,"hasSap":true,"hasIcf":false,"label":"Statistical Analysis Plan","date":"2018-06-25","uploadDate":"2022-02-09T11:33","filename":"SAP_001.pdf","size":919976}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-11-09","removedCountries":["Ghana","Rwanda","Tanzania"]},"conditionBrowseModule":{"meshes":[{"id":"D019142","term":"Hemorrhagic Fever, Ebola"},{"id":"D006482","term":"Hemorrhagic Fevers, Viral"}],"ancestors":[{"id":"D012327","term":"RNA Virus Infections"},{"id":"D014777","term":"Virus Diseases"},{"id":"D007239","term":"Infections"},{"id":"D018702","term":"Filoviridae Infections"},{"id":"D018701","term":"Mononegavirales Infections"}]}},"hasResults":true}